Antibodies that bind interleukin 13 and methods of use

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on Jun. 15, 2023, is named AOE-001WO_SL.xml and is 426,841 bytes in size.

BACKGROUND

Interleukin (IL)-13 is a T helper cell subclass 2 (Th2) cytokine and belongs to a family of type I cytokines, exhibiting pleiotropic effects across multiple cellular pathways. IL-13 is involved in the differentiation of naïve T cells into Th2 cells. IL-13 promotes B-cell proliferation and induces immunoglobulin isotype class switching to IgG4 and IgE when co-stimulated with CD40/CD40L. It also up-regulates FcεRI, and thus, helps in IgE priming of mast cells. In monocytes/macrophages, IL-13 up-regulates expression of CD23 and MHC class I and class II antigens, down-regulates the expression of CD14, inhibits antibody-dependent cytotoxicity, and promotes eosinophil survival, activation, and recruitment. IL-13 also manifests important functions on nonhematopoietic cells, such as smooth muscle cells, epithelial cells, endothelial cells, and fibroblast cells. IL-13 enhances proliferation and cholinergic-induced contractions of smooth muscles. In epithelial cells, IL-13 is a potent inducer of chemokine production, alters mucociliary differentiation, decreases ciliary beat frequency of ciliated epithelial cells, and results in goblet cell metaplasia. In endothelial cells, IL-13 is a potent inducer of vascular cell adhesion molecule 1 (VCAM-1), which is important for recruitment of eosinophils. In epithelial keratinocytes, IL-13 reduces the expression of barrier integrity molecules, such as filaggrin and loricrin, while stimulating CCL26 and CCL2 secretion responsible for the recruitment of several inflammatory cells of myeloid lineages. In human dermal fibroblasts, IL-13 induces type 1 collagen synthesis in human dermal fibroblasts.

The inhibition of IL-13 may be used to treat or prevent inflammatory diseases and conditions, such as those related to elevated levels of IgE, including but not limited to asthma, allergic rhinitis, urticaria, and allergic or atopic dermatitis. Thus, the development of potent and specific inhibitors of IL-13, for example, inhibitors that remain active for longer terms when administered to subjects, are needed for the prevention and/or treatment IL-13- and IgE-mediated diseases or conditions.

SUMMARY

In certain aspects, described herein is an isolated antibody that binds IL-13, i) comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and ii) a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3; wherein: a) CDR-H1 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 58-99 and 121; b) CDR-H2 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 100-111; c) CDR-H3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 112-120 and 130-140; d) CDR-L1 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 141-144 and 149-152; e) CDR-L2 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 153-158 and the amino acid sequence LAS; and f) CDR-L3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 165-172.

In certain embodiments, the isolated antibody comprises: a) CDR-H1 comprising a sequence selected from the sequences set forth in SEQ ID NOs: 58-66; b) CDR-H2 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 100-103; c) CDR-H3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 112-120; d) CDR-L1 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 141-144; e) CDR-L2 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 153-158; and f) CDR-L3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 165-172.

In certain embodiments, the isolated antibody comprises: a) CDR-H1 comprising a sequence selected from the sequences set forth in SEQ ID NOs: 67-83; b) CDR-H2 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 104-107; c) CDR-H3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 112-120; d) CDR-L1 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 141-144; e) CDR-L2 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 153-158; and f) CDR-L3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 165-172.

In certain embodiments, the isolated antibody comprises: a) CDR-H1 comprising a sequence selected from the sequences set forth in SEQ ID NOs: 84-99 and 121; b) CDR-H2 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 108-111; c) CDR-H3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 130-140; d) CDR-L1 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 149-152; e) CDR-L2 comprises the amino acid sequence LAS; and f) CDR-L3 comprises a sequence selected from the sequences set forth in SEQ ID NOs: 165-172.

In certain embodiments, the isolated antibody does not comprise: a) CDR-H1 set forth in SEQ ID NO: 58; CDR-H2 set forth in SEQ ID NO: 100; CDR-H3 set forth in SEQ ID NO: 112; CDR-L1 set forth in SEQ ID NO: 141; CDR-L2 set forth in SEQ ID NO: 153; and CDR-L3 set forth in SEQ ID NO: 165; or b) CDR-H1 set forth in SEQ ID NO: 67; CDR-H2 set forth in SEQ ID NO: 104; CDR-H3 set forth in SEQ ID NO: 112; CDR-L1 set forth in SEQ ID NO: 141; CDR-L2 set forth in SEQ ID NO: 153; and CDR-L3 set forth in SEQ ID NO: 165; or c) CDR-H1 set forth in SEQ ID NO: 84; CDR-H2 set forth in SEQ ID NO: 108; CDR-H3 set forth in SEQ ID NO: 130; CDR-L1 set forth in SEQ ID NO: 149; CDR-L2 set forth by amino acid sequence LAS; and CDR-L3 set forth in SEQ ID NO: 165.

In certain embodiments, the antibody does not comprise any combination of: a) CDR-H1 set forth in any of SEQ ID NOs: 58, 67, or 84; b) a CDR-H2 set forth in any of SEQ ID NOs: 100, 104, or 108; c) a CDR-H3 set forth in any of SEQ ID NOs: 112 or 130; d) a CDR-L1 set forth in any of SEQ ID NOs: 141 or 149; e) a CDR-L2 set forth in any of SEQ ID NOs: 153 or 154; and f) a CDR-L3 set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in any of SEQ ID NOs: 58, 67, or 68; a CDR-H2 comprising the sequence set forth in any of SEQ ID NOs: 100 or 104; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in any of SEQ ID NOs: 141 or 149; a CDR-L2 comprising the sequence set forth in any of SEQ ID NO: 153 or the amino acid sequence of LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 58; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 100; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 141; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 153; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 67; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 104; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 141; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 153; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 68; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 104; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 141; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 153; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 67; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 104; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 149; a CDR-L2 comprising the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 68; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 104; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 149; a CDR-L2 comprising the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in any of SEQ ID NOs: 58, 67, 68, 84, or 85; a CDR-H2 comprising the sequence set forth in any of SEQ ID NOs: 100, 104, or 108; a CDR-H3 comprising the sequence set forth in any of SEQ ID NOs: 112 or 130; a CDR-L1 comprising the sequence set forth in any of SEQ ID NOs: 141 or 149; a CDR-L2 comprising the sequence set forth in any of SEQ ID NO: 153 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 84; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 108; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 130; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 149; a CDR-L2 comprising the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 85; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 108; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 130; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 149; a CDR-L2 comprising the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in any of SEQ ID NOs: 58, 67, 68, 84, or 85; a CDR-H2 comprising the sequence set forth in any of SEQ ID NOs: 100, 104, or 108; a CDR-H3 comprising the sequence set forth in any of SEQ ID NOs: 112 or 130; a CDR-L1 comprising the sequence set forth in any of SEQ ID NOs: 141 or 149; a CDR-L2 comprising the sequence set forth in any of SEQ ID NO: 157 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 58; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 100; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 141; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 157; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 68; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 104; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 141; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 157; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in any of SEQ ID NOs: 58, 67, 68, 84, or 85; a CDR-H2 comprising the sequence set forth in any of SEQ ID NOs: 100, 104, or 108; a CDR-H3 comprising the sequence set forth in any of SEQ ID NOs: 112 or 130; a CDR-L1 comprising the sequence set forth in any of SEQ ID NOs: 141 or 149; a CDR-L2 comprising the sequence set forth in any of SEQ ID NO: 157 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 68; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 104; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 112; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 141; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 157; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 165.

In certain embodiments, the isolated antibody comprises a VH sequence selected from the sequences set forth in SEQ ID NOs: 1-32 and 470.

In certain embodiments, the isolated antibody comprises a VL sequence selected from the sequences set forth in SEQ ID NOs: 33-57 and 471.

In certain embodiments, the isolated antibody comprises a VH sequence selected from the sequences set forth in SEQ ID NOs: 1-32 and 470 and a VL sequence selected from the sequences set forth in SEQ ID NOs: 33-57 and 471.

In certain embodiments, the isolated antibody comprises a VH sequence selected from the sequences set forth in SEQ ID NOs: 1-32 and 470 and a VL sequence set forth in SEQ ID NO: 49.

In certain embodiments, the isolated antibody comprises a VH sequence selected from the sequences set forth in SEQ ID NOs: 1-32 and 470 and a VL sequence set forth in SEQ ID NO: 51.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 1 and a VL sequence set forth in SEQ ID NO: 33.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 2 and a VL sequence set forth in SEQ ID NO: 33.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 35.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 35.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 35.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 35.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 35.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 36.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 36.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 36.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 36.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 36.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 40.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 40.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 40.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 40.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 40.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 42.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 9 and a VL sequence set forth in SEQ ID NO: 43.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 44.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 45.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 46.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 47.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 48.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 49.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 50.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 52.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 53.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 54.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 55.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 56.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 57.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 10 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 11 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 12 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 13 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 14 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 16 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 17 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 18 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 19 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 20 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 21 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 22 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 23 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 24 and a VL sequence set forth in SEQ ID NO: 39.

The isolated antibody of claim 21, wherein the antibody comprises a VH sequence set forth in SEQ ID NO: 25 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 26 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 27 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 28 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 29 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 30 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 31 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 32 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 39.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 51.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471.

In certain embodiments, the isolated antibody is a humanized, human, or chimeric antibody. In certain embodiments, the isolated is a humanized antibody. In certain embodiments, the isolated antibody comprises a heavy chain human constant region of a class selected from IgG, IgA, IgD, IgE, and IgM. In certain embodiments, the human Fc region comprises a human heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4. In certain embodiments, the human Fc region comprises a human IgG1 Fc. In certain embodiments, the human Fc region comprises a human IgG4 Fc. In certain embodiments, the human Fc region comprises a human IgG2 Fc.

In certain embodiments of the antibodies described herein, the heavy chain comprises a constant heavy chain sequence selected from the sequences set forth in SEQ ID NOs: 425-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 1 and a VL sequence set forth in SEQ ID NO: 33; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 2 and a VL sequence set forth in SEQ ID NO: 33; and wherein the human Fc 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 439, 440, 446, 457, and 460.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 42; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 9 and a VL sequence set forth in SEQ ID NO: 43; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 44; and wherein the human Fc 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 45; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 46; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 47; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 48; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 49; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 50; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 52; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOS: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 53; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 54; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 55; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 56; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 57; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 10 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 11 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 12 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 13 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated comprises a VH sequence set forth in SEQ ID NO: 14 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 16 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 17 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 18 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 19 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 20 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 21 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 22 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 23 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 24 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 25 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 26 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 27 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 28 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 29 and a VL sequence selected from a sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 30 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 31 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 32 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc 436-468 and 484-539. In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 439.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 439.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 460.

In certain embodiments, the isolated antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 446. In certain embodiments, the isolated antibody light chain comprises a constant light chain sequence set forth by SEQ ID NO: 469.

In certain embodiments, the isolated antibody Fc region comprises one or more amino acid substitutions, wherein the one or more substitutions result in a change (e.g., an increase or a decrease) in antibody half-life, ADCC activity, ADCP activity, or CDC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is an increase in antibody half-life, an increase or a decrease in ADCC activity, an increase in ADCP activity or an increase in CDC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the one or more amino acid substitutions results in increased antibody half-life compared to an antibody comprising a wild-type Fc region. In certain embodiments, the isolated antibody comprising an Fc region with one or more amino acid substitutions has a half-life of about 80 to 110 days in a human.

In certain embodiments, the change is an increase or a decrease in antibody half-life, an increase or a decrease in ADCC activity, an increase or a decrease in ADCP activity, or an increase or a decrease in CDC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is an increase in antibody half-life as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is a decrease in antibody half-life as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is an increase in ADCC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is a decrease in ADCC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is an increase in ADCP activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is a decrease in ADCP activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is an increase in CDC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is a decrease in CDC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is an increase in antibody half-life, an increase in ADCC activity, an increase in ADCP activity and an increase in CDC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions. In certain embodiments, the change is an increase in antibody half-life, a decrease in ADCC activity, an increase in ADCP activity and an increase in CDC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions.

In certain embodiments, the change is an increase in antibody half-life as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions.

In certain embodiments, the change is an increase in ADCC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions.

In certain embodiments, the change is a decrease in ADCC activity as compared to an otherwise equivalent antibody comprising an Fc without the one or more substitutions.

In certain embodiments, the Fc region binds to Neonatal Fc receptor (FcRn). In certain embodiments, the Fc region binds an FcRn with higher affinity at pH 6.0 compared to an antibody comprising a wild-type Fc region. In certain embodiments, the Fc region binds to FcRn with a K_Dof <1×10⁻⁷M at pH 6.0.

In certain embodiments, the isolated antibody is a monoclonal antibody.

In certain embodiments, the antibody binds an IL-13 sequence set forth in SEQ ID NOs: 472-475.

In certain embodiments, the isolated antibody binds to an IL-13 sequence set forth in SEQ ID NOs: 472-475 with a K_Dof less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9×10⁻⁹M, as measured by surface plasmon resonance (SPR). In certain embodiments, the isolated antibody binds to an IL-13 sequence set forth in SEQ ID NOs: 472-475 with a K_Dof less than or equal to about 1×10⁻¹⁰M, as measured by SPR. In certain embodiments, the antibody binds to human IL-13 with a K_Dof less than or equal to about 1×10⁻⁹M, as measured by SPR.

In certain embodiments, the isolated antibody exhibits a melting temperature greater than 68° C. as measured by Differential Scanning Fluorometry (DSF). In certain embodiments, the antibody exhibits a melting temperature greater than 75° C. as measured by DSF. In certain embodiments, the antibody exhibits a aggregation temperature equal to or greater than 71.2° C. as measured by DSF.

In certain embodiments, the isolated antibody has a retention time of 15.2 minutes or less as measured by hydrophobic interaction chromatography.

In certain embodiments, the isolated antibody does not have a heavy chain variable region sequence set forth in SEQ ID NO: 470.

In certain embodiments, the isolated antibody is used in the treatment of an inflammatory disorder or disease. In certain embodiments, the isolated antibody is used in the treatment of atopic dermatitis. In certain embodiments, the treatment reduces disease severity in a subject and wherein disease severity is assessed by an Atopic Dermatitis Disease Severity Outcome Measure. In certain embodiments, the isolated antibody is used in the treatment of asthma. In certain embodiments, the isolated antibody is used in the treatment of idiopathic pulmonary fibrosis. In certain embodiments, the isolated antibody is used in the treatment of alopecia areata. In certain embodiments, the isolated antibody is used in the treatment of chronic sinusitis with nasal polyps. In certain embodiments, the isolated antibody is used in the treatment of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). In certain embodiments, the isolated antibody is used in the treatment of eosinophilic esophagitis (EoE). In certain embodiments, the isolated antibody is used in the treatment of an Eosinophilic gastrointestinal disorder or disease (ENID) selected from the group consisting of Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), and Eosinophilic Gastroenteritis (EGE). In certain embodiments, the isolated antibody is used in the treatment of Churg-Strauss syndrome/Eosinophilic granulomatosis with polyangiitis (EGPA). In certain embodiments, the isolated antibody is used in the treatment of Prurigo Nodularis (PN). In certain embodiments, the isolated antibody is used in the treatment of Chronic Spontaneous Urticaria (CSU). In certain embodiments, the isolated antibody is used in the treatment of Chronic Pruritis of Unknown Origin (CPUO). In certain embodiments, the isolated antibody is used in the treatment of Bullous Pemphigoid (BP). In certain embodiments, the isolated antibody is used in the treatment of Cold Inducible Urticaria (ColdU). In certain embodiments, the isolated antibody is used in the treatment of Allergic Fungal Rhinosinusitis (AFRS). In certain embodiments, the isolated antibody is used in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA). In certain embodiments, the isolated antibody is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD). In certain embodiments, the isolated antibody is used in the treatment of inflammatory bowel disease, such as Crohn disease or ulcerative colitis. In certain embodiments, the isolated antibody is used in the treatment of psoriasis. In certain embodiments, the isolated antibody is used in the treatment of lupus. In certain embodiments, the isolated antibody is used in the treatment of rheumatoid arthritis.

In certain aspects, described herein is an isolated polynucleotide or set of polynucleotides encoding an antibody described herein, a VH thereof, a VL thereof, a light chain thereof, a heavy chain thereof, or an antigen-binding portion thereof, and optionally, wherein the polynucleotide or set of polynucleotides comprises cDNA. In certain aspects, described herein is a vector or set of vectors comprising the polynucleotide or set of polynucleotides. In certain aspects, described herein is a host cell comprising the polynucleotide or set of polynucleotides or the vector or set of vectors.

In certain aspects, described herein is a method of producing an antibody, the method comprising expressing the antibody with the host cell described herein and isolating the expressed antibody.

In certain aspects, described herein is a pharmaceutical composition comprising an antibody described herein and a pharmaceutically acceptable excipient.

In certain aspects, described herein is a kit comprising an antibody described herein or a pharmaceutical composition described herein and instructions for use.

In certain aspects, described herein is a method for treating an inflammatory disorder or disease in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody described herein or a pharmaceutical composition described herein. In certain embodiments of the methods described herein, the inflammatory disorder or disease is atopic dermatitis. In certain embodiments, the inflammatory disorder or disease is asthma. In certain embodiments, the inflammatory disorder or disease is idiopathic pulmonary fibrosis. In certain embodiments, the inflammatory disorder or disease is alopecia areata. In certain embodiments, the inflammatory disorder or disease is chronic sinusitis with nasal polyps. In certain embodiments, the inflammatory disorder or disease is Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). In certain embodiments, the inflammatory disorder or disease is eosinophilic esophagitis (EoE). In certain embodiments, the inflammatory disorder or disease is an Eosinophilic gastrointestinal disorder or disease (ENID) selected from the group consisting of Eosinophilic Gastritis (EoG), Eosinophilic enteritis (EoN), Eosinophilic colitis (EoC), and Eosinophilic Gastroenteritis (EGE). In certain embodiments, the inflammatory disorder or disease is Churg-Strauss syndrome/Eosinophilic granulomatosis with polyangiitis (EGPA). In certain embodiments, the inflammatory disorder or disease is Prurigo Nodularis (PN). In certain embodiments, the inflammatory disorder or disease is Chronic Spontaneous Urticaria (CSU). In certain embodiments, the inflammatory disorder or disease is Chronic Pruritis of Unknown Origin (CPUO). In certain embodiments, the inflammatory disorder or disease is Bullous Pemphigoid (BP). In certain embodiments, the inflammatory disorder or disease is Cold Inducible Urticaria (ColdU). In certain embodiments, the inflammatory disorder or disease is Allergic Fungal Rhinosinusitis (AFRS). In certain embodiments, the inflammatory disorder or disease is Allergic Bronchopulmonary Aspergillosis (ABPA). In certain embodiments, the inflammatory disorder or disease is Chronic Obstructive Pulmonary Disease (COPD). In certain embodiments, the inflammatory disorder or disease is inflammatory bowel disease, such as Crohn disease or ulcerative colitis. In certain embodiments, the inflammatory disorder or disease is psoriasis. In certain embodiments, the inflammatory disorder or disease is lupus. In certain embodiments, the inflammatory disorder or disease is rheumatoid arthritis.

In certain aspects, described herein is a method for treating a pathology associated with elevated levels of IL-13 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody described herein or a pharmaceutical composition described herein.

In certain aspects, described herein is a method of reducing biological activity of IL-13 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody described herein or a pharmaceutical composition described herein.

In certain aspects, described herein is a method of inhibiting the TH2 type allergic response in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody described herein or a pharmaceutical composition described herein.

In certain aspects, described herein is a method of reducing levels of Thymus and Activation Regulated Chemokine (TARC)/CCL17 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody described herein or a pharmaceutical composition described herein.

In certain aspects, described herein is a method of preventing an inflammatory disorder or disease in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody of described herein or a pharmaceutical composition described herein.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, and accompanying drawings, where:

FIG. 1 is a three-dimensional rendering of human IL-13. The “1” gray highlights the epitope of lebrikizumab, which overlaps with the epitope of Construct 133 disclosed herein (see e.g., Tables 2-8). These epitopes also overlap with the IL-4Rα epitope on IL-13, shown in “2” gray. The epitope of tralokunumab-ldrm (Adbry™) is shown in “3” gray. The IL-13Rα1/IL-13Rα2 overlapping epitope is shown in “4” gray, and the IL-13Rα2 (non-overlapping) epitope is shown in “5” gray.

FIG. 2 is a graph depicting the percentage of inhibition of IL-13 binding to IL13Rα1/IL-4Rα overexpressing HEK293 cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by FACs.

FIG. 3 is a graph depicting the percentage of inhibition of IL-13-induced phosphorylation of STAT6 in HT-29 cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by FACs.

FIG. 4 is a graph depicting the percentage of inhibition of IL-13-induced release of thymus-and activation-regulated chemokine (TARC/CCL17) in the supernatant of A549 cell cultures that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by enzyme-linked immunoassay (ELISA).

FIG. 5 is a graph depicting the percentage of inhibition of IL-13-induced release of TARC in the supernatant of A549 cell cultures that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by ELISA.

FIG. 6 is a graph depicting the percentage of inhibition of IL-13-induced proliferation of TF-1 cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as quantified by a CellTiter-Glo assay.

FIG. 7 is a graph depicting the percentage of inhibition of IL-13-induced phosphorylation of STAT6 in human peripheral blood mononuclear cells (PBMCs) cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by FACs.

FIG. 8 is a graph depicting the percentage of inhibition of IL-13-induced CD23 expression in human peripheral blood mononuclear cells (PBMCs) cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by FACs.

FIG. 9 is a graph depicting the serum concentration (ng/mL) of Construct 133 and lebrikizumab over time (days post injection) in non-human primates (NHPs). The half-life of Construct 15 was 27.6 days, as compared to 17 to 18 days for lebrikizumab.

FIG. 10 is a graph depicting normalized AUC_0-∞ (C_norm*day), or area under the curve (AUC) from dosing to infinity, among antibodies with the YTE substitution.

FIG. 11 is a graph depicting the serum concentration (ng/ml) of the indicated engineered anti-IL-13 antibodies administered intravenously (IV) in NHPs.

FIG. 12 is a graph depicting the serum concentration (ng/mL) of the indicated engineered anti-IL-13 antibodies administered subcutaneously (SQ) in NHPs.

FIG. 13 is a graph depicting the percentage of inhibition of IL-13-induced CCL2 secretion in HaCaT cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by Luminex.

FIG. 14 is a graph depicting the percentage of inhibition of CCL26 secretion in HaCaT cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by Luminex.

FIG. 15 is a graph depicting the percentage of inhibition of NTRK1 gene expression in HaCaT cells that have been incubated with the indicated engineered anti-IL-13 antibodies, as determined by QuantiGene assay.

DETAILED DESCRIPTION

IL-13 signaling begins with the binding of IL-13 to IL-13Rα1, forming an inactive complex that then binds to IL-4Rα to form the complete, active receptor heterodimer. This active receptor heterodimer contributes to the pathogenesis of atopic dermatitis. The instant disclosure relates, in part, to anti-IL-13 antibodies that prevent the formation of this heterodimer.

As shown in FIG. 1, a three-dimensional rendering of human IL-13, “1” gray highlights the epitope of lebrikizumab, which overlaps with the epitope of certain antibodies disclosed herein. Importantly, these epitopes also overlap with the IL-4Rα epitope on IL-13. Without wishing to be bound by theory, it is believed that antibodies that bind to this region are likely to prevent the formation of the IL-13Rα1-IL-4Rα heterodimer, limiting the inflammatory signaling that leads to atopic dermatitis. In contrast, the epitope of tralokunumab-ldrm (Adbry™), highlighted in “3” gray, does not overlap with the IL-4Rα epitope on IL-13 and therefore may have a more limited ability to prevent heterodimerization.

Definitions

Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 4th ed. (2012) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.

As used herein, the singular form “a,” “an,” and “the” includes plural references unless indicated otherwise.

It is understood that aspects and embodiments of the invention described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments.

For all compositions described herein, and all methods using a composition described herein, the compositions can either comprise the listed components or steps, or can “consist essentially of” the listed components or steps. When a composition is described as “consisting essentially of” the listed components, the composition contains the components listed, and may contain other components which do not substantially affect the condition being treated, but do not contain any other components which substantially affect the condition being treated other than those components expressly listed; or, if the composition does contain extra components other than those listed which substantially affect the condition being treated, the composition does not contain a sufficient concentration or amount of the extra components to substantially affect the condition being treated. When a method is described as “consisting essentially of” the listed steps, the method contains the steps listed, and may contain other steps that do not substantially affect the condition being treated, but the method does not contain any other steps which substantially affect the condition being treated other than those steps expressly listed. As a non-limiting specific example, when a composition is described as “consisting essentially of” a component, the composition may additionally contain any amount of pharmaceutically acceptable carriers, vehicles, or diluents and other such components which do not substantially affect the condition being treated.

The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”

The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which an exogenous nucleic acid has been introduced, and the progeny of such cells. Host cells include “transformants” (or “transformed cells”) and “transfectants” (or “transfected cells”), which each include the primary transformed or transfected cell and progeny derived therefrom. Such progeny may not be completely identical in nucleic acid content to a parent cell, and may contain mutations. A “recombinant host cell” or “host cell” refers to a cell that includes an exogenous polynucleotide, regardless of the method used for insertion, for example, direct uptake, transduction, f-mating, or other methods known in the art to create recombinant host cells.

As used herein, the term “eukaryote” refers to organisms belonging to the phylogenetic domain Eucarya such as animals (including but not limited to, mammals, insects, reptiles, birds, etc.), ciliates, plants (including but not limited to, monocots, dicots, algae, etc.), fungi, yeasts, flagellates, microsporidia, protists, etc.

As used herein, the term “prokaryote” refers to prokaryotic organisms. For example, a non-eukaryotic organism can belong to the Eubacteria (including but not limited to, Escherichia coli, Thermus thermophilus, Bacillus stearothermophilus, Pseudomonas fluorescens, Pseudomonas aeruginosa, Pseudomonas putida, etc.) phylogenetic domain, or the Archaea (including but not limited to, Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacterium such as Haloferax volcanii and Halobacterium species NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pernix, etc.) phylogenetic domain.

An “effective amount” or “therapeutically effective amount” as used herein refers to an amount of therapeutic compound, such as an anti-IL-13 antibody, administered to an individual, either as a single dose or as part of a series of doses, which is effective to produce or contribute to a desired therapeutic effect, either alone or in combination with another therapeutic modality. Examples of a desired therapeutic effect is enhancing an immune response, slowing or delaying tumor development; stabilization of disease; amelioration of one or more symptoms. An effective amount may be given in one or more dosages.

The term “treating” (and variations thereof such as “treat” or “treatment”) refers to clinical intervention in an attempt to alter the natural course of a disease or condition in a subject in need thereof. Treatment can be performed during the course of clinical pathology. Desirable effects of treatment include preventing recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.

The term “sufficient amount” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate an immune response in a subject.

As used herein, the term “subject” or “individual” means a mammalian subject. Exemplary subjects include humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, goats, rabbits, and sheep. In certain embodiments, the subject is a human. In some embodiments the subject has a disease or condition that can be treated with an antibody provided herein. In some embodiments, the disease or condition is a cancer. In some embodiments, the disease or condition is a viral infection.

The term “in vitro” refers to processes that occur in a living cell growing separate from a living organism, e.g., growing in tissue culture.

The term “in vivo” refers to processes that occur in a living organism.

The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic or diagnostic products (e.g., kits) that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic or diagnostic products.

The term “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective in treating a subject, and which contains no additional components which are unacceptably toxic to the subject in the amounts provided in the pharmaceutical composition.

The terms “co-administration,” “co-administer,” and “in combination with” include the administration of two or more therapeutic agents either simultaneously, concurrently or sequentially within no specific time limits. In one embodiment, the agents are present in the cell or in the subject's body at the same time or exert their biological or therapeutic effect at the same time. In one embodiment, the therapeutic agents are in the same composition or unit dosage form. In other embodiments, the therapeutic agents are in separate compositions or unit dosage forms. In certain embodiments, a first agent can be administered prior to the administration of a second therapeutic agent.

The terms “modulate” and “modulation” refer to reducing or inhibiting or, alternatively, activating or increasing, a recited variable.

The terms “increase” and “activate” refer to an increase of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable.

The terms “reduce” and “inhibit” refer to a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable.

The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value±10%, ±5%, or ±1%. In certain embodiments, where applicable, the term “about” indicates the designated value(s)±one standard deviation of that value(s).

The term “agonize” refers to the activation of receptor signaling to induce a biological response associated with activation of the receptor. An “agonist” is an entity that binds to and agonizes a receptor.

The term “antagonize” refers to the inhibition of receptor signaling to inhibit a biological response associated with activation of the receptor. An “antagonist” is an entity that binds to and antagonizes a receptor.

For any of the structural and functional characteristics described herein, methods of determining these characteristics are known in the art.

The term “optionally” is meant, when used sequentially, to include from one to all of the enumerated combinations and contemplates all sub-combinations.

The term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

The term “affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen or epitope). Unless indicated otherwise, as used herein, “affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen or epitope).

The term “kd” (sec-1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koff value.

The term “ka” (M-1×sec-1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the kon value.

The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. KD=kd/ka. In some embodiments, the affinity of an antibody is described in terms of the KD for an interaction between such antibody and its antigen. For clarity, as known in the art, a smaller KD value indicates a higher affinity interaction, while a larger KD value indicates a lower affinity interaction.

The term “KA” (M-1), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction. KA=ka/kd.

The term “antibody” is used herein in its broadest sense and includes certain types of immunoglobulin molecules comprising one or more antigen-binding domains that specifically bind to an antigen or epitope. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), antibody fragments, and multi-specific antibodies.

A “anti-IL-13 antibody,” “IL-13 antibody,” or “IL-13 specific antibody” is an antibody, as provided herein, which specifically binds to the antigen IL-13.

The term “epitope” means a portion of an antigen that specifically binds to an antibody.

The term “hypervariable region” or “HVR,” as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”).

The term “antigen-binding domain” means the portion of an antibody that is capable of specifically binding to an antigen or epitope.

The term “chimeric antibody” refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

The term “human antibody” refers to an antibody which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.

The term “humanized antibody” refers to a protein having a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and/or additions, such that the humanized antibody is less likely to induce an immune response, and/or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject.

The term “multispecific antibody” refers to an antibody that comprises two or more different antigen-binding domains that collectively specifically bind two or more different epitopes.

A “monospecific antibody” is an antibody that comprises one or more binding sites that specifically bind to a single epitope. An example of a monospecific antibody is a naturally occurring IgG molecule which, while divalent (i.e., having two antigen-binding domains), recognizes the same epitope at each of the two antigen-binding domains. The binding specificity may be present in any suitable valency.

The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and/or to reduce its immunogenicity in a subject.

The term “single-chain” refers to a molecule comprising amino acid monomers linearly linked by peptide bonds. In a particular such embodiment, the C-terminus of the Fab light chain is connected to the N-terminus of the Fab heavy chain in the single-chain Fab molecule. As described in more detail herein, an scFv has a variable domain of light chain (VL) connected from its C-terminus to the N-terminal end of a variable domain of heavy chain (VH) by a polypeptide chain. Alternately the scFv comprises of polypeptide chain where in the C-terminal end of the VH is connected to the N-terminal end of VL by a polypeptide chain.

The “Fab fragment” (also referred to as fragment antigen-binding) contains the constant domain (CL) of the light chain and the first constant domain (CH1) of the heavy chain along with the variable domains VL and VH on the light and heavy chains respectively. The variable domains comprise the complementarity determining loops (CDR, also referred to as hypervariable region) that are involved in antigen-binding. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.

“F(ab′)2” fragments contain two Fab′ fragments joined, near the hinge region, by disulfide bonds. F(ab′)2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab′) fragments can be dissociated, for example, by treatment with β-mercaptoethanol.

“Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.

“Single-chain Fv” or “sFv” or “scFv” includes the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In one embodiment, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen-binding. For a review of scFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994). HER2 antibody scFv fragments are described in WO93/16185; U.S. Pat. Nos. 5,571,894; and 5,587,458.

“scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminal of the scFv. The Fc domain may follow the VH or VL, depending on the orientation of the variable domains in the scFv (i.e., VH-VL or VL-VH). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgG4 Fc domain.

The term “single domain antibody” or “sdAb” refers to a molecule in which one variable domain of an antibody specifically binds to an antigen without the presence of the other variable domain. Single domain antibodies, and fragments thereof, are described in Arabi Ghahroudi et al., FEBS Letters, 1998, 414:521-526 and Muyldermans et al., Trends in Biochem. Sci., 2001, 26:230-245, each of which is incorporated by reference in its entirety. Single domain antibodies are also known as sdAbs or nanobodies. Sdabs are fairly stable and easy to express as fusion partner with the Fc chain of an antibody (Harmsen M M, De Haard H J (2007). “Properties, production, and applications of camelid single-domain antibody fragments”. Appl. Microbiol Biotechnol. 77 (1): 13-22).

The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a naturally occurring antibody structure and having heavy chains that comprise an Fc region. For example, when used to refer to an IgG molecule, a “full length antibody” is an antibody that comprises two heavy chains and two light chains.

The term “antibody fragment” refers to an antibody that comprises a portion of an intact antibody, such as the antigen-binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab′)2 fragments, Fab′ fragments, scFv (sFv) fragments, and scFv-Fc fragments.

The term “Fc domain” or “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions.

The term “substantially purified” refers to a construct described herein, or variant thereof that may be substantially or essentially free of components that normally accompany or interact with the protein as found in its naturally occurring environment, i.e. a native cell, or host cell in the case of recombinantly produced antibody that in certain embodiments, is substantially free of cellular material includes preparations of protein having less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating protein.

The term percent “identity,” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., using publicly available computer software such as BLAST, BLASTP, BLASTN, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software or other algorithms available to persons of skill) or by visual inspection. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (ncbi.nlm.nih.gov). Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Depending on the application, the percent “identity” can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared.

For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., infra).

Ranges recited herein are understood to be shorthand for all of the values within the range, inclusive of the recited endpoints. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.

It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

Anti-IL-13 Antibodies

Antibody Structure

The present application provides antibodies and compositions comprising an antibody which binds IL-13.

The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. The “class” of an antibody or immunoglobulin refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminal domain of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chain domains respectively. The IgG1 heavy chain comprises of the VH, CH1, CH2, and CH3 domains respectively from the N- to C-terminus. The light chain comprises of the VL and CL domains from N- to C-terminus. The IgG1 heavy chain comprises a hinge between the CH1 and CH2 domains. In certain embodiments, the immunoglobulin constructs comprise at least one immunoglobulin domain from IgG, IgM, IgA, IgD, or IgE connected to a therapeutic polypeptide. In some embodiments, the immunoglobulin domain found in an antibody provided herein, is from or derived from an immunoglobulin based construct such as a diabody or a nanobody. In certain embodiments, the immunoglobulin constructs described herein comprise at least one immunoglobulin domain from a heavy chain antibody such as a camelid antibody. In certain embodiments, the immunoglobulin constructs provided herein comprise at least one immunoglobulin domain from a mammalian antibody such as a bovine antibody, a human antibody, a camelid antibody, a mouse antibody, or any chimeric antibody.

In some embodiments, the antibodies provided herein comprise a heavy chain. In one embodiment, the heavy chain is an IgA. In one embodiment, the heavy chain is an IgD. In one embodiment, the heavy chain is an IgE. In one embodiment, the heavy chain is an IgG. In one embodiment, the heavy chain is an IgM. In one embodiment, the heavy chain is an IgG1. In one embodiment, the heavy chain is an IgG2. In one embodiment, the heavy chain is an IgG3. In one embodiment, the heavy chain is an IgG4. In one embodiment, the heavy chain is an IgA1. In one embodiment, the heavy chain is an IgA2.

In some embodiments, an antibody is an IgG1 antibody. In some embodiments, an antibody is an IgG3 antibody. In some embodiments, an antibody is an IgG2 antibody. In some embodiments, an antibody is an IgG4 antibody.

Generally, native four-chain antibodies comprise six hypervariable regions (HVRs); three in the VH (H1, H2, and H3), and three in the VL (L1, L2, and L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the complementarity determining regions (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. HVRs are also referred to as CDRs, and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen-binding regions. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (“Chothia” numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (“IMGT” numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme); each of which is incorporated by reference in its entirety.

Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.

CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at www.bioinf.org.uk/abs/abnum/, and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.

TABLE 1

Table 1. Residues in CDRs according to

Kabat and Chothia numbering schemes.

CDR
Kabat
Chothia

L1
L24-L34
L24-L34

L2
L50-L56
L50-L56

L3
L89-L97
L89-L97

H1 (Kabat Numbering)
H31-H35B
H26-H32 or H34*

H1 (Chothia Numbering)
H31-H35
H26-H32

H2
H50-H65
H52-H56

H3
H95-H102
H95-H102

*The C-terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR.

The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.

One example of an antigen-binding domain is an antigen-binding domain formed by a VH-VL dimer of an antibody. Another example of an antigen-binding domain is an antigen-binding domain formed by diversification of certain loops from the tenth fibronectin type III domain of an Adnectin. An antigen-binding domain can include CDRs 1, 2, and 3 from a heavy chain in that order; and CDRs 1, 2, and 3 from a light chain in that order.

Epitopes frequently consist of surface-accessible amino acid residues and/or sugar side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter may be lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to IL-13 variants with different point-mutations or to chimeric IL-13 variants.

To screen for antibodies which bind to an epitope on a target antigen bound by an antibody of interest (e.g., IL-13), a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, or additionally, epitope mapping can be performed by methods known in the art.

Chimeric antibodies are antibodies in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

Human antibodies are antibodies which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.

A humanized antibody has a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and/or additions, such that the humanized antibody is less likely to induce an immune response, and/or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject. In one embodiment, certain amino acids in the framework and constant domains of the heavy and/or light chains of the non-human species antibody are mutated to produce the humanized antibody. In another embodiment, the constant domain(s) from a human antibody are fused to the variable domain(s) of a non-human species. In another embodiment, one or more amino acid residues in one or more CDR sequences of a non-human antibody are changed to reduce the likely immunogenicity of the non-human antibody when it is administered to a human subject, wherein the changed amino acid residues either are not critical for immunospecific binding of the antibody to its antigen, or the changes to the amino acid sequence that are made are conservative changes, such that the binding of the humanized antibody to the antigen is not significantly worse than the binding of the non-human antibody to the antigen. Examples of how to make humanized antibodies can be found in U.S. Pat. Nos. 6,054,297, 5,886,152 and 5,877,293. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.

The two or more different epitopes may be epitopes on the same antigen (e.g., a single IL-13) or on different antigens (e.g., different IL-13 molecules, or a IL-13 molecule and a non-IL-13 molecule). In some embodiments, a multi-specific antibody binds two different epitopes (i.e., a “bispecific antibody”). In some embodiments, a multi-specific antibody binds three different epitopes (i.e., a “trispecific antibody”).

Anti-IL-13 antibodies can include those described herein such as the clones set forth in the drawings and/or tables. In some embodiments, the antibody comprises an alternative scaffold. In some embodiments, the antibody consists of an alternative scaffold. In some embodiments, the antibody consists essentially of an alternative scaffold. In some embodiments, the antibody comprises an antibody fragment. In some embodiments, the antibody consists of an antibody fragment. In some embodiments, the antibody consists essentially of an antibody fragment.

In some embodiments the antibodies are monoclonal antibodies.

In some embodiments the antibodies are polyclonal antibodies.

In some embodiments the antibodies are produced by hybridomas. In other embodiments, the antibodies are produced by recombinant cells engineered to express the desired variable and constant domains.

In some embodiments the antibodies may be single chain antibodies or other antibody derivatives retaining the antigen specificity and the lower hinge region or a variant thereof.

In some embodiments the antibodies may be polyfunctional antibodies, recombinant antibodies, human antibodies, humanized antibodies, fragments or variants thereof. In particular embodiments, the antibody fragment or a derivative thereof is selected from a Fab fragment, a Fab′2 fragment, a CDR, and ScFv.

In some embodiments, the antibodies are capable of forming an immune complex. For example, an immune complex can be a tumor cell covered by antibodies.

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/).

Sequences of IL-13 Antibodies

VH Domains

In some embodiments, an antibody provided herein comprises a VH sequence selected from SEQ ID NOs: 1-32 and 470.

In some embodiments, an antibody provided herein comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an illustrative VH sequence provided in SEQ ID NOs: 1-32 and 470. In some embodiments, an antibody provided herein comprises a VH sequence provided in SEQ ID NOs: 1-32 and 470, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

VL Domains

In some embodiments, an antibody provided herein comprises a VL sequence selected from SEQ ID NOs: 33-57 and 471.

In some embodiments, an antibody provided herein comprises a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an illustrative VL sequence provided in SEQ ID NOs: 33-57 and 471. In some embodiments, an antibody provided herein comprises a VL sequence provided in SEQ ID NOs: 33-57 and 471 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

VH-VL Combinations

In some embodiments, an antibody provided herein comprises a VH sequence selected from SEQ ID NOs: 1-32 and 470; and a VL sequence selected from SEQ ID NOS: 33-57 and 471, such as the VH-VL combination set forth in Table 2, below.

In certain aspects, any of SEQ ID NOs: 1-32 and 470 can be combined with any of SEQ ID NOs: 33-57 and 471.

In certain embodiments, the antibody comprises a VH sequence selected from the sequences set forth in SEQ ID NOs: 1-32 and 470 and a VL sequence set forth in SEQ ID NO: 49.

In certain embodiments, the antibody comprises a VH sequence selected from the sequences set forth in SEQ ID NOs: 1-32 and 470 and a VL sequence set forth in SEQ ID NO: 51.

In some embodiments, an antibody provided herein comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an illustrative VH sequence provided in SEQ ID NOs: 1-32 and 470; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an illustrative VL sequence provided in SEQ ID NOs: 33-57 and 471. In some embodiments, an antibody provided herein comprises a VH sequence provided in SEQ ID NOs: 1-32 and 470, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions; and a VL sequence provided in SEQ ID NOs: 33-57 and 471, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises a VH sequence and a VL sequence selected from combinations set forth in Table 2, below. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 1 and a VL sequence set forth in SEQ ID NO: 33. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 2 and a VL sequence set forth in SEQ ID NO: 33. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 35. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 35. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 35. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 35. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 35. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 36. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 36. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 36. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 36. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 36. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 40. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 40. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 40. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 40. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 40. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 42. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 9 and a VL sequence set forth in SEQ ID NO: 43. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 44. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 45. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 47. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 48. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 49. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 50. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 52. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 53. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 54. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 55. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 56. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 57. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 10 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 11 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 12 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 13 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 14 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 16 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 17 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 18 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 19 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 20 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 21 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 22 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 23 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 24 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 25 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 26 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 27 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 28 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 28 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 29 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 30 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 31 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 32 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 39. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 51. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471.

In certain embodiments, the isolated antibody comprises a heavy chain variable domain comprising a framework region sequence selected from a sequence set forth in SEQ ID NOs: 198-229, 255-256, 258-259, 261-285, 311-315, 317-342, 368-369, 371-399, and 540-580. In certain embodiments, the isolated antibody comprises a heavy chain variable domain comprising 1, 2, 3, or 4 framework region sequences selected from a sequence set forth in SEQ ID NOs: 198-229, 255-256, 258-259, 261-285, 311-315, 317-342, 368-369, 371-399, and 540-580.

In certain embodiments, the isolated antibody comprises a light chain variable domain comprising a framework region sequence selected from a sequence set forth in SEQ ID NOs: 230-231, 233-235, 239, 241-254, 286, 288, 290-291, 293, 296-310, 343-345, 347, 400-424, and 581-609. In certain embodiments, the isolated antibody comprises a light chain variable domain comprising 1, 2, 3, or 4 framework region sequences selected from a sequence set forth in SEQ ID NOs: 230-231, 233-235, 239, 241-254, 286, 288, 290-291, 293, 296-310, 343-345, 347, 400-424, and 581-609.

In certain embodiments, the isolated antibody comprises a heavy chain variable domain comprising 1, 2, 3, or 4 framework region sequences selected from a sequence set forth in SEQ ID NOs: 198-229, 255-256, 258-259, 261-285, 311-315, 317-342, 368-369, 371-399, and 540-580, and comprises a light chain variable domain comprising 1, 2, 3, or 4 framework region sequences selected from a sequence set forth in SEQ ID NOs: 230-231, 233-235, 239, 241-254, 286, 288, 290-291, 293, 296-310, 343-345, 347, 400-424, and 581-609.

TABLE 2

Anti-interleukin (IL)-13 antibody VH-VL sequences

VH; VL; HC

constant;

and LC

constant

Construct
names,

ID
respectively*
VH sequence
VL sequence

1
Lebrikizumab-
QVTLRESGPALVKPTQ
DIVMTQSPDSLSVSLGER

(Lebrikizumab)
HC;
TLTLTCTVSGFSLSAYS
ATINCRASKSVDSYGNSF

Lebrikizumab-
VNWIRQPPGKALEWLA
MHWYQQKPGQPPKLLIY

LC;
MIWGDGKIVYNSALKS
LASNLESGVPDRFSGSGS

IgG4-SP;
RLTISKDTSKNQVVLT
GTDFTLTISSLQAEDVAV

Human
MTNMDPVDTATYYCA
YYCQQNNEDPRTFGGGT

kappa LC
GDGYYPYAMDNWGQ
KVEIK (SEQ ID NO: 471)

GSLVTVSS (SEQ ID NO:

470)

2
Lebrikizumab-
QVTLRESGPALVKPTQ
DIVMTQSPDSLSVSLGER

HC;
TLTLTCTVSGFSLSAYS
ATINCRASKSVDSYGNSF

Lebrikizumab-
VNWIRQPPGKALEWLA
MHWYQQKPGQPPKLLIY

LC;
MIWGDGKIVYNSALKS
LASNLESGVPDRFSGSGS

hIgG1-
RLTISKDTSKNQVVLT
GTDFTLTISSLQAEDVAV

LAGA YTE;
MTNMDPVDTATYYCA
YYCQQNNEDPRTFGGGT

Human
GDGYYPYAMDNWGQ
KVEIK (SEQ ID NO: 471)

kappa LC
GSLVTVSS (SEQ ID NO:

470)

3
HC0; LC0;
QVQLQESGPGLVAPSQ
NIVLTQSPASLAVSLGQR

hIgG1-
SLSITCTVSGFSLNAYS
ATISCRASKSVDSYGNSF

LAGA YTE;
VNWVRQPPGKGLEWL
MHWYQQKPGQPPKLLIY

Human
GMIWGDGKIVYNSALK
LASNLESGVPARFSGSGS

kappa LC
SRLNISKDSSKSQVFLK
RTDFTLTIDPVEADDAAS

MSSLQSDDTARYYCAG
YYCQQNNEDPRTFGGGT

DGYYPYAMDNWGHGT
KLEIK (SEQ ID NO: 33)

SVTVSS (SEQ ID NO: 1)

4
HC0_M;
QVQLQESGPGLVAPSQ
NIVLTQSPASLAVSLGQR

LC0; hIgG1-
SLSITCTVSGFSLNAYS
ATISCRASKSVDSYGNSF

LAGA YTE;
VNWVRQPPGKGLEWL
MHWYQQKPGQPPKLLIY

Human
GMIWGDGKIVYNSALK
LASNLESGVPARFSGSGS

kappa LC
SRLTISKDSSKSQVFLK
RTDFTLTIDPVEADDAAS

MSSLQSDDTARYYCAG
YYCQQNNEDPRTFGGGT

DGYYPYAMDNWGHGT
KLEIK (SEQ ID NO: 33)

SVTVSS (SEQ ID NO: 2)

5
HC1; LC2;
EVQLQESGPGLVKPSET
DIQLTQSPSSLSASVGDRV

hIgG1-
LSLTCTVSGFSLNAYSV
TITCRASKSVDSYGNSFM

LAGA YTE;
NWIRQPPGKGLEWLG
HWYQQKPGKAPKLLIYL

Human
MIWGDGKIVYNSALKS
ASNLESGVPSRFSGSGSRT

kappa LC
RLTISKDSSKNQVSLKL
DFTLTISSLQPEDFATYYC

SSVTAADTAVYYCAGD
QQNNEDPRTFGGGTKVEI

GYYPYAMDNWGQGTT
K (SEQ ID NO: 35)

VTVSS (SEQ ID NO: 3)

6
HC2; LC2;
EVQLVQSGAEVKKPGA
DIQLTQSPSSLSASVGDRV

hIgG1-
SVKVSCKASGFSLNAY
TITCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGKAPKLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGVPSRFSGSGSRT

kappa LC
KSRLTITKDSSTSTVYM
DFTLTISSLQPEDFATYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 35)

GTTVTVSS (SEQ ID NO:

4)

7
HC3; LC2;
EVQLVQSGAEVKKPGS
DIQLTQSPSSLSASVGDRV

hIgG1-
SVKVSCKASGFSLNAY
TITCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGKAPKLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGVPSRFSGSGSRT

kappa LC
KSRLTITKDSSTSTVYM
DFTLTISSLQPEDFATYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 35)

GTTVTVSS (SEQ ID NO:

5)

8
HC4; LC2;
EVQLVESGGGLVKPGG
DIQLTQSPSSLSASVGDRV

hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSRT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLKTEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 35)

GTTVTVSS (SEQ ID NO:

6)

9
HC5; LC2;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSRT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 35)

GTTVTVSS (SEQ ID NO:

7)

10
HC1; LC3;
EVQLQESGPGLVKPSET
EIVLTQSPATLSVSPGERA

hIgG1-
LSLTCTVSGFSLNAYSV
TLSCRASKSVDSYGNSFM

LAGA YTE;
NWIRQPPGKGLEWLG
HWYQQKPGQAPRLLIYL

Human
MIWGDGKIVYNSALKS
ASNLESGIPARFSGSGSRT

kappa LC
RLTISKDSSKNQVSLKL
EFTLTISSLQSEDFAVYYC

SSVTAADTAVYYCAGD
QQNNEDPRTFGGGTKVEI

GYYPYAMDNWGQGTT
K (SEQ ID NO: 36)

VTVSS (SEQ ID NO: 3)

11
HC2; LC3;
EVQLVQSGAEVKKPGA
EIVLTQSPATLSVSPGERA

hIgG1-
SVKVSCKASGFSLNAY
TLSCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGQAPRLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGIPARFSGSGSRT

kappa LC
KSRLTITKDSSTSTVYM
EFTLTISSLQSEDFAVYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 36)

GTTVTVSS (SEQ ID NO:

4)

12
HC3; LC3;
EVQLVQSGAEVKKPGS
EIVLTQSPATLSVSPGERA

hIgG1-
SVKVSCKASGFSLNAY
TLSCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGQAPRLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGIPARFSGSGSRT

kappa LC
KSRLTITKDSSTSTVYM
EFTLTISSLQSEDFAVYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 36)

GTTVTVSS (SEQ ID NO:

5)

13
HC4; LC3;
EVQLVESGGGLVKPGG
EIVLTQSPATLSVSPGERA

hIgG1-
SLRLSCAASGFSLNAYS
TLSCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGQAPRLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGIPARFSGSGSRT

kappa LC
SRLTISKDSSKNTVYLQ
EFTLTISSLQSEDFAVYYC

MNSLKTEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 36)

GTTVTVSS (SEQ ID NO:

6)

14
HC5; LC3;
EVQLLESGGGLVQPGG
EIVLTQSPATLSVSPGERA

hIgG1-
SLRLSCAASGFSLNAYS
TLSCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGQAPRLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGIPARFSGSGSRT

kappa LC
SRLTISKDSSKNTVYLQ
EFTLTISSLQSEDFAVYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 36)

GTTVTVSS (SEQ ID NO:

7)

15
HC1; LC6;
EVQLQESGPGLVKPSET
DIQLTQSPSSLSASVGDRV

hIgG1-
LSLTCTVSGFSLNAYSV
TITCRASKSVDSYGNSFM

LAGA YTE;
NWIRQPPGKGLEWLG
HWYQQKPGKAPKLLIYL

Human
MIWGDGKIVYNSALKS
ASNLESGVPSRFSGSGSGT

kappa LC
RLTISKDSSKNQVSLKL
DFTLTISSLQPEDFATYYC

SSVTAADTAVYYCAGD
QQNNEDPRTFGGGTKVEI

GYYPYAMDNWGQGTT
K (SEQ ID NO: 39)

VTVSS (SEQ ID NO: 3)

16
HC2; LC6;
EVQLVQSGAEVKKPGS
DIQLTQSPSSLSASVGDRV

hIgG1-
SVKVSCKASGFSLNAY
TITCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGKAPKLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGVPSRFSGSGSGT

kappa LC
KSRLTITKDSSTSTVYM
DFTLTISSLQPEDFATYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

4)

17
HC3; LC6;
EVQLVQSGAEVKKPGS
DIQLTQSPSSLSASVGDRV

hIgG1-
SVKVSCKASGFSLNAY
TITCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGKAPKLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGVPSRFSGSGSGT

kappa LC
KSRLTITKDSSTSTVYM
DFTLTISSLQPEDFATYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

5)

18
HC4; LC6;
EVQLVESGGGLVKPGG
DIQLTQSPSSLSASVGDRV

hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLKTEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

6)

19
HC5; LC6;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

7)

20
HC1; LC7;
EVQLQESGPGLVKPSET
EIVLTQSPATLSVSPGERA

hIgG1-
LSLTCTVSGFSLNAYSV
TLSCRASKSVDSYGNSFM

LAGA YTE;
NWIRQPPGKGLEWLG
HWYQQKPGQAPRLLIYL

Human
MIWGDGKIVYNSALKS
ASNLESGIPARFSGSGSGT

kappa LC
RLTISKDSSKNQVSLKL
EFTLTISSLQSEDFAVYYC

SSVTAADTAVYYCAGD
QQNNEDPRTFGGGTKVEI

GYYPYAMDNWGQGTT
K (SEQ ID NO: 40)

VTVSS (SEQ ID NO: 3)

21
HC2; LC7;
EVQLVQSGAEVKKPGS
EIVLTQSPATLSVSPGERA

hIgG1-
SVKVSCKASGFSLNAY
TLSCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGQAPRLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGIPARFSGSGSGT

kappa LC
KSRLTITKDSSTSTVYM
EFTLTISSLQSEDFAVYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 40)

GTTVTVSS (SEQ ID NO:

4)

22
HC3; LC7;
EVQLVQSGAEVKKPGS
EIVLTQSPATLSVSPGERA

hIgG1-
SVKVSCKASGFSLNAY
TLSCRASKSVDSYGNSFM

LAGA YTE;
SVNWVRQAPGQGLEW
HWYQQKPGQAPRLLIYL

Human
LGMIWGDGKIVYNSAL
ASNLESGIPARFSGSGSGT

kappa LC
KSRLTITKDSSTSTVYM
EFTLTISSLQSEDFAVYYC

ELSSLRSEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 40)

GTTVTVSS (SEQ ID NO:

5)

23
HC4; LC7;
EVQLVESGGGLVKPGG
EIVLTQSPATLSVSPGERA

hIgG1-
SLRLSCAASGFSLNAYS
TLSCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGQAPRLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGIPARFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
EFTLTISSLQSEDFAVYYC

MNSLKTEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 40)

GTTVTVSS (SEQ ID NO:

6)

24
HC5; LC7;
EVQLLESGGGLVQPGG
EIVLTQSPATLSVSPGERA

hIgG1-
SLRLSCAASGFSLNAYS
TLSCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGQAPRLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGIPARFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
EFTLTISSLQSEDFAVYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 40)

GTTVTVSS (SEQ ID NO:

7)

25
HC6; LC9;
EVQLQESGPGLVKPSET
DIVLTQSPASLAVSPGERA

hIgG1-
LSLTCTVSGGSLNAYSV
TISCRASKSVDSYGNSFM

LAGA YTE;
NWVRQPPGKGLEWLG
HWYQQKPGQPPKLLIYLA

Human
MIWGDGKIVYNSALKS
SNLESGVPDRFSGSGSGT

kappa LC
RLTISLDTSKSQVFLKM
DFTLTISRVEADDVAVYY

SSLTAADTAVYYCARD
CQQNNEDPRTFGGGTKLE

GYYPYAMDNWGQGTT
IK (SEQ ID NO: 42)

VTVSS (SEQ ID NO: 8)

26
HC7; LC10;
QVQLQESGPGLVKPSE
DIVLTQSPASLAVSPGERA

hIgG1-
TLSLTCTVSGGSLNAYS
TISCRASQSVDSNGNNFL

LAGA YTE;
WNWVRQPPGKGLEWL
HWYQQKPGQPPKLLIYLA

Human
GYIYGDGKTNYNPALK
SNRESGVPDRFSGSGSGT

kappa LC
SRLTISLDTSKSQVFLK
DFTLTISRVEADDVAVYY

MSSLTAADTAVYYCAR
CQQNNHTPRTFGGGTKLE

DGYYYYAMDVWGQG
IK (SEQ ID NO: 43)

TTVTVSS (SEQ ID NO:

9)

90
HC5; LC6;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

7)

91
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m1;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSRM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 44)

GTTVTVSS (SEQ ID NO:

7)

92
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m2;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSSM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 45)

GTTVTVSS (SEQ ID NO:

7)

93
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m3;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIRL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 46)

GTTVTVSS (SEQ ID NO:

7)

94
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m4;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIFLA

LAGA YTE;
GMIWGDGKIVYNSALK
SNLESGVPSRFSGSGSGTD

Human
SRLTISKDSSKNTVYLQ
FTLTISSLQPEDFATYYCQ

kappa LC
MNSLRAEDTAVYYCA
QNNEDPRTFGGGTKVEIK

GDGYYPYAMDNWGQ
(SEQ ID NO: 47)

GTTVTVSS (SEQ ID NO:

7)

95
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m5;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASHLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 48)

GTTVTVSS (SEQ ID NO:

7)

96
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m6;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASDLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 49)

GTTVTVSS (SEQ ID NO:

7)

97
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m7;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASQLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 50)

GTTVTVSS (SEQ ID NO:

7)

98
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m8;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASELESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 51)

GTTVTVSS (SEQ ID NO:

7)

99
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m9;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNHEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 52)

GTTVTVSS (SEQ ID NO:

7)

100
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m10;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNYEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 53)

GTTVTVSS (SEQ ID NO:

7)

101
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m11;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNSEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 54)

GTTVTVSS (SEQ ID NO:

7)

102
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m12;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNRDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 55)

GTTVTVSS (SEQ ID NO:

7)

103
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m13;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNDDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 56)

GTTVTVSS (SEQ ID NO:

7)

104
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6_m14;
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

hIgG1-
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

LAGA YTE;
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

Human
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

kappa LC
MNSLRAEDTAVYYCA
QQNNQDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 57)

GTTVTVSS (SEQ ID NO:

7)

105
HC5_m1;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGYSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

10)

106
HC5_m2;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLRAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

11)

107
HC5_m3;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLHAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

12)

108
HC5_m4;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLDAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

13)

109
HC5_m5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLYAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

14)

110
HC5_m6;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLSAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

15)

111
HC5_m7;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNRYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

16)

112
HC5_m8;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNKYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

17)

113
HC5_m9;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNHYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

18)

114
HC5_m10;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNQYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

19)

115
HC5_m11;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNEYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

20)

116
HC5_m12;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNSYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

21)

117
HC5_m13;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNYYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

22)

118
HC5_m14;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAES
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

23)

119
HC5_m15;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWSDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

24)

120
HC5_m16;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWADGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

25)

121
HC5_m17;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GHGYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

26)

122
HC5_m18;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDLYYPYAMDNWGQG
K (SEQ ID NO: 39)

TTVTVSS (SEQ ID NO:

27)

123
HC5_m19;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDKYYPYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

28)

124
HC5_m20;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYGYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

29)

125
HC5_m21;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYAYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

30)

126
HC5_m22;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYSYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

31)

127
HC5_m23;
EVQLLESGGGLVQPGG
DIQLTQSPSSLSASVGDRV

LC6; hIgG1-
SLRLSCAASGFSLNAYS
TITCRASKSVDSYGNSFM

LAGA YTE;
VNWVRQAPGKGLEWL
HWYQQKPGKAPKLLIYL

Human
GMIWGDGKIVYNSALK
ASNLESGVPSRFSGSGSGT

kappa LC
SRLTISKDSSKNTVYLQ
DFTLTISSLQPEDFATYYC

MNSLRAEDTAVYYCA
QQNNEDPRTFGGGTKVEI

GDGYYTYAMDNWGQ
K (SEQ ID NO: 39)

GTTVTVSS (SEQ ID NO:

32)

128
Lebrikizumab-
QVTLRESGPALVKPTQ
DIVMTQSPDSL

HC;
TLTLTCTVSGFSLSAYS
SVSLGERATIN

Lebrikizumab-
VNWIRQPPGKALEWL
CRASKSVDSY

LC;
AMIWGDGKIVYNSAL
GNSFMHWYQ

hIgG4-YTE;
KSRLTISKDTSKNQVV
QKPGQPPKLLI

Human
LTMTNMDPVDTATYY
YLASNLESGVP

kappa LC
CAGDGYYPYAMDNW
DRFSGSGSGTD

GQGSLVTVSS (SEQ ID
FTLTISSLQAED

NO: 470)
VAVYYCQQNN

EDPRTFGGGTK

VEIK (SEQ ID

NO: 471)

129
Lebrikizumab-
QVTLRESGPALVKPTQ
DIVMTQSPDSL

HC;
TLTLTCTVSGFSLSAYS
SVSLGERATIN

Lebrikizumab-
VNWIRQPPGKALEWL
CRASKSVDSY

LC;
AMIWGDGKIVYNSAL
GNSFMHWYQ

hIgG4-LS;
KSRLTISKDTSKNQVV
QKPGQPPKLLI

Human
LTMTNMDPVDTATYY
YLASNLESGVP

kappa LC
CAGDGYYPYAMDNW
DRFSGSGSGTD

GQGSLVTVSS (SEQ ID
FTLTISSLQAED

NO: 470)
VAVYYCQQNN

EDPRTFGGGTK

VEIK (SEQ ID

NO: 471)

130
Lebrikizumab-
QVTLRESGPALVKPTQ
DIVMTQSPDSL

HC;
TLTLTCTVSGFSLSAYS
SVSLGERATIN

Lebrikizumab-
VNWIRQPPGKALEWL
CRASKSVDSY

LC;
AMIWGDGKIVYNSAL
GNSFMHWYQ

hIgG1-
KSRLTISKDTSKNQVV
QKPGQPPKLLI

LALA-YTE;
LTMTNMDPVDTATYY
YLASNLESGVP

Human
CAGDGYYPYAMDNW
DRFSGSGSGTD

kappa LC
GQGSLVTVSS (SEQ ID
FTLTISSLQAED

NO: 470)
VAVYYCQQNN

EDPRTFGGGTK

VEIK (SEQ ID

NO: 471)

131
Lebrikizumab-
QVTLRESGPALVKPTQ
DIVMTQSPDSL

HC;
TLTLTCTVSGFSLSAYS
SVSLGERATIN

Lebrikizumab-
VNWIRQPPGKALEWL
CRASKSVDSY

LC;
AMIWGDGKIVYNSAL
GNSFMHWYQ

hIgG1-
KSRLTISKDTSKNQVV
QKPGQPPKLLI

LALA-LS;
LTMTNMDPVDTATYY
YLASNLESGVP

Human
CAGDGYYPYAMDNW
DRFSGSGSGTD

kappa LC
GQGSLVTVSS (SEQ ID
FTLTISSLQAED

NO: 470)
VAVYYCQQNN

EDPRTFGGGTK

VEIK (SEQ ID

NO: 471)

132
HC5; LC6;
EVQLLESGGGLVQPGG
DIQLTQSPSSLS

hIgG1-
SLRLSCAASGFSLNAY
ASVGDRVTITC

LALA YTE;
SVNWVRQAPGKGLEW
RASKSVDSYG

Human
LGMIWGDGKIVYNSA
NSFMHWYQQ

kappa LC
LKSRLTISKDSSKNTVY
KPGKAPKLLIY

LQMNSLRAEDTAVYY
LASNLESGVPS

CAGDGYYPYAMDNW
RFSGSGSGTDF

GQGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 7)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 39)

133
HC1; LC6;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

hIgG1-
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

LALA YTE;
VNWIRQPPGKGLEWL
RASKSVDSYG

Human
GMIWGDGKIVYNSAL
NSFMHWYQQ

kappa LC
KSRLTISKDSSKNQVSL
KPGKAPKLLIY

KLSSVTAADTAVYYC
LASNLESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 39)

134
HC1; LC6;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

hIgG4-YTE;
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

Human
VNWIRQPPGKGLEWL
RASKSVDSYG

kappa LC
GMIWGDGKIVYNSAL
NSFMHWYQQ

KSRLTISKDSSKNQVSL
KPGKAPKLLIY

KLSSVTAADTAVYYC
LASNLESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 39)

135
HC1; LC6;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

hIgG4-LS;
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

Human
VNWIRQPPGKGLEWL
RASKSVDSYG

kappa LC
GMIWGDGKIVYNSAL
NSFMHWYQQ

KSRLTISKDSSKNQVSL
KPGKAPKLLIY

KLSSVTAADTAVYYC
LASNLESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 39)

136
HC1; LC6;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

hIgG1-
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

LALA LS;
VNWIRQPPGKGLEWL
RASKSVDSYG

Human
GMIWGDGKIVYNSAL
NSFMHWYQQ

kappa LC
KSRLTISKDSSKNQVSL
KPGKAPKLLIY

KLSSVTAADTAVYYC
LASNLESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 39)

137
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLS

LC6_m8;
SLRLSCAASGFSLNAY
ASVGDRVTITC

hIgG1-
SVNWVRQAPGKGLEW
RASKSVDSYG

LALA YTE;
LGMIWGDGKIVYNSA
NSFMHWYQQ

Human
LKSRLTISKDSSKNTVY
KPGKAPKLLIY

kappa LC
LQMNSLRAEDTAVYY
LASELESGVPS

CAGDGYYPYAMDNW
RFSGSGSGTDF

GQGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 7)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

138
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLS

LC6_m8;
SLRLSCAASGFSLNAY
ASVGDRVTITC

hIgG4-YTE;
SVNWVRQAPGKGLEW
RASKSVDSYG

Human
LGMIWGDGKIVYNSA
NSFMHWYQQ

kappa LC
LKSRLTISKDSSKNTVY
KPGKAPKLLIY

LQMNSLRAEDTAVYY
LASELESGVPS

CAGDGYYPYAMDNW
RFSGSGSGTDF

GQGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 7)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

139
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLS

LC6_m8;
SLRLSCAASGFSLNAY
ASVGDRVTITC

hIgG4-LS;
SVNWVRQAPGKGLEW
RASKSVDSYG

Human
LGMIWGDGKIVYNSA
NSFMHWYQQ

kappa LC
LKSRLTISKDSSKNTVY
KPGKAPKLLIY

LQMNSLRAEDTAVYY
LASELESGVPS

CAGDGYYPYAMDNW
RFSGSGSGTDF

GQGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 7)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

140
HC5;
EVQLLESGGGLVQPGG
DIQLTQSPSSLS

LC6_m8;
SLRLSCAASGFSLNAY
ASVGDRVTITC

hIgG1-
SVNWVRQAPGKGLEW
RASKSVDSYG

LALA LS;
LGMIWGDGKIVYNSA
NSFMHWYQQ

Human
LKSRLTISKDSSKNTVY
KPGKAPKLLIY

kappa LC
LQMNSLRAEDTAVYY
LASELESGVPS

CAGDGYYPYAMDNW
RFSGSGSGTDF

GQGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 7)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

141
HC1;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

LC6_m8;
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

hIgG1-
VNWIRQPPGKGLEWL
RASKSVDSYG

LALA YTE;
GMIWGDGKIVYNSAL
NSFMHWYQQ

Human
KSRLTISKDSSKNQVSL
KPGKAPKLLIY

kappa LC
KLSSVTAADTAVYYC
LASELESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

142
HC1;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

LC6_m8;
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

hIgG4 YTE;
VNWIRQPPGKGLEWL
RASKSVDSYG

Human
GMIWGDGKIVYNSAL
NSFMHWYQQ

kappa LC
KSRLTISKDSSKNQVSL
KPGKAPKLLIY

KLSSVTAADTAVYYC
LASELESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

143
HC1;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

LC6_m8;
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

hIgG4 LS;
VNWIRQPPGKGLEWL
RASKSVDSYG

Human
GMIWGDGKIVYNSAL
NSFMHWYQQ

kappa LC
KSRLTISKDSSKNQVSL
KPGKAPKLLIY

KLSSVTAADTAVYYC
LASELESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

144
HC1;
EVQLQESGPGLVKPSE
DIQLTQSPSSLS

LC6_m8;
TLSLTCTVSGFSLNAYS
ASVGDRVTITC

hIgG1-
VNWIRQPPGKGLEWL
RASKSVDSYG

LALA LS;
GMIWGDGKIVYNSAL
NSFMHWYQQ

Human
KSRLTISKDSSKNQVSL
KPGKAPKLLIY

kappa LC
KLSSVTAADTAVYYC
LASELESGVPS

AGDGYYPYAMDNWG
RFSGSGSGTDF

QGTTVTVSS (SEQ ID
TLTISSLQPEDF

NO: 3)
ATYYCQQNNE

DPRTFGGGTK

VEIK (SEQ ID

NO: 51)

*Names correspond with name in informal sequence listing

In some embodiments, such a IgG4-SP HC constant domain has the sequence:

(SEQ ID NO: 427)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS

NTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY

RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE

PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN

YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH

YTQKSLSLSLGK.

In some embodiments, such a hIgG1-LALA-YTE HC constant domain has the sequence:

(SEQ ID NO: 439)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS

NTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLY

ITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN

STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP

ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HNHYTQKSLSLSPG.

In some embodiments, such a hIgG1-LAGA YTE HC constant domain has the sequence:

(SEQ ID NO: 440)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS

NTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLY

ITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN

STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP

ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HNHYTQKSLSLSPG.

In some embodiments, such a hIgG1-LALA-LS HC constant domain has the sequence:

(SEQ ID NO: 446)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS

NTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLM

ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN

STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP

ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEAL

HSHYTQKSLSLSPG.

In some embodiments, such a IgG4-YTE HC constant domain has the sequence:

(SEQ ID NO: 457)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS

NTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLYITR

EPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY

RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE

PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN

YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH

YTQKSLSLSLGK.

In some embodiments, such a IgG4-LS HC constant domain has the sequence:

(SEQ ID NO: 460)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS

NTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISR

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY

RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE

PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN

YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHSY

TQKSLSLSLGK.

In some embodiments, such a human kappa LC constant domain has the sequence:

(SEQ ID NO: 469)

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN

ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT

HQGLSSPVTKSFNRGEC.

CDRs

In some embodiments, an antibody provided herein comprises one to three CDRs of a VH domain selected from SEQ ID NOs: 1-32 and 470, such as any of the CDRs listed in Table 3, Table 4, or Table 5, below. In some embodiments, an antibody provided herein comprises two to three CDRs of a VH domain selected from SEQ ID NOs: 1-32 and 470. In some embodiments, an antibody provided herein comprises three CDRs of a VH domain selected from SEQ ID NOs: 1-32 and 470. In some embodiments, the CDRs are Exemplary CDRs. In some embodiments, the CDRs are Kabat CDRs. In some embodiments, the CDRs are Chothia CDRs. In some embodiments, the CDRs are IMGT CDRs. In some embodiments, the CDRs are AbM CDRs. In some embodiments, the CDRs are Contact CDRs.

In some embodiments, the CDRs are CDRs having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with a CDR-H1, CDR-H2, or CDR-H3 of SEQ ID NOs: 58-140. In some embodiments, the CDR-H1 is a CDR-H1 of a VH domain selected from SEQ ID NOs: 1-32 and 470, with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some embodiments, the CDR-H2 is a CDR-H2 of a VH domain of SEQ ID NO: 1-32 and 470, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the CDR-H3 is a CDR-H3 of a VH domain selected from SEQ ID NOs: 1-32 and 470, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises one to three CDRs of a VL domain of SEQ ID NOs: 33-57 and 471, such as any of the CDRs listed in Table 6, Table 7, or Table 8, below. In some embodiments, an antibody provided herein comprises two to three CDRs of a VL domain of SEQ ID NOs: 33-57 and 471. In some embodiments, an antibody provided herein comprises three CDRs of a VL domain of SEQ ID NOs: 33-57 and 471. In some embodiments, the CDRs are Exemplary CDRs. In some embodiments, the CDRs are Kabat CDRs. In some embodiments, the CDRs are Chothia CDRs. In some embodiments, the CDRs are IMGT CDRs. In some embodiments, the CDRs are AbM CDRs. In some embodiments, the CDRs are Contact CDRs.

In some embodiments, the CDRs are CDRs having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with a CDR-L1, CDR-L2, or CDR-L3 of SEQ ID NOs: 141-188. In some embodiments, the CDR-L1 is a CDR-L1 of a VL domain of SEQ ID NOs: 33-57 and 471, with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some embodiments, the CDR-L2 is a CDR-L2 of a VL domain of SEQ ID NOs: 33-57 and 471, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the CDR-L3 is a CDR-L3 of a VL domain of SEQ ID NOs: 33-57 and 471, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises one to three CDRs of a VH domain selected from SEQ ID NOs: 1-32 and 470 and one to three CDRs of a VL domain of SEQ ID NOs: 33-57 and 471. In some embodiments, an antibody provided herein comprises two to three CDRs of a VH domain selected from SEQ ID NOs: 1-32 and 470 and two to three CDRs of a VL domain of SEQ ID NOs: 33-57 and 471. In some embodiments, an antibody provided herein comprises three CDRs of a VH domain selected from SEQ ID NOs: 1-32 and 470 and three CDRs of a VL domain of SEQ ID NOs: 33-57 and 471. In some embodiments, the CDRs are Exemplary CDRs. In some embodiments, the CDRs are Kabat CDRs. In some embodiments, the CDRs are Chothia CDRs. In some embodiments, the CDRs are IMGT CDRs. In some embodiments, the CDRs are AbM CDRs. In some embodiments, the CDRs are Contact CDRs.

In some embodiments, an antibody provided herein comprises a CDR-H3 selected of SEQ ID NOs: 112-120 and 130-40. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H3 of SEQ ID NOs: 112-120 or 130-40. In some embodiments, the CDR-H3 is a CDR-H3 selected of SEQ ID NOs: 112-120 and 130-40, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises a CDR-H1 of SEQ ID NOs: 58-99 and 121. In some embodiments, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H1 of SEQ ID NOs: 58-99 or 121. In some embodiments, the CDR-H1 is a CDR-H1 of SEQ ID NOs: 58-99 or 121, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises a CDR-H2 of any one of SEQ ID NOs: 100-111. In some embodiments, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H2 of any one of SEQ ID NOs: 100-111. In some embodiments, the CDR-H2 is a CDR-H2 of any one of SEQ ID NOs: 100-111, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises a CDR-L3 selected from SEQ ID NOs: 165-172. In some embodiments, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L3 of SEQ ID NOs: 165-172. In some embodiments, the CDR-L3 is a CDR-L3 of SEQ ID NOs: 165-172, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises a CDR-L2 selected from SEQ ID NOs: 153-158 and the amino acid sequence LAS. In some embodiments, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L2 selected from SEQ ID NOs: 153-158 and the amino acid sequence LAS. In some embodiments, the CDR-L2 is a CDR-L2 selected from SEQ ID NOs: 153-158 and the amino acid sequence LAS, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises a CDR-L1 selected from SEQ ID NOs: 141-144 and 149-152. In some embodiments, the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L1 selected from SEQ ID NOs: 141-144 and 149-152. In some embodiments, the CDR-L1 is a CDR-L1 selected from SEQ ID NOs: 141-144 and 149-152, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In some embodiments, an antibody provided herein comprises a CDR-H3 selected from SEQ ID NOs: 112-120 and 130-140, a CDR-H2 of SEQ ID NOs: 100-111, a CDR-H1 selected from SEQ ID NOs: 58-99 and 121, a CDR-L3 selected from SEQ ID NOs: 165-172, a CDR-L2 selected from SEQ ID NOs: 153-158 and the amino acid sequence LAS, and a CDR-L1 selected from SEQ ID NOs: 141-144 and 149-152. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H3 selected from SEQ ID NOs: 112-120 and 130-140, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H2 of SEQ ID NOs: 100-111, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H1 selected from SEQ ID NOs: 58-99 and 121, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L3 selected from SEQ ID NOs: 165-172, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L2 selected from SEQ ID NOs: 153-158 and the amino acid sequence LAS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L1 selected from SEQ ID NOs: 141-144 and 149-152. In some embodiments, the CDR-H3 is a CDR-H3 selected from SEQ ID NOs: 112-120 and 130-140, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of SEQ ID NOs: 100-111, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 selected from SEQ ID NOs: 58-99 and 121, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 selected from SEQ ID NOs: 165-172, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 selected from SEQ ID NOs: 153-158 and the amino acid sequence LAS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 selected from SEQ ID NOs: 141-144 and 149-152, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

In some embodiments, an antibody provided herein comprises a CDR-H3 of SEQ ID NOs: 112, 121, and 130, a CDR-H2 of SEQ ID NOs: 100, 104, and 108, a CDR-H1 of SEQ ID NOs: 58, 68, and 85, a CDR-L3 of SEQ ID NOs: 168, 173, and 181, a CDR-L2 of SEQ ID NOs: 153 and the amino acid sequence LAS, and a CDR-L1 of SEQ ID NOs: 141 and 149. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H3 of SEQ ID NOs: 112 or 130, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H2 of SEQ ID NOs: 100, 104 or 108, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H1 of SEQ ID NOs: 58, 68 or 85, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L3 of SEQ ID NO: 168, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L2 of SEQ ID NOs: 153 or the amino acid sequence LAS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 is a CDR-H3 of SEQ ID NOs: 112 or 130, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of SEQ ID NOs: 100, 104 or 108, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 of SEQ ID NOs: 58, 68 or 85, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 of SEQ ID NO: 168 with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 of SEQ ID NOs: 153 or the amino acid sequence LAS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 of SEQ ID NOs: 141 or 149, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

In some embodiments, an antibody provided herein comprises a CDR-H3 of SEQ ID NOs: 112, 121 or 130, a CDR-H2 of SEQ ID NOs: 100, 104 or 108, a CDR-H1 of SEQ ID NOs: 58, 68, or 85, a CDR-L3 of SEQ ID NO: 165, a CDR-L2 of SEQ ID NOs: 153 or the amino acid sequence LAS, and a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H3 of SEQ ID NOs: 112 or 130, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H2 of SEQ ID NOs: 100, 104 or 108, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H1 of SEQ ID NOs: 58, 68 or 85, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L3 of SEQ ID NO: 165, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L2 of SEQ ID NOs: 153 or the amino acid sequence LAS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 is a CDR-H3 of SEQ ID NOs: 112 or 130, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of SEQ ID NOs: 100, 104 or 108, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 of SEQ ID NOs: 58, 68 or 85, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 of SEQ ID NO: 165, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 of SEQ ID NO: 153 or the amino acid sequence LAS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 of SEQ ID NOs: 141 or 149, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

In some embodiments, an antibody provided herein comprises a CDR-H3 of SEQ ID NOs: 112 or 130, a CDR-H2 of SEQ ID NOs: 100, 104, or 108, a CDR-H1 of SEQ ID NOs: 58, 68, or 85, a CDR-L3 of SEQ ID NO: 165, a CDR-L2 of SEQ ID NO: 158 or the amino acid sequence LAS, and a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H3 of SEQ ID NOs: 112 or 130, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H2 of SEQ ID NOs: 100, 104, or 108, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H1 of SEQ ID NOs: 58, 68 or 85, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L3 of SEQ ID NO: 165, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L2 of SEQ ID NO: 158 or the amino acid sequence LAS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 is a CDR-H3 of SEQ ID NOs: 112 or 130, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of SEQ ID NOs: 100, 104, or 108, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 of SEQ ID NOs: 58, 68, or 85, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 of SEQ ID NO: 165, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 of SEQ ID NO: 158 or the amino acid sequence LAS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 of SEQ ID NOs: 141 or 149, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

In some embodiments, an antibody provided herein comprises a CDR-H3 of SEQ ID NOs: 112, 121 or 130, a CDR-H2 of SEQ ID NOs: 100, 104 or 108, a CDR-H1 of SEQ ID NOs: 58, 67, or 84, a CDR-L3 of SEQ ID NO: 165, a CDR-L2 of SEQ ID NOs: 153 or the amino acid sequence LAS, and a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H3 of SEQ ID NOs: 112 or 130, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H2 of SEQ ID NOs: 100, 104 or 108, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H1 of SEQ ID NOs: 58, 67 or 84, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L3 of SEQ ID NO: 165, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L2 of SEQ ID NOs: 153 or the amino acid sequence LAS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 is a CDR-H3 of SEQ ID NOs: 112 or 130, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of SEQ ID NOs: 100, 104 or 108, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 of SEQ ID NOs: 58, 67 or 84, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 of SEQ ID NO: 165, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 of SEQ ID NO: 153 or the amino acid sequence LAS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 of SEQ ID NOs: 141 or 149, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

In some embodiments, an antibody provided herein comprises a CDR-H3 of SEQ ID NOs: 112 or 130, a CDR-H2 of SEQ ID NOs: 100, 104, or 108, a CDR-H1 of SEQ ID NOs: 58, 67, or 84, a CDR-L3 of SEQ ID NO: 165, a CDR-L2 of SEQ ID NO: 158 or the amino acid sequence LAS, and a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H3 of SEQ ID NOs: 112 or 130, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H2 of SEQ ID NOs: 100, 104, or 108, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-H1 of SEQ ID NOs: 58, 67 or 84, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L3 of SEQ ID NO: 165, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L2 of SEQ ID NO: 158 or the amino acid sequence LAS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with a CDR-L1 of SEQ ID NOs: 141 or 149. In some embodiments, the CDR-H3 is a CDR-H3 of SEQ ID NOs: 112 or 130, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of SEQ ID NOs: 100, 104, or 108, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 of SEQ ID NOs: 58, 67, or 84, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 of SEQ ID NO: 165, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 of SEQ ID NO: 158 or the amino acid sequence LAS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 of SEQ ID NOs: 141 or 149, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this disclosure are referred to herein as “variants” or “clones”. In some embodiments, such variants or clones are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants or cones are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

In certain aspects, the antibodies disclosed herein do not include antibodies disclosed in U.S. Pat. No. 9,067,994.

TABLE 3

Anti-interleukin (IL)-13 antibody Heavy Chain Kabat CDRs

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

Construct

ID

ID

ID

ID

ID

ID

ID

ID
VH Name*
FR1
NO:
CDR1
NO:
FR2
NO:
CDR2
NO:
FR3
NO:
CDR3
NO:
FR4
NO:

1
Lebrikizumab
QVTLR
540
AYSVN
58
WIRQP
255
MIWGD
100
RLTIS
311
DGYYP
112
WGQGS
368

(lebrikizumab),
-HC
ESGPA

PGKAL

GKIVY

KDTSK

YAMDN

LVTVS

2, and 128-

LVKPT

EWLA

NSALK

NQVVL

S

131

QTLTL

S

TMTNM

TCTVS

DPVDT

GFSLS

ATYYC

AG

3
HC0
QVQLQ
198
AYSVN
58
WVRQP
256
MIWGD
100
RLNIS
312
DGYYP
112
WGHGT
369

ESGPG

PGKGL

GKIVY

KDSSK

YAMDN

SVTVS

LVAPS

EWLG

NSALK

SQVFL

S

QSLSI

S

KMSSL

TCTVS

QSDDT

GFSLN

ARYYC

AG

4
HC0_M
QVQLQ
198
AYSVN
58
WVRQP
256
MIWGD
100
RLTIS
313
DGYYP
112
WGHGT
369

ESGPG

PGKGL

GKIVY

KDSSK

YAMDN

SVTVS

LVAPS

EWLG

NSALK

SQVFL

S

QSLSI

S

KMSSL

TCTVS

QSDDT

GFSLN

ARYYC

AG

5, 10, 15,
HC1
EVQLQ
200
AYSVN
58
WIRQP
258
MIWGD
100
RLTIS
314
DGYYP
112
WGQGT
371

20, 133-

ESGPG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

136, and

LVKPS

EWLG

NSALK

NQVSL

S

141-144

ETLSL

S

KLSSV

TCTVS

TAADT

GFSLN

AVYYC

AG

6, 11, 16,
HC2
EVQLV
201
AYSVN
58
WVRQA
259
MIWGD
100
RLTIT
315
DGYYP
112
WGQGT
371

and 21

QSGAE

PGQGL

GKIVY

KDSST

YAMDN

TVTVS

VKKPG

EWLG

NSALK

STVYM

S

ASVKV

S

ELSSL

SCKAS

RSEDT

GFSLN

AVYYC

AG

7, 12, 17,
HC3
EVQLV
202
AYSVN
58
WVRQA
259
MIWGD
100
RLTIT
315
DGYYP
112
WGQG
371

and 22

QSGAE

PGQGL

GKIVY

KDSST

TTVTV

VKKPG

EWLG

NSALK

STVYM

YAMD

SSVKV

S

ELSSL

N

SS

SCKAS

RSEDT

GFSLN

AVYYC

AG

8, 13, 18,
HC4
EVQLV
203
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
317
DGYYP
112
WGQGT
371

and 23

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVKPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

KTEDT

GFSLN

AVYYC

AG

9, 14, 19,
HC5
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

24, 90-

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

104, 132,

LVQPG

EWLG

NSALK

NTVYL

S

and 137-

GSLRL

S

QMNSL

140

SCAAS

RAEDT

GFSLN

AVYYC

AG

25
HC6
EVQLQ
205
AYSVN
58
WVRQP
256
MIWGD
100
RLTIS
319
DGYYP
112
WGQGT
371

ESGPG

PGKGL

GKIVY

LDTSK

YAMDN

TVTVS

LVKPS

EWLG

NSALK

SQVFL

S

ETLSL

S

KMSSL

TCTVS

TAADT

GGSLN

AVYYC

AR

26
HC7
QVQLQ
206
AYSWN
541
WVRQP
256
YIYGD
101
RLTIS
319
DGYYY
113
WGQGT
371

ESGPG

PGKGL

GKTNY

LDTSK

YAMDV

TVTVS

LVKPS

EWLG

NPALK

SQVFL

S

ETLSL

S

KMSSL

TCTVS

TAADT

GGSLN

AVYYC

AR

105
HC5_m1
EVQLL
207
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GYSLN

AVYYC

AG

106
HC5_m2
EVQLL
208
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLR

AVYYC

AG

107
HC5_m3
EVQLL
209
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLH

AVYYC

AG

108
HC5_m4
EVQLL
210
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLD

AVYYC

AG

109
HC5_m5
EVQLL
211
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLY

AVYYC

AG

110
HC5_m6
EVQLL
212
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLS

AVYYC

AG

111
HC5_m7
EVQLL
204
RYSVN
59
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

112
HC5_m8
EVQLL
204
KYSVN
60
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

113
HC5_m9
EVQLL
204
HYSVN
61
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

114
HC5_m10
EVQLL
204
QYSVN
62
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

115
HC5_ml1
EVQLL
204
EYSVN
63
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

116
HC5_m12
EVQLL
204
SYSVN
64
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

117
HC5_m13
EVQLL
204
YYSVN
65
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

118
HC5_m14
EVQLL
204
AESVN
66
WVRQA
262
MIWGD
100
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

119
HC5_m15
EVQLL
204
AYSVN
58
WVRQA
262
MIWSD
102
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

120
HC5_m16
EVQLL
204
AYSVN
58
WVRQA
262
MIWAD
103
RLTIS
318
DGYYP
112
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

121
HC5_m17
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
HGYYP
114
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

122
HC5_m18
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DLYYP
115
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

123
HC5_m19
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DKYYP
116
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

124
HC5_m20
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYG
117
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

125
HC5_m21
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYA
118
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

126
HC5_m22
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYS
119
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

127
HC5_m24
EVQLL
204
AYSVN
58
WVRQA
262
MIWGD
100
RLTIS
318
DGYYT
120
WGQGT
371

ESGGG

PGKGL

GKIVY

KDSSK

YAMDN

TVTVS

LVQPG

EWLG

NSALK

NTVYL

S

GSLRL

S

QMNSL

SCAAS

RAEDT

GFSLN

AVYYC

AG

*Names correspond with name in informal sequence listing.

TABLE 4

Anti-interleukin (IL)-13 antibody Heavy Chain Chothia CDRs

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

Construct

ID

ID

ID

ID

ID

ID

ID

ID
VH Name*
FR1
NO:
CDR1
NO:
FR2
NO:
CDR2
NO:
FR3
NO:
CDR3
NO:
FR4
NO:

1
Lebrikizumab
QVTLR
542
GFSLS
67
SVNWI
550
WGDG
104
IVYNS
556
DGYYP
112
WGQG
368

(lebrikizumab),
-HC
ESGPA

AY

RQPPG

K

ALKSR

YAMD

SLVT

2, and

LVKPT

KALE

LTISKD

N

VSS

128-131

QTLTL

WLAMI

TSKNQ

TCTVS

VVLTM

TNMDP

VDTAT

YYCAG

3
HC0
QVQLQ
543
GFSLN
68
SVNW
551
WGDG
104
IVYNS
557
DGYYP
112
WGHG
369

ESGPG

AY

VRQPP

K

ALKSR

YAMD

TSVT

LVAPS

GKGLE

LNISK

N

VSS

QSLSIT

WLGMI

DSSKS

CTVS

QVFLK

MSSLQ

SDDTA

RYYCA

G

4
HC0_M
QVQLQ
543
GFSLN
68
SVNW
551
WGDG
104
IVYNS
558
DGYYP
112
WGHG
369

ESGPG

AY

VRQPP

K

ALKSR

YAMD

TSVTV

LVAPS

GKGLE

LTISKD

N

SS

QSLSIT

WLGMI

SSKSQ

CTVS

VFLKM

SSLQS

DDTAR

YYCAG

5, 10, 15,
HC1
EVQLQ
544
GFSLN
68
SVNWI
552
WGDG
104
IVYNS
559
DGYYP
112
WGQG
371

20, 133-

ESGPG

AY

RQPPG

K

ALKSR

YAMD

TTVT

136, and

LVKPS

KGLE

LTISKD

N

VSS

141-144

ETLSL

WLGMI

SSKNQ

TCTVS

VSLKL

SSVTA

ADTAV

YYCAG

6, 11, 16,
HC2
EVQLV
545
GFSLN
68
SVNW
553
WGDG
104
IVYNS
560
DGYYP
112
WGQG
371

and 21

QSGAE

AY

VRQAP

K

ALKSR

YAMD

TTVT

VKKPG

GQGLE

LTITK

N

VSS

ASVKV

WLGMI

DSSTS

SCKAS

TVYME

LSSLRS

EDTAV

YYCAG

7, 12, 17,
HC3
EVQLV
546
GFSLN
68
SVNW
553
WGDG
104
IVYNS
560
DGYYP
112
WGQG
371

and 22

QSGAE

AY

VRQAP

K

ALKSR

YAMD

TTVT

VKKPG

GQGLE

LTITK

N

VSS

SSVKV

WLGMI

DSSTS

SCKAS

TVYME

LSSLRS

EDTAV

YYCAG

8, 13, 18,
HC4
EVQLV
547
GFSLN
68
SVNW
554
WGDG
104
IVYNS
561
DGYYP
112
WGQG
371

and 23

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVKPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLK

TEDTA

VYYCA

G

9, 14, 19,
HC5
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

24, 90-104,

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

132, and

LVQPG

GKGLE

LTISKD

N

VSS

137-140

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

25
HC6
EVQLQ
544
GGSLN
69
SVNW
551
WGDG
104
IVYNS
563
DGYYP
112
WGQG
371

ESGPG

AY

VRQPP

K

ALKSR

YAMD

TTVT

LVKPS

GKGLE

LTISLD

N

VSS

ETLSL

WLGMI

TSKSQ

TCTVS

VFLKM

SSLTA

ADTAV

YYCAR

26
HC7
QVQLQ
549
GGSLN
69
SWNW
555
YGDG
105
TNYNP
564
DGYY
113
WGQG
371

ESGPG

AY

VRQPP

K

ALKSR

YYAM

TTVT

LVKPS

GKGLE

LTISLD

DV

VSS

ETLSL

WLGYI

TSKSQ

TCTVS

VFLKM

SSLTA

ADTAV

YYCAR

105
HC5_m1
EVQLL
548
GYSLN
71
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

106
HC5_m2
EVQLL
548
GFSLR
72
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

107
HC5_m3
EVQLL
548
GFSLH
73
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

108
HC5_m4
EVQLL
548
GFSLD
74
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

109
HC5_m5
EVQLL
548
GFSLY
75
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

110
HC5_m6
EVQLL
548
GFSLS
67
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

111
HC5_m7
EVQLL
548
GFSLN
76
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

RY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

112
HC5_m8
EVQLL
548
GFSLN
77
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

KY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

113
HC5_m9
EVQLL
548
GFSLN
78
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

HY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

114
HC5_m10
EVQLL
548
GFSLN
79
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

QY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

115
HC5_m11
EVQLL
548
GFSLN
80
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

EY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

116
HC5_m12
EVQLL
548
GFSLN
81
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

SY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

117
HC5_m13
EVQLL
548
GFSLN
82
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

YY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

118
HC5_m14
EVQLL
548
GFSLN
83
SVNW
554
WGDG
104
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AE

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

119
HC5_m15
EVQLL
548
GFSLN
68
SVNW
554
WSDG
106
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

120
HC5_m16
EVQLL
548
GFSLN
68
SVNW
554
WADG
107
IVYNS
562
DGYYP
112
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

121
HC5_m17
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
HGYYP
114
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

122
HC5_m18
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
DLYYP
115
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

123
HC5_m19
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
DKYYP
116
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

124
HC5_m20
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
DGYY
117
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

GYAM

TTVT

LVQPG

GKGLE

LTISKD

DN

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

125
HC5_m21
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
DGYY
118
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

AYAM

TTVT

LVQPG

GKGLE

LTISKD

DN

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

126
HC5_m22
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
DGYYS
119
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

127
HC5_m24
EVQLL
548
GFSLN
68
SVNW
554
WGDG
104
IVYNS
562
DGYYT
120
WGQG
371

ESGGG

AY

VRQAP

K

ALKSR

YAMD

TTVT

LVQPG

GKGLE

LTISKD

N

VSS

GSLRL

WLGMI

SSKNT

SCAAS

VYLQ

MNSLR

AEDTA

VYYCA

G

*Names correspond with name in informal sequence listing.

TABLE 5

Anti-interleukin (IL)-13 antibody Heavy Chain IMGT CDRs

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

Construct

ID

ID

ID

ID

ID

ID

ID

ID
VH Name*
FR1
NO:
CDR1
NO:
FR2
NO:
CDR2
NO:
FR3
NO:
CDR3
NO:
FR4
NO:

1
Lebrikiz-
QVTLR
542
GFSLS
84
VNWI
566
IWGDG
108
VYNSA
572
AGDG
130
WGQG
368

(lebrikiz-
umab - HC
ESGPA

AYS

RQPP

KI

LKSRL

YYPY

SLVT

umab), 2,

LVKPT

GKAL

TISKD

AMDN

VSS

and 128-

QTLTL

EWLA

TSKNQ

131

TCTVS

M

VVLTM

TNMDP

VDTAT

YYC

3
HC0
QVQLQ
543
GFSLN
85
VNWV
567
IWGDG
108
VYNSA
573
AGDG
130
WGHG
369

ESGPG

AYS

RQPP

KI

LKSRL

YYPY

TSVT

LVAPS

GKGL

NISKD

AMDN

VSS

QSLSI

EWLG

SSKSQ

TCTVS

M

VFLKM

SSLQS

DDTAR

YYC

4
HC0_M
QVQLQ
543
GFSLN
85
VNWV
567
IWGDG
108
VYNSA
574
AGDG
130
WGHG
369

ESGPG

AYS

RQPP

KI

LKSRL

YYPY

TSVT

LVAPS

GKGL

TISKD

AMDN

VSS

QSLSI

EWLG

SSKSQ

TCTVS

M

VFLKM

SSLQS

DDTAR

YYC

5, 10, 15,
HC1
EVQLQ
544
GFSLN
85
VNWI
568
IWGDG
108
VYNSA
575
AGDG
130
WGQG
371

20, and

ESGPG

AYS

RQPP

KI

LKSRL

YYPY

TTVT

133-136

LVKPS

GKGL

TISKD

AMDN

VSS

ETLSL

EWLG

SSKNQ

TCTVS

M

VSLKL

SSVTA

ADTAV

YYC

6, 11, 16,
HC2
EVQLV
545
GFSLN
85
VNWV
569
IWGDG
108
VYNSA
576
AGDG
130
WGQG
371

and 21

QSGAE

AYS

RQAP

KI

LKSRL

YYPY

TTVT

VKKPG

GQGL

TITKD

AMDN

VSS

ASVKV

EWLG

SSTST

SCKAS

M

VYMEL

SSLRS

EDTAV

YYC

7, 12, 17,
HC3
EVQLV
546
GFSLN
85
VNWV
569
IWGDG
108
VYNSA
576
AGDG
130
WGQG
371

and 22

QSGAE

AYS

RQAP

KI

LKSRL

YYPY

TTVT

VKKPG

GQGL

TITKD

AMDN

VSS

SSVKV

EWLG

SSTST

SCKAS

M

VYMEL

SSLRS

EDTAV

YYC

8, 13, 18,
HC4
EVQLV
547
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
577
AGDG
130
WGQG
371

and 23

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVKPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLKT

EDTAV

YYC

9, 14,
HC5
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

19, 24,

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

90-104,

LVQPG

GKGL

TISKD

AMDN

VSS

132, and

GSLRL

EWLG

SSKNT

137-140

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

25
HC6
EVQLQ
544
GGSLN
86
VNWV
567
IWGDG
108
VYNSA
579
ARDG
131
WGQG
371

ESGPG

AYS

RQPP

KI

LKSRL

YYPY

TTVT

LVKPS

GKGL

TISLD

AMDN

VSS

ETLSL

EWLG

TSKSQ

TCTVS

M

VFLKM

SSLTA

ADTAV

YYC

26
HC7
QVQLQ
549
GGSLN
86
WNWV
571
IYGDG
109
NYNPA
580
ARDG
132
WGQG
371

ESGPG

AYS

RQPP

KT

LKSRL

YYYY

TTVT

LVKPS

GKGL

TISLD

AMDV

VSS

ETLSL

EWLG

TSKSQ

TCTVS

Y

VFLKM

SSLTA

ADTAV

YYC

105
HC5_m1
EVQLL
548
GYSLN
87
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

106
HC5_m2
EVQLL
548
GFSLR
88
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

107
HC5_m3
EVQLL
548
GFSLH
89
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

108
HC5_m4
EVQLL
548
GFSLD
90
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

109
HC5_m5
EVQLL
548
GFSLY
91
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

110
HC5_m6
EVQLL
548
GFSLS
84
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

111
HC5_m7
EVQLL
548
GFSLN
93
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

RYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

112
HC5_m8
EVQLL
548
GFSLN
94
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

KYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

113
HC5_m9
EVQLL
548
GFSLN
95
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

HYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

114
HC5_m10
EVQLL
548
GFSLN
96
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

QYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

115
HC5_m11
EVQLL
548
GFSLN
97
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

EYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

116
HC5_m12
EVQLL
548
GFSLN
565
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

SYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

117
HC5_m13
EVQLL
548
GFSLN
98
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

YYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

118
HC5_m14
EVQLL
548
GFSLN
99
VNWV
570
IWGDG
108
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AES

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

119
HC5_m15
EVQLL
548
GFSLN
85
VNWV
570
IWSDG
110
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

120
HC5_m16
EVQLL
548
GFSLN
85
VNWV
570
IWADG
111
VYNSA
578
AGDG
130
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

121
HC5_m17
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGHG
133
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

122
HC5_m18
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGDL
134
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

123
HC5_m19
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGDK
135
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYPY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

124
HC5_m20
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGDG
136
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYGY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

125
HC5_m21
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGDG
137
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYAY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

126
HC5_m22
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGDG
138
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYSY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

127
HC5_m24
EVQLL
548
GFSLN
85
VNWV
570
IWGDG
108
VYNSA
578
AGDG
139
WGQG
371

ESGGG

AYS

RQAP

KI

LKSRL

YYTY

TTVT

LVQPG

GKGL

TISKD

AMDN

VSS

GSLRL

EWLG

SSKNT

SCAAS

M

VYLQM

NSLRA

EDTAV

YYC

*Names correspond with name in informal sequence listing.

TABLE 6

Anti-interleukin (IL)-13 antibody Light Chain Kabat CDRs

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

Construct

ID

ID

ID

ID

ID

ID

ID

ID
VL Name*
FR1
NO:
CDR1
NO:
FR2
NO:
CDR2
NO:
FR3
NO:
CDR3
NO:
FR4
NO:

1
Lebrikizumab-
DIVMT
581
RASKS
141
WYQQ
286
LASNL
153
GVPDR
343
QQNNE
165
FGGGT
400

(lebrikizumab),
LC
QSPDS

VDSYG

KPGQP

ES

FSGSG

DPRT

KVEIK

2,

LSVSL

NSFMH

PKLLIY

SGTDF

and 128-

GERAT

TLTISS

131

INC

LQAED

VAVY

YC

3 and 4
LC0
NIVLT
230
RASKS
141
WYQQ
286
LASNL
153
GVPAR
344
QQNNE
165
FGGGT
401

QSPAS

VDSYG

KPGQP

ES

FSGSG

DPRT

KLEIK

LAVSL

NSFMH

PKLLIY

SRTDF

GQRAT

TLTIDP

ISC

VEADD

AASYY

C

—
LC1
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
345
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SRTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

5-9
LC2
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
345
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SRTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

10-14
LC3
EIVLT
233
RASKS
141
WYQQ
290
LASNL
153
GIPARF
347
QQNNE
165
FGGGT
400

QSPAT

VDSYG

KPGQA

ES

SGSGS

DPRT

KVEIK

LSVSP

NSFMH

PRLLIY

RTEFT

GERAT

LTISSL

LSC

QSEDF

AVYYC

—
LC4
DIVLT
234
RASKS
141
WYLQ
291
LASNL
153
GVPDR
348
QQNNE
165
FGGGT
400

QSPLS

VDSYG

KPGQS

ES

FSGSG

DPRT

KVEIK

LPVTP

NSFMH

PQLLIY

SRTDF

GEPASI

TLKISR

SC

VEAED

VGVY

YC

—
LC5
DIVLT
235
RASKS
141
WYQQ
286
LASNL
153
GVPDR
343
QQNNE
165
FGGGT
400

QSPDS

VDSYG

KPGQP

ES

FSGSG

DPRT

KVEIK

LAVSL

NSFMH

PKLLIY

SGTDF

GERAT

TLTISS

INC

LQAED

VAVY

YC

15-19, 90,
LC6
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

105-127,

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

and 132-

SASVG

NSFMH

PKLLIY

SGTDF

136

DRVTI

TLTISS

TC

LQPED

FATYY

C

20-24
LC7
EIVLT
233
RASKS
141
WYQQ
290
LASNL
153
GIPARF
351
QQNNE
165
FGGGT
400

QSPAT

VDSYG

KPGQA

ES

SGSGS

DPRT

KVEIK

LSVSP

NSFMH

PRLLIY

GTEFT

GERAT

LTISSL

LSC

QSEDF

AVYYC

—
LC8
DIVLT
234
RASKS
141
WYLQ
291
LASNL
153
GVPDR
352
QQNNE
165
FGGGT
400

QSPLS

VDSYG

KPGQS

ES

FSGSG

DPRT

KVEIK

LPVTP

NSFMH

PQLLIY

SGTDF

GEPASI

TLKISR

SC

VEAED

VGVY

YC

25
LC9
DIVLT
239
RASKS
141
WYQQ
286
LASNL
153
GVPDR
353
QQNNE
165
FGGGT
401

QSPAS

VDSYG

KPGQP

ES

FSGSG

DPRT

KLEIK

LAVSP

NSFMH

PKLLIY

SGTDF

GERAT

TLTISR

ISC

VEADD

VAVY

YC

26
LC10
DIVLT
239
RASQS
142
WYQQ
286
LASNR
158
GVPDR
353
QQNN
166
FGGGT
401

QSPAS

VDSNG

KPGQP

ES

FSGSG

HTPRT

KLEIK

LAVSP

NNFLH

PKLLIY

SGTDF

GERAT

TLTISR

ISC

VEADD

VAVY

YC

91
LC6_m1
DIQLT
231
RASKS
143
WYQQ
288
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSRMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

92
LC6_m2
DIQLT
231
RASKS
144
WYQQ
288
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSSMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

93
LC6_m3
DIQLT
231
RASKS
141
WYQQ
300
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIR

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

94
LC6_m4
DIQLT
231
RASKS
141
WYQQ
301
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIF

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

95
LC6_m5
DIQLT
231
RASKS
141
WYQQ
288
LASHL
154
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

96
LC6_m6
DIQLT
231
RASKS
141
WYQQ
288
LASDL
155
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

97
LC6_m7
DIQLT
231
RASKS
141
WYQQ
288
LASQL
156
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

98 and
LC6_m8
DIQLT
231
RASKS
141
WYQQ
288
LASEL
157
GVPSR
349
QQNNE
165
FGGGT
400

137-140

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

99
LC6_m9
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNHE
167
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

100
LC6_m10
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNYE
168
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

101
LC6_m11
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNSE
169
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

102
LC6_m12
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNNR
170
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

103
LC6_m13
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNN
171
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DDPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

104
LC6_m14
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNN
172
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

QDPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

*Names correspond with name in informal sequence listing.

TABLE 7

Anti-interleukin (IL)-13 antibody Light Chain Chothia CDRs

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

ID

ID

ID

ID

ID

ID

ID

IDConstruct
VL Name*
FR1
NO:
CDR1
NO:
FR2
NO:
CDR2
NO:
FR3
NO:
CDR3
NO:
FR4
NO:

1
Lebrikizumab-
DIVMT
581
RASKS
141
WYQQ
286
LASNL
153
GVPDR
343
QQNNE
165
FGGGT
400

(lebrikizumab),
LC
QSPDS

VDSYG

KPGQP

ES

FSGSG

DPRT

KVEIK

2,

LSVSL

NSFMH

PKLLIY

SGTDF

and 128-

GERAT

TLTISS

131

INC

LQAED

VAVY

YC

3 and 4
LC0
NIVLT
230
RASKS
141
WYQQ
286
LASNL
153
GVPAR
344
QQNNE
165
FGGGT
401

QSPAS

VDSYG

KPGQP

ES

FSGSG

DPRT

KLEIK

LAVSL

NSFMH

PKLLIY

SRTDF

GQRAT

TLTIDP

ISC

VEADD

AASYY

C

—
LC1
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
345
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SRTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

5-9
LC2
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
345
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SRTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

10-14
LC3
EIVLT
233
RASKS
141
WYQQ
290
LASNL
153
GIPARF
347
QQNNE
165
FGGGT
400

QSPAT

VDSYG

KPGQA

ES

SGSGS

DPRT

KVEIK

LSVSP

NSFMH

PRLLIY

RTEFT

GERAT

LTISSL

LSC

QSEDF

AVYYC

—
LC4
DIVLT
234
RASKS
141
WYLQ
291
LASNL
153
GVPDR
348
QQNNE
165
FGGGT
400

QSPLS

VDSYG

KPGQS

ES

FSGSG

DPRT

KVEIK

LPVTP

NSFMH

PQLLIY

SRTDF

GEPASI

TLKISR

SC

VEAED

VGVY

YC

—
LC5
DIVLT
235
RASKS
141
WYQQ
286
LASNL
153
GVPDR
343
QQNNE
165
FGGGT
400

QSPDS

VDSYG

KPGQP

ES

FSGSG

DPRT

KVEIK

LAVSL

NSFMH

PKLLIY

SGTDF

GERAT

TLTISS

INC

LQAED

VAVY

YC

15-19, 90,
LC6
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

105-127,

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

and 132-

SASVG

NSFMH

PKLLIY

SGTDF

136

DRVTI

TLTISS

TC

LQPED

FATYY

C

20-24
LC7
EIVLT
233
RASKS
141
WYQQ
290
LASNL
153
GIP ARF
351
QQNNE
165
FGGGT
400

QSPAT

VDSYG

KPGQA

ES

SGSGS

DPRT

KVEIK

LSVSP

NSFMH

PRLLIY

GTEFT

GERAT

LTISSL

LSC

QSEDF

AVYYC

—
LC8
DIVLT
234
RASKS
141
WYLQ
291
LASNL
153
GVPDR
352
QQNNE
165
FGGGT
400

QSPLS

VDSYG

KPGQS

ES

FSGSG

DPRT

KVEIK

LPVTP

NSFMH

PQLLIY

SGTDF

GEPASI

TLKISR

SC

VEAED

VGVY

YC

25
LC9
DIVLT
239
RASKS
141
WYQQ
286
LASNL
153
GVPDR
353
QQNNE
165
FGGGT
401

QSPAS

VDSYG

KPGQP

ES

FSGSG

DPRT

KLEIK

LAVSP

NSFMH

PKLLIY

SGTDF

GERAT

TLTISR

ISC

VEADD

VAVY

YC

26
LC10
DIVLT
239
RASQS
142
WYQQ
286
LASNR
158
GVPDR
353
QQNN
166
FGGGT
401

QSPAS

VDSNG

KPGQP

ES

FSGSG

HTPRT

KLEIK

LAVSP

NNFLH

PKLLIY

SGTDF

GERAT

TLTISR

ISC

VEADD

VAVY

YC

91
LC6_m1
DIQLT
231
RASKS
143
WYQQ
288
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSRMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

92
LC6_m2
DIQLT
231
RASKS
144
WYQQ
288
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSSMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

93
LC6_m3
DIQLT
231
RASKS
141
WYQQ
300
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIR

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

94
LC6_m4
DIQLT
231
RASKS
141
WYQQ
301
LASNL
153
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIF

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

95
LC6_m5
DIQLT
231
RASKS
141
WYQQ
288
LASHL
154
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

96
LC6_m6
DIQLT
231
RASKS
141
WYQQ
288
LASDL
155
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

97
LC6_m7
DIQLT
231
RASKS
141
WYQQ
288
LASQL
156
GVPSR
349
QQNNE
165
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

98 and
LC6_m8
DIQLT
231
RASKS
141
WYQQ
288
LASEL
157
GVPSR
349
QQNNE
165
FGGGT
400

137-144

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

99
LC6_m9
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNHE
167
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

100
LC6_m10
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNYE
168
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

101
LC6_m11
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNSE
169
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

102
LC6_m12
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNNR
170
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

103
LC6_m13
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNN
171
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

DDPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

104
LC6_m14
DIQLT
231
RASKS
141
WYQQ
288
LASNL
153
GVPSR
349
QQNN
172
FGGGT
400

QSPSSL

VDSYG

KPGKA

ES

FSGSG

QDPRT

KVEIK

SASVG

NSFMH

PKLLIY

SGTDF

DRVTI

TLTISS

TC

LQPED

FATYY

C

*Names correspond with name in informal sequence listing.

TABLE 8

Anti-interleukin (IL)-13 antibody Light Chain IMGT CDRs

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

Construct

ID

ID

ID

ID

ID

ID

ID
VL Name*
FR1
NO:
CDR1
NO:
FR2
NO:
CDR2
FR3
NO:
CDR3
NO:
FR4
NO:

1
Lebrikizumab-
DIVMT
582
KSVDS
149
MHWY
589
LAS
NLESG
596
QQNNE
165
FGGGT
400

(lebrikizumab),
LC
QSPDS

YGNSF

QQKPG

VPDRF

DPRT

KVEIK

2,

LSVSL

QPPKL

SGSGS

and 128-

GERAT

LIY

GTDFT

131

INCRA

LTISSL

S

QAEDV

AVYYC

3 and 4
LC0
NIVLT
583
KSVDS
149
MHWY
589
LAS
NLESG
597
QQNNE
165
FGGGT
401

QSPAS

YGNSF

QQKPG

VPARF

DPRT

KLEIK

LAVSL

QPPKL

SGSGS

GQRAT

LIY

RTDFT

ISCRAS

LTIDPV

EADDA

ASYYC

—
LC1
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
598
QQNNE
165
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

RTDFT

TCRAS

LTISSL

QPEDF

ATYYC

5-9
LC2
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
598
QQNNE
165
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

RTDFT

TCRAS

LTISSL

QPEDF

ATYYC

10-14
LC3
EIVLT
585
KSVDS
149
MHWY
591
LAS
NLESGI
599
QQNNE
165
FGGGT
400

QSPAT

YGNSF

QQKPG

PARFS

DPRT

KVEIK

LSVSP

QAPRL

GSGSR

GERAT

LIY

TEFTL

LSCRA

TISSLQ

S

SEDFA

VYYC

—
LC4
DIVLT
586
KSVDS
149
MHWY
592
LAS
NLESG
600
QQNNE
165
FGGGT
400

QSPLS

YGNSF

LQKPG

VPDRF

DPRT

KVEIK

LPVTP

QSPQL

SGSGS

GEPASI

LIY

RTDFT

SCRAS

LKISR

VEAED

VGVY

YC

—
LC5
DIVLT
587
KSVDS
149
MHWY
589
LAS
NLESG
596
QQNNE
165
FGGGT
400

QSPDS

YGNSF

QQKPG

VPDRF

DPRT

KVEIK

LAVSL

QPPKL

SGSGS

GERAT

LIY

GTDFT

INCRA

LTISSL

S

QAEDV

AVYYC

15-19, 90,
LC6
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
601
QQNNE
165
FGGGT
400

105-127,

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

and 132-

SASVG

KAPKL

SGSGS

136

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

20-24
LC7
EIVLT
585
KSVDS
149
MHWY
591
LAS
NLESGI
602
QQNNE
165
FGGGT
400

QSPAT

YGNSF

QQKPG

PARFS

DPRT

KVEIK

LSVSP

QAPRL

GSGSG

GERAT

LIY

TEFTL

LSCRA

TISSLQ

S

SEDFA

VYYC

—
LC8
DIVLT
586
KSVDS
149
MHWY
592
LAS
NLESG
603
QQNNE
165
FGGGT
400

QSPLS

YGNSF

LQKPG

VPDRF

DPRT

KVEIK

LPVTP

QSPQL

SGSGS

GEPASI

LIY

GTDFT

SCRAS

LKISR

VEAED

VGVY

YC

25
LC9
DIVLT
588
KSVDS
149
MHWY
589
LAS
NLESG
604
QQNNE
165
FGGGT
401

QSPAS

YGNSF

QQKPG

VPDRF

DPRT

KLEIK

LAVSP

QPPKL

SGSGS

GERAT

LIY

GTDFT

ISCRAS

LTISRV

EADDV

AVYYC

26
LC10
DIVLT
588
QSVDS
150
LHWY
593
LAS
NRESG
605
QQNN
166
FGGGT
401

QSPAS

NGNNF

QQKPG

VPDRF

HTPRT

KLEIK

LAVSP

QPPKL

SGSGS

GERAT

LIY

GTDFT

ISCRAS

LTISRV

EADDV

AVYYC

91
LC6_m1
DIQLT
584
KSVDS
151
MHWY
590
LAS
NLESG
601
QQNNE
165
FGGGT
400

QSPSSL

YGNSR

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

92
LC6_m2
DIQLT
584
KSVDS
152
MHWY
590
LAS
NLESG
601
QQNNE
165
FGGGT
400

QSPSSL

YGNSS

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

93
LC6_m3
DIQLT
584
KSVDS
149
MHWY
594
LAS
NLESG
601
QQNNE
165
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIR

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

94
LC6_m4
DIQLT
584
KSVDS
149
MHWY
595
LAS
NLESG
601
QQNNE
165
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIF

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

95
LC6_m5
DIQLT
584
KSVDS
149
MHWY
590
LAS
HLESG
606
QQNNE
165
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

96
LC6_m6
DIQLT
584
KSVDS
149
MHWY
590
LAS
DLESG
607
QQNNE
165
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

97
LC6_m7
DIQLT
584
KSVDS
149
MHWY
590
LAS
QLESG
608
QQNNE
165
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

98 and
LC6_m8
DIQLT
584
KSVDS
149
MHWY
590
LAS
ELESG
609
QQNNE
165
FGGGT
400

137-144

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

99
LC6_m9
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
601
QQNHE
167
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

100
LC6_m10
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
601
QQNYE
168
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

101
LC6_m11
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
601
QQNSE
169
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

102
LC6_m12
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
601
QQNNR
170
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

103
LC6_m13
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
601
QQNN
171
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

DDPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

104
LC6_m14
DIQLT
584
KSVDS
149
MHWY
590
LAS
NLESG
601
QQNN
172
FGGGT
400

QSPSSL

YGNSF

QQKPG

VPSRF

QDPRT

KVEIK

SASVG

KAPKL

SGSGS

DRVTI

LIY

GTDFT

TCRAS

LTISSL

QPEDF

ATYYC

*Names correspond with name in informal sequence listing.

Fc Region

The structures of the Fc regions of various immunoglobulins, and the glycosylation sites contained therein, are known in the art. See Schroeder and Cavacini, J. Allergy Clin. Immunol., 2010, 125: S41-52, incorporated by reference in its entirety. The Fc region may be a naturally occurring Fc region or an Fc region modified as described in the art or elsewhere in this disclosure.

Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. An “Fc polypeptide” of a dimeric Fc as used herein refers to one of the two polypeptides forming the dimeric Fc domain, i.e., a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association. For example, an Fc polypeptide of a dimeric IgG Fc comprises an IgG CH2 and an IgG CH3 constant domain sequence. An Fc can be of the class IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂.

The terms “Fc receptor” and “FcR” are used to describe a receptor that binds to the Fc region of an antibody. For example, an FcR can be a native sequence human FcR. Generally, an FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an “activating receptor”) and FcγRIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Immunoglobulins of other isotypes can also be bound by certain FcRs (see, e.g., Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999)). Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (reviewed in Daëron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term “FcR” herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976); and Kim et al., J. Immunol. 24:249 (1994)).

Modifications in the CH2 domain can affect the binding of FcRs to the Fc. A number of amino acid modifications in the Fc region are known in the art for selectively altering the affinity of the Fc for different Fcgamma receptors. In some embodiments, the Fc comprises one or more modifications to promote selective binding of Fc-gamma receptors.

Exemplary mutations that alter the binding of FcRs to the Fc are listed below:

- S298A/E333A/K334A, S298A/E333A/K334A/K326A (Lu Y, Vernes J M, Chiang N, et al. J Immunol Methods. 2011 Feb. 28; 365 (1-2): 132-41);
- F243L/R292P/Y300L/V305I/P396L, F243L/R292P/Y300L/L235V/P396L (Stavenhagen J B, Gorlatov S, Tuaillon N, et al. Cancer Res. 2007 Sep. 15; 67 (18): 8882-90; Nordstrom J L, Gorlatov S, Zhang W, et al. Breast Cancer Res. 2011 Nov. 30; 13 (6): R123);
- F243L (Stewart R, Thom G, Levens M, et al. Protein Eng Des Sel. 2011 September; 24 (9): 671-8.), S298A/E333A/K334A (Shields R L, Namenuk A K, Hong K, et al. J Biol Chem. 2001 Mar. 2; 276 (9): 6591-604);
- S239D/1332E/A330L, S239D/1332E (Lazar G A, Dang W, Karki S, et al. Proc Natl Acad Sci USA. 2006 Mar. 14; 103 (11): 4005-10);
- S239D/S267E, S267E/L328F (Chu S Y, Vostiar I, Karki S, et al. Mol Immunol. 2008 September; 45 (15): 3926-33); and
- S239D/D265S/S298A/1332E, S239E/S298A/K326A/A327H, G237F/S298A/A330L/1332E, S239D/1332E/S298A, S239D/K326E/A330L/1332E/S298A, G236A/S239D/D270L/1332E, S239E/S267E/H268D, L234F/S267E/N325L, G237F/V266L/S267D and other mutations listed in WO2011/120134 and WO2011/120135, herein incorporated by reference. Therapeutic Antibody Engineering (by William R. Strohl and Lila M. Strohl, Woodhead Publishing series in Biomedicine No 11, ISBN 1 907568 37 9, October 2012) lists mutations on page 283.

In some embodiments an antibody described herein includes modifications to improve its ability to mediate effector function. Such modifications are known in the art and include afucosylation, or engineering of the affinity of the Fc towards an activating receptor, mainly FCGR3a for ADCC, and towards C1q for CDC. The following Table 9 summarizes various designs reported in the literature for effector function engineering.

Methods of producing antibodies with little or no fucose on the Fc glycosylation site (Asn 297 EU numbering) without altering the amino acid sequence are well known in the art. The GlymaX® technology (ProBioGen AG) is based on the introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis into cells used for antibody production. This prevents the addition of the sugar “fucose” to the N-linked antibody carbohydrate part by antibody-producing cells (von Horsten et al. (2010) Glycobiology. 2010 December; 20 (12): 1607-18). Another approach to obtaining antibodies with lowered levels of fucosylation can be found in U.S. Pat. No. 8,409,572, which teaches selecting cell lines for antibody production for their ability to yield lower levels of fucosylation on antibodies can be fully afucosylated (meaning they contain no detectable fucose) or they can be partially afucosylated, meaning that the isolated antibody contains less than 95%, less than 85%, less than 75%, less than 65%, less than 55%, less than 45%, less than 35%, less than 25%, less than 15%, or less than 5% of the amount of fucose normally detected for a similar antibody produced by a mammalian expression system.

Thus, in one embodiment, an antibody described herein can include a dimeric Fc that comprises one or more amino acid modifications as noted in Table 9 that confer improved effector function. In another embodiment, the antibody can be afucosylated to improve effector function.

TABLE 9

CH2 domains and effector function engineering

Reference
Mutations
Effect

Lu, 2011, Ferrara
Afucosylated
Increased ADCC

2011, Mizushima

2011

Lu, 2011
S298A/E333A/K334A
Increased ADCC

Lu, 2011
S298A/E333A/K334A/K326A
Increased ADCC

Stavenhagen,
F243L/R292P/Y300L/V305I/
Increased ADCC

2007
P396L

Nordstrom, 2011
F243L/R292P/Y300L/L235V/
Increased ADCC

P396L

Stewart, 2011
F243L
Increased ADCC

Shields, 2001
S298A/E333A/K334A
Increased ADCC

Lazar, 2006
S239D/1332E/A330L
Increased ADCC

Lazar, 2006
S239D/1332E
Increased ADCC

Bowles, 2006
AME-D, not specified mutations
Increased ADCC

Heider, 2011
37.1, mutations not disclosed
Increased ADCC

Moore, 2010
S267E/H268F/S324T
Increased CDC

Fc modifications reducing FcgR and/or complement binding and/or effector function are known in the art. Recent publications describe strategies that have been used to engineer antibodies with reduced or silenced effector activity (see Strohl, W R (2009), Curr Opin Biotech 20:685-691, and Strohl, W R and Strohl L M, “Antibody Fc engineering for optimal antibody performance” In Therapeutic Antibody Engineering, Cambridge: Woodhead Publishing (2012), pp 225-249). These strategies include reduction of effector function through modification of glycosylation, use of IgG2/IgG4 scaffolds, or the introduction of mutations in the hinge or CH2 regions of the Fc. For example, U.S. Patent Publication No. 2011/0212087 (Strohl), International Patent Publication No. WO 2006/105338 (Xencor), U.S. Patent Publication No. 2012/0225058 (Xencor), U.S. Patent Publication No. 2012/0251531 (Genentech), and Strop et al. ((2012) J. Mol. Biol. 420:204-219) describe specific modifications to reduce FcgR or complement binding to the Fc.

Specific, non-limiting examples of known amino acid modifications to reduce FcgR or complement binding to the Fc include those identified in the following Table 10:

TABLE 10

Modifications to reduce FcgR or complement binding to the Fc

Company
Mutations

GSK
N297A

Ortho Biotech
L234A/L235A

Protein Design labs
IGG2 V234A/G237A

Wellcome Labs
IGG4 L235A/G237A/E318A

GSK
IGG4 S228P/L236E

Alexion
IGG2/IGG4combo

Merck
IGG2 H268Q/V309L/A330S/A331S

Bristol-Myers
C220S/C226S/C229S/P238S

Seattle Genetics
C226S/C229S/E3233P/L235V/L235A

Amgen

E. coli production, non glyco

Medimune
L234F/L235E/P331S

Trubion
Hinge mutant, possibly C226S/P230S

Examples of cell lines capable of producing defucosylated antibody include CHO-DG44 with stable overexpression of the bacterial oxidoreductase GDP-6-deoxy-D-lyxo-4-hexylose reductase (RMD) (see Henning von Horsten et al., Glycobiol 2010, 20:1607-1618) or Lec13 CHO cells, which are deficient in protein fucosylation (see Ripka et al., Arch. Biochem. Biophys., 1986, 249:533-545; U.S. Pat. Pub. No. 2003/0157108; WO 2004/056312; each of which is incorporated by reference in its entirety), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene or FUT8 knockout CHO cells (see Yamane-Ohnuki et al., Biotech. Bioeng., 2004, 87:614-622; Kanda et al., Biotechnol. Bioeng., 2006, 94:680-688; and WO 2003/085107; each of which is incorporated by reference in its entirety). Another approach to obtaining antibodies with lowered levels of fucosylation can be found in U.S. Pat. No. 8,409,572, which teaches selecting cell lines for antibody production for their ability to yield lower levels of fucosylation on antibodies.

Antibodies can be fully afucosylated (meaning they contain no detectable fucose) or they can be partially afucosylated, meaning that the isolated antibody contains less than 95%, less than 85%, less than 75%, less than 65%, less than 55%, less than 45%, less than 35%, less than 25%, less than 15%, or less than 5% of the amount of fucose normally detected for a similar antibody produced by a mammalian expression system.

In some embodiments, an antibody provided herein comprises an IgG1 domain with reduced fucose content at position Asn 297 compared to a naturally occurring IgG1 domain. Such Fc domains are known to have improved ADCC. See Shields et al., J. Biol. Chem., 2002, 277:26733-26740, incorporated by reference in its entirety. In some embodiments, such antibodies do not comprise any fucose at position Asn 297. The amount of fucose may be determined using any suitable method, for example as described in WO 2008/077546, incorporated by reference in its entirety.

In certain embodiments, an antibody provided herein comprises an Fc region with one or more amino acid substitutions which improve ADCC, such as a substitution at one or more of positions 298, 333, and 334 of the Fc region. In some embodiments, an antibody provided herein comprises an Fc region with one or more amino acid substitutions at positions 239, 332, and 330, as described in Lazar et al., Proc. Natl. Acad. Sci. USA, 2006,103:4005-4010, incorporated by reference in its entirety.

Other illustrative glycosylation variants which may be incorporated into the antibodies provided herein are described, for example, in U.S. Pat. Pub. Nos. 2003/0157108, 2004/0093621, 2003/0157108, 2003/0115614, 2002/0164328, 2004/0093621, 2004/0132140, 2004/0110704, 2004/0110282, 2004/0109865; International Pat. Pub. Nos. 2000/61739, 2001/29246, 2003/085119, 2003/084570, 2005/035586, 2005/035778; 2005/053742, 2002/031140; Okazaki et al., J. Mol. Biol., 2004, 336:1239-1249; and Yamane-Ohnuki et al., Biotech. Bioeng., 2004, 87:614-622; each of which is incorporated by reference in its entirety.

In some embodiments, an antibody provided herein comprises an Fc region with at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Examples of such antibody variants are described, for example, in WO 1997/30087; WO 1998/58964; and WO 1999/22764; each of which his incorporated by reference in its entirety.

In some embodiments, an antibody provided herein comprises one or more alterations that improves or diminishes C1q binding and/or CDC. See U.S. Pat. No. 6,194,551; WO 99/51642; and Idusogie et al., J. Immunol., 2000, 164:4178-4184; each of which is incorporated by reference in its entirety.

In certain embodiments, an antibody provided herein comprises a heavy chain comprising a constant heavy chain sequence selected from the sequences set forth in SEQ ID NOs: 425-468 and 484-539.

In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 1 and a VL sequence set forth in SEQ ID NO: 33; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 2 and a VL sequence set forth in SEQ ID NO: 33; and wherein the human Fc 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 35; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 36; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 439, 440, 446, 457 and 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 4 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 5, and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 6 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 40; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 42; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 9 and a VL sequence set forth in SEQ ID NO: 43; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7, and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 44; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 45; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 46; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 47; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 48; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 49; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 50; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 52; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 53; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 54; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 55; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 56; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 57; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 10 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 11 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 12 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 13 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 14 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 16 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 17 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 18 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 19 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 20 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 21 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 22 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 23 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 24 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 25 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 26 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 27 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 28 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 28 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 29 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 30 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 31 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 32 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NOs: 436-468 and 484-539.

In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 15 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 8 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 39; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 3 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 7 and a VL sequence set forth in SEQ ID NO: 51; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 460. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 439. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 446. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 457. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 470 and a VL sequence set forth in SEQ ID NO: 471; and wherein the human Fc region comprises a human IgG sequence selected from a sequence set forth in SEQ ID NO: 460.

In certain embodiments, the isolated antibody described herein comprises a constant light chain sequence set forth by SEQ ID NO: 469.

In certain embodiments, the Fc region comprises one or more amino acid substitutions, wherein the one or more substitutions result in increased antibody half-life, increased ADCC activity, increased ADCP activity, or increased CDC activity compared with the Fc without the one or more substitutions. In certain embodiments, the one or more amino acid substitutions results in increased antibody half-life at pH 6.0 compared to an antibody comprising a wild-type Fc region. In certain embodiments, the isolated antibody comprising an Fc region with one or more amino acid substitutions has a half-life of about 80 to 110 days in a human.

In certain embodiments, the antibody has an increased half-life that is about 10,000-fold, 1,000-fold, 500-fold, 100-fold, 50-fold, 20-fold, 10-fold, 9-fold, 8-fold, 7-fold, 6-fold, 5-fold, 4.5-fold, 4-fold, 3.5-fold, 3-fold, 2.5-fold, 2-fold, 1.95-fold, 1.9-fold, 1.85-fold, 1.8-fold, 1.75-fold, 1.7-fold, 1.65-fold, 1.6-fold, 1.55-fold, 1.50-fold, 1.45-fold, 1.4-fold, 1.35-fold, 1.3-fold, 1.25-fold, 1.2-fold, 1.15-fold, 1.1-fold, or 1.05-fold longer compared to an antibody comprising a wild-type Fc region. In certain embodiments, the antibody has an increased half-life that is about 10,000-fold, 1,000-fold, 500-fold, 100-fold, 50-fold, 20-fold, 10-fold, 9-fold, 8-fold, 7-fold, 6-fold, 5-fold, 4.5-fold, 4-fold, 3.5-fold, 3-fold, 2.5-fold, 2-fold, 1.95-fold, 1.9-fold, 1.85-fold, 1.8-fold, 1.75-fold, 1.7-fold, 1.65-fold, 1.6-fold, 1.55-fold, 1.50-fold, 1.45-fold, 1.4-fold, 1.35-fold, 1.3-fold, 1.25-fold, 1.2-fold, 1.15-fold, 1.1-fold, or 1.05-fold longer compared to lebrikizumab.

In certain embodiments, the Fc region comprises one or more amino acid substitutions, wherein the one or more substitutions result in increased antibody half-life, a decrease in one or more of ADCC activity, ADCP activity, or CDC activity compared with the Fc without the one or more substitutions. In certain embodiments, the one or more amino acid substitutions results in increased antibody half-life at pH 6.0 compared to an antibody comprising a wild-type Fc region. In certain embodiments, the isolated antibody comprising an Fc region with one or more amino acid substitutions has a half-life of about 80 to 110 days in a human.

In certain embodiments, the one or more amino acid substitutions is selected from the group consisting of S228P (SP); M252Y, S254T, T256E, T256D, T250Q, H285D, T307A, T307Q, T307R, T307W, L309D, Q411H, Q311V, A378V, E380A, M428L, N434A, N434S, N297A, D265A, L234A, L235A, and N434W. In certain embodiments, the one or more amino acid substitutions comprises a plurality of amino acid substitutions selected from the group consisting of M428L/N434S (LS); M252Y/S254T/T256E (YTE); T250Q/M428L; T307A/E380A/N434A; T256D/T307Q (DQ); T256D/T307W (DW); M252Y/T256D (YD); T307Q/Q311V/A378V (QVV); T256D/H285D/T307R/Q311V/A378V (DDRVV); L309D/Q311H/N434S (DHS); S228P/L235E (SPLE); L234A/L235A (LALA), M428L/N434A (LA), L234A/G237A (LAGA), L234A/L235A/G237A (LALAGA), L234A/L235A/P329G (LALAPG), N297A, D265A/YTE, LALA/YTE, LAGA/YTE, LALAGA/YTE, LALAPG/YTE, N297A/LS; D265A/LS; LALA/LS; LALAGA/LS; LALAPG/LS; N297A/DHS; D265A/DHS; LALA/DHS; LAGA/DHS; LALAGA/DHS; LALAPG/DHS; SP/YTE; SPLE/YTE; SP/LS; SPLE/LS, SP/DHS; SPLE/DHS; N297A/LA; D265A/LA, LALA/LA, LAGA/LA, LALAGA/LA, LALAPG/LA, N297A/N434A; D265A/N434A; LALA/N434A, LAGA/N434A, LALAGA/N434A, LALAPG/N434A, N297A/N434W, D265A/N434W, LALA/N434W, LAGA/N434W, LALAGA/N434W, LALAPG/N434W, N297A/DQ, D265A/DQ, LALA/DQ, LAGA/DQ, LALAGA/DQ, LALAPG/DQ, N297A/DW, D265A/DW, LALA/DW, LAGA/DW, LALAGA/DW, LALAPG/DW N297A/YD, D265A/YD, LALA/YD, LAGA/YD, LALAGA/YD, LALAPG/YD, T307Q/Q311V/A378V (QVV), N297A/QVV, D265A/QVV, LALA/QVV, LAGA/QVV, LALAGA/QVV, LALAPG/QVV, DDRVV, N297A/DDRVV, D265A/DDRVV, LALA/DDRVV, LAGA/DDRVV, LALAGA/DDRVV, and LALAPG/DDRVV.

In certain embodiments, the one or more amino acid substitutions is selected from the group consisting of LALA/YTE, LAGA/YTE, LALA/LS, YTE, and LS.

In certain embodiments, the one or more amino acid substitutions comprises or consists of LALA/YTE. In certain embodiments, the one or more amino acid substitutions comprises or consists of LAGA/YTE. In certain embodiments, the one or more amino acid substitutions comprises or consists of LALA/LS. In certain embodiments, the one or more amino acid substitutions comprises or consists of YTE. In certain embodiments, the one or more amino acid substitutions comprises or consists of LS.

In certain embodiments, the Fc region binds an Fcγ Receptor selected from the group consisting of: FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb. In certain embodiments, the Fc region binds an Fcγ Receptor with higher affinity at pH 6.0 compared to an antibody comprising a wild-type Fc region.

Binding

The affinity of a molecule X for its partner Y can be represented by the dissociation equilibrium constant (K_D). The kinetic components that contribute to the dissociation equilibrium constant are described in more detail below. Affinity can be measured by common methods known in the art, including those described herein, such as surface plasmon resonance (SPR) technology (e.g., BIACORE®) or biolayer interferometry (e.g., FORTEBIO®).

With regard to the binding of an antibody to a target molecule, the terms “bind,” “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction (e.g., with a non-target molecule). Specific binding can be measured, for example, by measuring binding to a target molecule (i.e., IL-13) and comparing it to binding to a non-target molecule. Specific binding can also be determined by competition with a control molecule that mimics the epitope recognized on the target molecule. In that case, specific binding is indicated if the binding of the antibody to the target molecule is competitively inhibited by the control molecule. In some embodiments, the affinity of an anti-IL-13 antibody for a non-target molecule is less than about 50% of the affinity for IL-13. In some embodiments, the affinity of an anti-IL-13 antibody for a non-target molecule is less than about 40% of the affinity for IL-13. In some embodiments, the affinity of an anti-IL-13 antibody for a non-target molecule is less than about 30% of the affinity for IL-13. In some embodiments, the affinity of an anti-IL-13 antibody for a non-target molecule is less than about 20% of the affinity for IL-13. In some embodiments, the affinity of an anti-IL-13 antibody for a non-target molecule is less than about 10% of the affinity for IL-13. In some embodiments, the affinity of an anti-IL-13 antibody for a non-target molecule is less than about 1% of the affinity for IL-13. In some embodiments, the affinity of an anti-IL-13 antibody for a non-target molecule is less than about 0.1% of the affinity for IL-13.

When used herein in the context of two or more antibodies, the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen (e.g., IL-13). In one exemplary assay, IL-13 is coated on a surface and contacted with a first anti-IL-13 antibody, after which a second anti-IL-13 antibody is added. In another exemplary assay, a first anti-IL-13 antibody is coated on a surface and contacted with IL-13, and then a second anti-IL-13 antibody is added. If the presence of the first anti-IL-13 antibody reduces binding of the second anti-IL-13 antibody, in either assay, then the antibodies compete with each other. The term “competes with” also includes combinations of antibodies where one antibody reduces binding of another antibody, but where no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding of each other, regardless of the order in which they are added. In some embodiments, one antibody reduces binding of another antibody to its antigen by at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% as measured in a competitive binding assay. A skilled artisan can select the concentrations of the antibodies used in the competition assays based on the affinities of the antibodies for IL-13 and the valency of the antibodies. The assays described in this definition are illustrative, and a skilled artisan can utilize any suitable assay to determine if antibodies compete with each other. Suitable assays are described, for example, in Cox et al., “Immunoassay Methods,” in Assay Guidance Manual [Internet], Updated Dec. 24, 2014 (ncbi.nlm.nih.gov/books/NBK92434/; accessed Sep. 29, 2015); Silman et al., Cytometry, 2001, 44:30-37; and Finco et al., J. Pharm. Biomed. Anal., 2011, 54:351-358; each of which is incorporated by reference in its entirety.

A test antibody competes with a reference antibody if an excess of a test antibody (e.g., at least 2×, 5×, 10×, 20×, or 100×) inhibits or blocks binding of the reference antibody by, e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% as measured in a competitive binding assay. Antibodies identified by competition assay (competing antibody) include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur. For example, a second, competing antibody can be identified that competes for binding to IL-13 with a first antibody described herein. In certain instances, the second antibody can block or inhibit binding of the first antibody by, e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% as measured in a competitive binding assay. In certain instances, the second antibody can displace the first antibody by greater than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%.

In certain embodiments, the antibody binds a human IL-13.

In certain embodiments, the antibody binds an IL-13 sequence set forth in SEQ ID NOs: 472-475.

In certain embodiments, the antibody is cross-reactive to cynomolgus monkey IL-13.

In certain embodiments, the antibody binds to an IL-13 sequence set forth in SEQ ID NOs: 472-475 with a K_Dof less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9×10⁻⁹M, as measured by SPR. In certain embodiments, the antibody binds to an IL-13 sequence set forth in SEQ ID NOs: 472-475 with a K_Dof less than or equal to about 1×10⁻¹⁰M, as measured by SPR. In certain embodiments, the antibody binds to human IL-13 with a K_Dof less than or equal to about 1×10⁻⁹M, as measured by SPR.

In some embodiments, an antibody provided herein binds IL-13 with a K_Dof less than or equal to about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 1.95, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, or 10×10⁻⁸M, as measured by ELISA or any other suitable method known in the art. In some embodiments, an antibody provided herein binds IL-13 with a K_Dof less than or equal to about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 1.95, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, or 10×10⁻⁹M, as measured by ELISA or any other suitable method known in the art.

In some embodiments, the K_Dof the antibody provided herein for the binding of IL-13 is between about 0.001-0.01, 0.01-0.1, 0.01-0.05, 0.05-0.1, 0.1-0.5, 0.5-1, 0.25-0.75, 0.25-0.5, 0.5-0.75, 0.75-1, 0.75-2, 1.1-1.2, 1.2-1.3, 1.3-1.4, 1.4-1.5, 1.5-1.6, 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2, 1-2, 1-5, 2-7, 3-8, 3-5, 4-6, 5-7, 6-8, 7-9, 7-10, or 5-10×10⁻⁸M, as measured by ELISA or any other suitable method known in the art. In some embodiments, an antibody provided herein binds IL-13 with a K_Dof less than or equal to about 1×10⁻⁸M, or less than or equal to above 1×10⁻⁹M as measured by ELISA or any other suitable method known in the art.

In some embodiments, the antibody provided herein binds IL-13 with a K_Dof less than or equal to about 10, 9, 8, 7, 6, 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.98, 1.95, 1.9, 1.85, 1.8, 1.75, 1.7, 1.65, 1.6, 1.55, 1.50, 1.45, 1.4, 1.3, 1.2, 1.1, 1, 0.9, 0.85, 0.8, 0.75, 0.7, 0.65, 0.6, 0.55, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, or 0.0001×10⁻⁸M, or less, as measured by ELISA or any other suitable method known in the art. In some embodiments, the antibody provided herein binds IL-13 with a K_Dbetween 5-3, 4-2, 3-1, 1.9-1.8, 1.8-1.7, 1.7-1.6, 1.6-1.5, 1.9-1.5, 1.5-1, 1-0.8, 1-0.5, 0.9-0.6, 0.7-0.4, 0.6-0.2, 0.5-0.3, 0.3-0.2, 0.2-0.1, 0.1-0.01, 0.01-0.001, or 0.001-0.0001×10⁻⁸M as measured by ELISA or any other suitable method known in the art.

Function

“Effector functions” refer to those biological activities mediated by the Fc region of an antibody, which activities may vary depending on the antibody isotype. Examples of antibody effector functions include receptor ligand blocking, agonism, or antagonism, C1q binding to activate complement dependent cytotoxicity (CDC), Fc receptor binding to activate antibody-dependent cellular cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). In some embodiments, the effector function of the anti-IL-13 antibody described herein is antagonism and blocks the IL-13 receptor binding to IL-13.

Pharmaceutical Compositions

The present application provides compositions comprising the antibodies including pharmaceutical compositions comprising any one or more of the antibodies described herein with one or more pharmaceutically acceptable excipients. In some embodiments the composition is sterile. The pharmaceutical compositions generally comprise an effective amount of an antibody.

These compositions can comprise, in addition to one or more of the antibodies disclosed herein, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material can depend on the route of administration, e.g., oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Pharmaceutical compositions for oral administration can be in tablet, capsule, powder or liquid form. A tablet can include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol can be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants and/or other additives can be included, as required.

The anti-IL-13 antibody that is to be given to an individual, administration is preferably in a “therapeutically effective amount” or “prophylactically effective amount” (as the case can be, although prophylaxis can be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of protein aggregation disease being treated. Prescription of treatment, e.g., decisions on dosage etc., is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16^thedition, Osol, A. (ed), 1980.

A composition can be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Methods

Methods of Preparation

Antibodies described herein can be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, an isolated nucleic acid encoding an antibody described herein is provided. Such a nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody) or an amino acid sequence comprising the VHH of a single domain antibody. In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In one embodiment, the nucleic acid is provided in a multicistronic vector. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antigen-binding polypeptide construct, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antigen-binding polypeptide construct and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antigen-binding polypeptide construct. In one embodiment, the host cell is eukaryotic, e.g., a Chinese Hamster Ovary (CHO) cell, or human embryonic kidney (HEK) cell, or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an antibody is provided, wherein the method comprises culturing a host cell comprising nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

For recombinant production of the antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

When an antibody or variant thereof is recombinantly produced by the host cells, the protein in certain embodiments is present at about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%, about 2%, or about 1% or less of the dry weight of the cells. When the antibody or variant thereof is recombinantly produced by the host cells, the protein, in certain embodiments, is present in the culture medium at about 5 g/L, about 4 g/L, about 3 g/L, about 2 g/L, about 1 g/L, about 750 mg/L, about 500 mg/L, about 250 mg/L, about 100 mg/L, about 50 mg/L, about 10 mg/L, or about 1 mg/L or less of the dry weight of the cells. In certain embodiments, “substantially purified” antibody produced by the methods described herein, has a purity level of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, specifically, a purity level of at least about 75%, 80%, 85%, and more specifically, a purity level of at least about 90%, a purity level of at least about 95%, a purity level of at least about 99% or greater as determined by appropriate methods such as SDS/PAGE analysis, RP-HPLC, SEC, and capillary electrophoresis.

Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.

Recombinant host cells or host cells are cells that include an exogenous polynucleotide, regardless of the method used for insertion, for example, direct uptake, transduction, f-mating, or other methods known in the art to create recombinant host cells. The exogenous polynucleotide may be maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome. Host cells can include CHO, derivatives of CHO, NS0, Sp20, CV-1, VERO-76, HeLa, HepG2, Per.C6, or BHK.

For example, antibody may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments in E. coli.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

In one embodiment, the antibodies described herein are produced in stable mammalian cells, by a method comprising: transfecting at least one stable mammalian cell with: nucleic acid encoding the antibody, in a predetermined ratio; and expressing the nucleic acid in the at least one mammalian cell. In some embodiments, the predetermined ratio of nucleic acid is determined in transient transfection experiments to determine the relative ratio of input nucleic acids that results in the highest percentage of the antibody in the expressed product.

In some embodiments, is the method of producing an antibody in stable mammalian cells as described herein wherein the expression product of the at least one stable mammalian cell comprises a larger percentage of the desired glycosylated antibody as compared to the monomeric heavy or light chain polypeptides, or other antibodies.

In some embodiments, is the method of producing a glycosylated antibody in stable mammalian cells described herein, said method comprising identifying and purifying the desired glycosylated antibody. In some embodiments, the said identification is by one or both of liquid chromatography and mass spectrometry.

If required, the antibodies can be purified or isolated after expression. Proteins may be isolated or purified in a variety of ways known to those skilled in the art. Standard purification methods include chromatographic techniques, including ion exchange, hydrophobic interaction, affinity, sizing or gel filtration, and reversed-phase, carried out at atmospheric pressure or at high pressure using systems such as FPLC and HPLC. Purification methods also include electrophoretic, immunological, precipitation, dialysis, and chromatofocusing techniques. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. As is well known in the art, a variety of natural proteins bind Fc and antibodies, and these proteins can find use in the present invention for purification of antibodies. For example, the bacterial proteins A and G bind to the Fc region. Likewise, the bacterial protein L binds to the Fab region of some antibodies. Purification can often be enabled by a particular fusion partner. For example, antibodies may be purified using glutathione resin if a GST fusion is employed, Ni⁺²affinity chromatography if a His-tag is employed or immobilized anti-flag antibody if a flag-tag is used. For general guidance in suitable purification techniques, see, e.g., incorporated entirely by reference Protein Purification: Principles and Practice, 3^rdEd., Scopes, Springer-Verlag, NY, 1994, incorporated entirely by reference. The degree of purification necessary will vary depending on the use of the antibodies. In some instances, no purification is necessary.

In certain embodiments, the antibodies are purified using Anion Exchange Chromatography including, but not limited to, chromatography on Q-sepharose, DEAE sepharose, poros HQ, poros DEAF, Toyopearl Q, Toyopearl QAE, Toyopearl DEAE, Resource/Source Q and DEAE, Fractogel Q and DEAE columns.

In specific embodiments, the proteins described herein are purified using Cation Exchange Chromatography including, but not limited to, SP-sepharose, CM sepharose, poros HS, poros CM, Toyopearl SP, Toyopearl CM, Resource/Source S and CM, Fractogel S and CM columns and their equivalents and comparables.

In addition, antibodies described herein can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W. H. Freeman & Co., N.Y and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4diaminobutyric acid, alpha-amino isobutyric acid, 4aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, alanine, fluoro-amino acids, designer amino acids such as methyl amino acids, C-methyl amino acids, N-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

In certain embodiments, an antibody described herein has an aggregation temperature greater than about 69° C., greater than about 70° C., greater than about 71° C., greater than about 72° C., greater than about 73° C., greater than about 74° C., greater than about 75° C., or greater than about 76° C., for example, between about 69° C. and about 77° C., between about 70° C. and about 76° C., between about 71° C. and about 75° C. In certain embodiments, aggregation temperature is measured using DSF.

In certain embodiments, an antibody described herein has reduced hydrophobicity as compared to lebrikizumab as measured by hydrophobic interaction chromatography (HIC). In certain embodiments, the antibody exhibits an HIC retention time that is less than about 15.2 min. In certain embodiments, the antibody exhibits an HIC retention time that is between about 13 min and about 15 min.

Methods of Use

In an aspect, the present application provides methods of contacting IL-13 with an anti-IL-13 antibody, such as a human or humanized antibody, which results in inhibition of IL-13 binding to an IL-13 receptor expressed on a cell.

In an aspect, the present application provides methods of using the isolated anti-IL-13 antibodies described herein for treatment of a disorder or disease in a subject. In certain aspects, described herein is a method for treating a subject in need thereof with an anti-IL-13 antibody, the method comprising administering to a mammalian subject a therapeutically effective amount of an anti-IL-13 antibody or pharmaceutical composition comprising an anti-IL-13 antibody described herein. In certain embodiments, the present application provides methods of treating a disorder or disease associated with elevated levels of IL-13 and/or IgE in a subject.

In certain aspects, described herein are methods for treating a pathology associated with IL-13 activity, the method comprising administering to a mammalian subject a therapeutically effective amount an isolated anti-IL-13 antibody or a pharmaceutical composition comprising an isolated anti-IL-13 antibody described herein.

In certain aspects, described herein is a method for treating an inflammatory disorder or disease in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody described herein or a pharmaceutical composition described herein. In certain embodiments of the methods described herein, the inflammatory disorder or disease is atopic dermatitis. In certain embodiments, the inflammatory disorder or disease is asthma. In certain embodiments, the inflammatory disorder or disease is idiopathic pulmonary fibrosis. In certain embodiments of the methods described herein, the inflammatory disorder or disease is alopecia areata. In certain embodiments, the inflammatory disorder or disease is chronic sinusitis with nasal polyps. In certain embodiments, the inflammatory disorder or disease is Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). In certain embodiments, the inflammatory disorder or disease is eosinophilic esophagitis (EoE). In certain embodiments, the inflammatory disorder or disease is an Eosinophilic gastrointestinal disorder or disease (ENID) selected from the group consisting of Eosinophilic Gastritis (EoG), Eosinophilic enteritis (EN), Eosinophilic colitis (EoC), and Eosinophilic Gastroenteritis (EGE). In certain embodiments, the inflammatory disorder or disease is Churg-Strauss syndrome/Eosinophilic granulomatosis with polyangiitis (EGPA). In certain embodiments, the inflammatory disorder or disease is Prurigo Nodularis (PN). In certain embodiments, the inflammatory disorder or disease is Chronic Spontaneous Urticaria (CSU). In certain embodiments, the inflammatory disorder or disease is Chronic Pruritis of Unknown Origin (CPUO). In certain embodiments, the inflammatory disorder or disease is Bullous Pemphigoid (BP). In certain embodiments, the inflammatory disorder or disease is Cold Inducible Urticaria (ColdU). In certain embodiments, the inflammatory disorder or disease is Allergic Fungal Rhinosinusitis (AFRS). In certain embodiments, the inflammatory disorder or disease is Allergic Bronchopulmonary Aspergillosis (ABPA). In certain embodiments, the inflammatory disorder or disease is Chronic Obstructive Pulmonary Disease (COPD). In certain embodiments, the inflammatory disorder or disease is inflammatory bowel disease, such as Crohn disease or ulcerative colitis. In certain embodiments, the inflammatory disorder or disease is psoriasis. In certain embodiments, the inflammatory disorder or disease is lupus. In certain embodiments, the inflammatory disorder or disease is rheumatoid arthritis.

In certain aspects, described herein are methods for treating a pathology associated with elevated levels of IL-13 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody or a pharmaceutical composition described herein.

In certain aspects, described herein are methods of reducing biological activity of IL-13 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody or a pharmaceutical composition described herein.

In certain aspects, described herein are methods for inhibiting the TH2 type allergic response in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody or a pharmaceutical composition described herein.

In certain aspects, described herein are methods for inhibiting IL-13-induced phosphorylation of STAT6 in a cell, the method comprising contacting the cell with an antibody described herein.

In certain aspects, described herein are methods for inhibiting IL-13-induced CD23 expression in a cell, the method comprising contacting the cell with an antibody described herein.

In certain aspects, described herein are methods for inhibiting IL-13-induced secretion of CCL2 and CCL26 from a cell, the method comprising contacting the cell with an antibody described herein.

In certain aspects, described herein are methods for inhibiting IL-13-induced NTRK1 expression in a cell, the method comprising contacting the cell with an antibody described herein.

In certain aspects, described herein are methods for reducing levels of Thymus and Activation Regulated Chemokine (TARC)/CCL17 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody or a pharmaceutical composition described herein.

In certain aspects, described herein are methods of preventing an inflammatory disorder or disease in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount an antibody or a pharmaceutical composition described herein.

Methods of Administration

In some embodiments, the methods provided herein are useful for the treatment of a disease or disorder in an individual. In an embodiment, the individual is a human and the antibody is an anti-IL-13 antibody described herein.

In some embodiments, an antibody is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. An effective amount of an anti-IL-13 antibody may be administered for the treatment of a disease or disorder. The appropriate dosage of the anti-IL-13 antibody may be determined based on the type of disease or disorder to be treated, the type of the anti-IL-13 antibody, the severity and course of the disease or disorder, the clinical condition of the individual, the individual's clinical history and response to the treatment, and the discretion of the attending physician.

In some embodiments, an antibody provided herein is administered with at least one additional therapeutic agent. Any suitable additional therapeutic or immunotherapeutic agent may be administered with an antibody provided herein. Additional therapeutic agents include agents that are used to treat or prevent a disease or disorder such as, but not limited to, an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.

The additional therapeutic agent can be administered by any suitable means. In some embodiments, an antibody provided herein and the additional therapeutic agent are included in the same pharmaceutical composition. In some embodiments, an antibody provided herein and the additional therapeutic agent are included in different pharmaceutical compositions.

In embodiments where an antibody provided herein and the additional therapeutic agent are included in different pharmaceutical compositions, administration of the antibody can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent. In some embodiments, administration of an antibody provided herein and the additional therapeutic agent occur within about one month of each other. In some embodiments, administration of an antibody provided herein and the additional therapeutic agent occur within about one week of each other. In some embodiments, administration of an antibody provided herein and the additional therapeutic agent occur within about one day of each other. In some embodiments, administration of an antibody provided herein and the additional therapeutic agent occur within about twelve hours of each other. In some embodiments, administration of an antibody provided herein and the additional therapeutic agent occur within about one hour of each other.

Kits and Articles of Manufacture

The present application provides kits comprising any one or more of the antibody compositions described herein and instructions for use. In some embodiments, the kits further contain a component selected from any of secondary antibodies, reagents for immunohistochemistry analysis, pharmaceutically acceptable excipient and instruction manual and any combination thereof. In one specific embodiment, the kit comprises a pharmaceutical composition comprising any one or more of the antibody compositions described herein, with one or more pharmaceutically acceptable excipients.

The present application also provides articles of manufacture comprising any one of the antibody compositions or kits described herein. Examples of an article of manufacture include vials (including sealed vials).

EXAMPLES

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2^ndEdition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18^thEdition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3^rdEd. (Plenum Press) Vols A and B (1992).

Methods

Humanization of Mouse Hybridoma Sequence of Anti-IL-13 Antibody 228B/C-1

Complementarity-determining region (CDR) grafting technology was used to humanize the parental mouse anti-human IL-13 228B/C-1, the parental monoclonal antibody of Lebrikizumab. The parental mouse heavy and light sequences were modeled onto a human antibody framework as described below. A set of human heavy and light chains were selected for humanization. The goal was to design pairs of these heavy and light chains that resulted in improved biophysical properties of the parental antibody while retaining binding. These humanized molecules were designed for improved developability profile during scale up in bioprocess.

Humanization of Light Chains

The parental mAb light chain sequence of mouse hybridoma sequence of anti-IL13 antibody (Lebrikizumab) was compared to a group of human variable region light chain (VK) germlines amino acid sequences (Lefranc, M.-P. IMGT, the international ImMunoGeneTics database Nucleic Acids Res., 29, D207-209 (2001). DOI:10.1093/nar/29.1.207. PMID:11125093.). A total of 4 human VK germlines were selected. Of these, one belonged to Vk4 family (IGKV4-1), two belonged to VK1 family (IGKV1-39 and IGKV3-15) and one belonged to VK2 family (IGKV2-28). One substitution on light chain framework 3, R to G was also designed. This back mutation from human to mouse can alter binding. Human germline KJ4 was selected for the J region based on sequence similarity with the mouse sequence. The humanized VL domains were cloned into a vector encoding for a kappa light chain constant domain.

The following nomenclature was used for the light chains: “LC0” corresponds to the mouse hybridoma sequence. “LC1” corresponds to IGKV4-1_KJ4. “LC2” corresponds to IGKV1-39_KJ4. “LC3” corresponds to IGKV3-15_KJ4. “LC4” corresponds to IGKV2-28_KJ4. “LC5” corresponds to IGKV4-1_R to G_KJ. “LC6” corresponds to IGK V1-39_R to G_KJ4. “LC7” corresponds to IGKV3-15_R to G_KJ4. “LC8” corresponds to IGKV2-28_R to G_KJ4.

Humanization of Heavy Chain

The parental mAb heavy chain sequence of mouse hybridoma sequence of anti-IL13 antibody (Lebrikizumab) was compared to a group of human variable region heavy chain (VH) germline amino acid sequences. A total of 5 human VH germlines were selected. Of these, one belonged to VH4 family (IGHV4-59), two belonged to VH1 family (IGHV1-46, IGHV1-69) and two belonged to VH3 family (IGHV3-15, IGHV3-23). The N-terminal Q in heavy chain was substituted with E to prevent potential pyroglutamate conversion. Human germline HJ6 was selected for the J region based on sequence similarity with the mouse sequence. The humanized VH domains were cloned into a vector encoding for human IgG1 HC constant domain.

The following nomenclature was used for the heavy chains: “HC0”-corresponds to the mouse hybridoma heavy chain. “HC0_M” corresponds to HC0_NIS to TIS in FR3 (to prevent potential glycosylation). “HC1” corresponds to humanized sequence IGHV4-59_HJ6. “HC2” corresponds to humanized sequence IGHV1-46_HJ6. “HC3” corresponds to humanized sequence IGHV1-69_HJ6. “HC4” corresponds to humanized sequence IGHV3-15_HJ6. “HC5” corresponds to humanized sequence IGHV3-23_HJ6.

Gene Synthesis and Plasmid Construction

The coding sequences for HC and LC of the antibody were generated by DNA synthesis and PCR, subsequently subcloned into pTT5-based plasmid for protein expression in mammalian cell system. The gene sequences in the expression vectors were confirmed by DNA sequencing.

Expression of Antibody Constructs

Transient expression of antibodies was performed by co-transfection of paired HC and LC constructs into CHO cells using PEI method. Briefly, CHO cells at approximately 5.5×10⁶/mL in a shake flask was used as the host. Transfection was initiated by adding a mixture of 1 mg/L DNA and 7 mg/L PEI in OptiMEM™ medium (Invitrogen) to the cells followed by gentle mixing. Cells were then cultured in an incubator shaker at 120 rpm, 37° C., and 8% CO₂, for 9 days. Feeding with peptone and glucose was carried out 24 h later and every 2-3 days thereafter depending on the cell density and viability. The cell culture was terminated on day 9 when cell viability reduced to <80%. The conditioned medium was harvested for protein purification.

Purification of Antibody Construct

Protein purification by affinity chromatography, and ion exchange chromatography was performed using an AKTA pure instrument (GE Lifesciences). Conditional medium expressing target antibody was harvested by centrifugation at 4000 rpm, 50 min, and filtered with a 0.22 μm filter. The harvested supernatants were loaded to a column of Mabselect™ SuRe™ (GE Healthcare). After washing column with Buffer A (PBS, PH 7.4), the protein was eluted with Buffer B (1 M Glycine, pH 2.7), and immediately neutralized with 1/10 volume of Buffer D (1 M sodium citrate, pH 6.0). The affinity purified antibody was then buffer exchanged into 20 mM sodium acetate pH 5.5.

TABLE 11

Size exclusion chromatograph of anti-IL-13 constructs

Construct ID*
Percent Monomer

lebrikizumab (Construct 1)
99%

Construct 2
96%

Construct 3
95%

Construct 4
93%

Construct 5
95%

Construct 6
97%

Construct 7
97%

Construct 8
98%

Construct 9
96%

Construct 10
99%

Construct 11
98%

Construct 12
98%

Construct 13
98%

Construct 14
98%

Construct 15
98%

Construct 16
98%

Construct 17
99%

Construct 18
98%

Construct 19
98%

Construct 20
99%

Construct 21
98%

Construct 22
98%

Construct 23
99%

Construct 24
100%

Construct 25
99%

Construct 26
97%

Construct 90
98%

Construct 91
98%

Construct 92
98%

Construct 93
98%

Construct 94
99%

Construct 95
98%

Construct 96
99%

Construct 97
97%

Construct 98
98%

Construct 99
98%

Construct 100
97%

Construct 101
99%

Construct 102
98%

Construct 103
100%

Construct 104
100%

Construct 105
100%

Construct 106
99%

Construct 107
100%

Construct 108
99%

Construct 109
99%

Construct 110
99%

Construct 111
100%

Construct 112
98%

Construct 113
98%

Construct 114
98%

Construct 115
97%

Construct 116
98%

Construct 117
98%

Construct 118
97%

Construct 119
98%

Construct 120
97%

Construct 121
96%

Construct 122
98%

Construct 123
95%

Construct 124
98%

Construct 125
98%

Construct 126
97%

Construct 127
98%

*See construct sequences in Tables 2-8.

SEC-HPLC Analysis of Antibody Construct

Analytical SEC-HPLC was performed using Shimadzu LC-10 HPLC instrument (Shimadzu Corp.). 20 μl sample on 1 mg/mL was loaded to a Superdex® 200 Increase 5/150GL column (GE Lifesciences). The mobile phase was 2*PBS with a flow rate of 0.3 mL/min, 15 min.

Measuring Antibody-IL13 Binding Kinetics Using Surface Plasmon Resonance

A Biacore 8K SPR system (GE HealthCare) equipped with Series S Sensor Chip Protein G (Cytiva, Cat. 29179315) was used to determine the binding kinetic rate and affinity constants at 25° C. and in a running buffer of HBS-EP+ (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Surfactant P20). Following a stabilization period in running buffer, the anti-IL13 mAb constructs (diluted to 1 μg/mL were captured onto flow cell 2 (active) for 60 sec at a flow rate of 10 uL/min. Recombinant Human IL-13 Protein, His Tag (Acro Cat. IL3-H52H4) was prepared at concentrations of 0, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5 and 0 nM and injected over flow cell 1 (reference) and flow cell 2 (active) for 180 sec at a flow rate of 30 μL/min. Recombinant Cynomolgus IL-13 Protein, His Tag (SINO BIOLOGICAL, Cat. 11057-C07H) was prepared at concentrations of 0, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 0 nM and injected over flow cell 1 (reference) and flow cell 2 (active) for 180 sec at a flow rate of 30 μL/min. Samples were injected in a multi-cycle manner over freshly captured mAb, by regenerating the capture surfaces with injection of glycine pH 1.5 for 30 sec at a flow rate of 30 μL/min. The data was processed and analyzed with Biacore Insight Evaluation Software Version 2.0.15.12933 (GE Healthcare) as follows. Responses from flow cell 1 (reference) were subtracted from the responses from flow cell 2 (active). The responses from the two buffer blank injections were then subtracted from the reference subtracted data (2-1) to yield double-referenced data, which were fit to an 1:1 binding model to determine the apparent association (ka) and dissociation rate constants (kd). Their ratio provided the apparent equilibrium dissociation constant or affinity constant (KD=kd/ka).

Determination of Antibody Affinity to Fc Receptors and C1q

Binding affinity (K_D) of antibodies to Fc receptors and C1q were determined through surface plasmon resonance (SPR) using a Biacore 8K. Briefly, an SPR chip functionalized with an anti-kappa light-chain antibody was used to capture purified antibodies normalized to 5 mg/mL, at a flow rate of 10 uL/min for 90 seconds or 120 seconds. A paired channel with only buffer was used as reference. Subsequently, varying concentrations of recombinant human CD32a (167H), CD32a (167R), CD32b, CD16a (176V), CD16a (176F), FcRn, CD64, and C1q were injected over the surface with captured purified antibody as well as the reference channel. Regeneration of the chip between different concentrations of different antigens were performed with 10 mM Glycine HCl, pH 1.5 and antibody was again captured. Association and dissociation rate constants were subsequently determined through fitting to a 1:1 Langmuir binding model or steady-state analysis model, whichever applicable, using the Biacore Insight Evaluation Software from which a K_Dvalue was derived.

Assessing Blockade by Cell-Line-Based Assays

Multiple assays were used to assess blockade of the full signalling complex of IL-13/IL13Rα1/IL-4Rα and prevention of downstream signalling. Briefly, HEK293 previously transduced to stably express both hIL-13Rα and hIL-4Rα were cultured and harvested. Cells were seeded at 200,000 cells in 100 uL per well. Cells were washed and the supernatant was discarded. A 100 uL mixture of biotinylated hIL-13 and purified antibody (1:1 by volume) that had been previously made and incubated for 1 hour was added to resuspend the cells, resulting in a final concentration of 0.05 ug/mL of hIL-13 and 0-100 nM of purified antibody. The cells were stained in this mixture at 4° C. for 1 hour. Cells were then washed and stained with 100 uL of Alexa Fluor 488-conjugated streptavidin at a 1:1000 dilution to detect binding of biotinylated hIL-13 on the cell surface. Cells were incubated at 4° C. for 1 hour, protected from light. Cells were then washed and the median fluorescence intensity (MFI) of cells in each well were recorded by FACS using a BD FACSCanto II. Subsequent data were analyzed using GraphPad Prism. IC₅₀values were determined as the concentration of antibody required to inhibit 50% of the maximum MFI of biotinylated hIL-13 surface detected with incubation of 0.05 ug/mL of hIL-13 alone.

Cell-line-based assays included: inhibition of phosphorylation of STAT6 in HT-29 cells, inhibition of release of TARC in A549 cells, and inhibition of proliferation of TF-1 cells. Primary human lymphocyte-based assays included: inhibition of phosphorylation of STAT6 and inhibition of CD23 expression.

Inhibition of Phosphorylation of STAT6 in HT-29 Cells

Inhibition of STAT6 phosphorylation in HT-29 cells was used to evaluate the functional activity of antibodies to block IL-13-induced biological activity. Briefly, HT-29 cells were starved in RMPI 1640+0.1% FBS overnight. Cells were collected and seeded at 50,000 cells per well in 100 μL. Concurrently, a 100 μL mixture of hIL-13 and purified antibody (1:1 by volume) was added to the same well, resulting in a final concentration of 10 ng/ml of hIL-13 and 0-50 nM of purified antibody. Cells were incubated at 37° C. for 1 hour and subsequently fixed, permeabilized, and stained with a PE-conjugated anti-pSTAT6 antibody. The MFI of cells in each well were recorded by FACS using a BD FACSCanto II and subsequent data were analyzed using GraphPad Prism. IC50 values were determined as the concentration of antibody required to inhibit 50% of the maximum MFI of pSTAT6 detected with incubation of 10 ng/ml of hIL-13 alone. Results are summarized below.

Inhibition of Release of TARC in A549 Cells

Inhibition of TARC secretion by A549 cells was used to evaluate the functional activity of antibodies to block IL-13-induced biological activity. Briefly, A549 cells were seeded at 20,000 cells in 100 μL of DMEM+10% FBS and cultured overnight at 37° C. The next day, the cell culture media was discarded and cells were gently washed with fresh media. A 150 μL mixture of hIL-13, purified antibody, and hTNFα (1:1:1 by volume) were added to the wells, resulting in a final concentration of 20 ng/mL hIL-13, 0-100 nM purified antibody, and 200 ng/ml. Cells were incubated in this mixture at 37° C. for 20-24 hour. Following incubation, culture supernatant was collected and the amount of TARC present was analyzed using a commercial TARC ELISA kit (R&D Systems), analyzed according to manufacturer's instructions. The determined concentrations of TARC in each well were analyzed using GraphPad Prism. IC50 values were determined as the concentration of antibody required to inhibit 50% of the maximum TARC concentration detected with incubation of only 20 ng/ml of hIL-13 and 200 ng/ml hTNFα. Results are summarized below.

Inhibition of Proliferation of TF-1 Cells

The proliferation or inhibition thereof of TF-1 cells was used to evaluate the functional activity of antibodies to block IL-13-induced biological activity. Briefly, TF-1 cells were harvested and starved in RPMI1640+10% FBS without additional cytokine for 4 hours. During this time, a mixture of hIL-13 and purified antibody (1:1 by volume) was prepared 50 μL was added per well. Following starvation, TF-1 cells were again harvested and seeded at 15,000 cells in 50 μL per well, resulting in a final concentration of 4 ng/ml of hIL-13 and 0-5 nM purified antibody. Cells were subsequently incubated at 37° C. for 72 hours and proliferation of cells was quantified using CellTiter-Glo (Promega) according to manufacturer's instructions. Luminescence was recorded by SpectraMax M5 Multimode Plate Reader and data was analyzed using GraphPad Prism. IC50 values were determined as the concentration of antibody required to result in 50% of the maximum luminescence detected when TF-1 cells are incubated and cultured with 4 ng/ml of hIL-13 alone. Results are summarized below.

Inhibition of STAT6 Phosphorylation and CD23 Expression in Primary Human Lymphocytes

To confirm the antagonistic activity of antibodies herein in primary cells, human peripheral blood mononuclear cells (PBMCs) obtained from healthy donors were used to evaluate the ability of antibodies herein to inhibit IL-13-induced phosphorylation of STAT6 and upregulation of CD23 expression.

Frozen human PBMCs from a previously-identified IL-13 responsive donors were thawed and revived. To determine the in vitro potency of antibodies herein in inhibiting STAT6 phosphorylation, total PBMCs were stimulated with 10 ng/ml of IL-13 and purified antibody (1:1 by volume). These cells were allowed to incubate for 15 minutes at 37° C. Phosphorylation of STAT6 was subsequently analysed by flow cytometry using a commercial anti-phosphoSTAT6 antibody, staining assessed within the specific immune population gated by lineage-specific markers CD14 and CD19. In a separate set of PBMCs, cells were allowed to incubate for 24 hours at 37° C. CD23 expression was subsequently analyzed by flow cytometry using an anti-CD23 antibody and its intensity of staining assessed within the specific immune population gated by lineage-specific markers CD14 and CD19.

Median fluorescence intensity (MFI) data from either pSTAT6 or CD23 staining was analyzed using GraphPad Prism. IC₅₀values were determined as the concentration of antibody required to result in 50% of the maximum MFI detected for each marker when primary human PBMCs are incubated and cultured with 10 ng/ml of hIL-13 alone.

Protein Thermal Stability Test by Differential Scanning Fluorimetry (DSF)

SYPRO® Orange (Thermo Fisher #S6651) was supplied at 5000× concentration in 100% DMSO and diluted to 40× in the appropriate formulation buffer. The antibodies were mixed with the dye, and nine microliters of this mixture was loaded into a UNi (Unchained Labs, Cat No. 201-1010) and run with the “T_musing SYPRO” application on UNCLE (Unchained Labs). Samples were subjected to a thermal ramp from 25-95° C., with a ramp rate of 0.5° C./minute and excitation at 473 nm. Full spectra were collected from 250-720 nm and UNCLE software was used to measure the area under the curve between 510-680 nm to calculate the inflection points (T_m) of the transition curves.

HIC-HPLC Analysis of Antibody Construct

Analytical HIC-HPLC was performed using Thermo UltiMate™ 3000 instrument. A 20 μl sample at 1 mg/mL was loaded to a Thermo Scientific™ MAbPac™ HIC-Butyl HPLC column (5 μm, 4.6 mm×100 mm; Cat No. 088558). The mobile phase A was 1.5 M Ammonium sulfate+50 mM PB buffer+5% (v/v) isopropyl alcohol, pH 6.95 and the mobile phase B was 50 mM PB buffer+20% (v/v) isopropyl alcohol, pH 6.95. The gradient was 0% to 100% mobile phase B over 20 min, and flow rate was 0.5 mL/min.

Inhibition of CCL26 and CCL2 Secretion and NTRK1 Expression

Inhibition of CCL26 and CCL2 secretion and NTRK1 expression by HaCaT cells was used to evaluate the functional activity of antibodies to block IL-13-induced biological activity. HaCaT cells were seeded at 20,000 cells in 100 uL of DMEM+10% FBS and cultured overnight at 37° C. The next day, a 150 uL mixture of hIL-13 and purified antibody were added to the wells, resulting in a final concentration of 50 ng/ml of IL-13 with 0-206.5 nM purified antibody. Cells were then further incubated at 37° C. for 48 hours. Following incubation, culture supernatant was collected and levels of secreted CCL26 and CCL2 were measured using a commercial Luminex-based immunoassay kit (R&D Systems) and analyzed according to manufacturer's instructions. Determined concentrations of CCL26 and CCL2 in each well were analyzed using GraphPad Prism. IC₅₀values were determined as the concentration of antibody required to inhibit 50% of the maximum concentration detected with incubation of 50 ng/ml of IL-13 alone.

Cells remaining in the assay plates were lysed and mRNA extracted for analysis of NTRK1 gene expression using a commercial Quantigene kit (ThermoFisher). Levels of NTRK1 mRNA were determined according to the manufacturer's protocol and analyzed in GraphPad Prism. NTRK1 gene expression was quantified as a ratio of NTRK1 mRNA levels relative to the housekeeping gene, PPIB, and IC₅₀values calculated as the concentration of antibody required to inhibit 50% of the maximum gene expression detected using 50 ng/ml of hIL-13 alone.

Example 1: Engineered Anti-IL-13 Antibodies Exhibit Improved Affinity and Potency of Blockade of IL-13

Results

Determination of Antibody Affinity to IL-13

Using the methods described above, the affinity of Construct 133 (see construct sequence in Tables 2-8) to IL-13 and the binding kinetics thereof were assessed using surface plasmon resonance (SPR) as compared to dupilumab, lebrikizumab, and a variant of lebrikizumab with one or more amino acid substitutions in the heavy chain constant region (Construct 2 (Lebrikizumab—HC; Lebrikizumab—LC; hIgG1-LAGA YTE; Human kappa LC); see construct sequence in Tables 2-8), and tralokinumab.

As measured by SPR, Construct 133 had an affinity of 77 pM compared to 131 pM and 116 pM for lebrikizumab and tralokinumab, respectively.

The affinity of variants of lebrikizumab with one or more amino acid substitutions in the heavy chain constant region (Constructs 128-131), variants of Constructs 15 or 98 with one or more amino acid substitutions in the heavy chain constant region (Constructs 133-136 or 137-140, respectively), and variants with one or more amino acid substitutions in the heavy chain constant region (Constructs 132 and 141-144) to human and cynomolgus monkey IL-13 and the binding kinetics thereof were also assessed using SPR.

It was observed that all antibodies bound to human IL-13 with low picomolar affinity comparable to the variants of lebrikizumab. Additionally, all antibodies tested were cross-reactive to cynomolgus monkey IL-13 with sub-nanomolar affinities (Table 12).

TABLE 12

Antibody Affinity to IL-13

SPR Hu
SPR Cyno
ELISA Hu

IL-13 K_D
IL-13 K_D
IL-13 K_D

Construct ID*
(pM)
(pM)
(pM)

Lebrikizumab
131
309
N.T.

Tralokinumab
116
1480
N.T.

Construct 128
91.5
298
67

Construct 129
239
882
36

Construct 130
112
227
27

Construct 131
75.6
123
19

Construct 132
135
331
N.T.

Construct 133
77.7
208
19

Construct 134
105
330
50

Construct 135
130
588
N.T.

Construct 136
69.8
161
18

Construct 137
42.1
246
26

Construct 138
108
348
N.T.

Construct 139
114
705
N.T.

Construct 140
47.5
252
20

Construct 141
107
329
25

Construct 142
108
326
54

Construct 143
119
685
N.T.

Construct 144
26.3
228
14

*See construct sequences in Tables 2-8.

N.T.—Not Tested

Antibody Affinity to Fc Receptors and C1q

All antibody hIgG1-LALA YTE variants compared to lebrikizumab showed near or complete ablation of binding to all Fc gamma receptors, significantly decreased binding to C1q, and significantly increased binding to FcRn at pH 5.8 (Table 13).

TABLE 13

Antibody Affinity to Fc Receptors and C1q

cRn,
cRn,

D32a
D32a

D16a
D16a

pH
pH

(167H)
(167R)
D32b
(176V)
(176F)
D64
C1q (Signal
7.4
5.8

Construct
K_D
K_D
K_D
K_D
K_D
K_D
Relative to
K_D
K_D

ID*
(mM)
(mM)
(mM)
(mM)
(mM)
(nM)
Rituximab)
(mM)
(mM)

Lebrikizumab
5.27
2.38
2.93
n.d.
n.d.
1.12
39.6%
n.d.
1.06

Construct
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
15.9%
n.d.
0.15

133

Construct
n.d.
8.14
8.62
n.d.
n.d.
2.80
25.3%
n.d.
0.16

134

Construct
4.54
2.40
2.17
n.d.
n.d.
0.86
30.8%
n.d.
0.10

135

Construct
n.d.
n.d.
n.d.
4.67
n.d.
n.d.
25.4%
n.d.
0.09

136

*See construct sequences in Tables 2-8.

n.d.—not detectable

Blockade

A. Inhibition of IL-13 Binding to hIL-13Rα/hIL-4Rα. Overexpressing Cells

IL-13 binding to cells overexpressing hIL-13Rα/hIL-4Rα was used to evaluate the functional blockade of antibodies against this binding interaction. The results of the functional blockade of antibodies described herein in blocking IL-13 binding to cells overexpressing hIL-13Rα/hIL-4Rα are provided in Table 14 and FIG. 2. In the cell-line-based assays, Construct 133 exhibited an IC₅₀of 0.89 nM and inhibited IL-13 binding on an IL-13Rα1/IL-4Rα overexpression cell line, as compared to an IC₅₀1.11 nM for lebrikizumab.

TABLE 14

Blockade of IL-13 Binding to hIL-13Rα/hIL-

4Rα Overexpressing Cells

Blockade of IL-13

Construct ID*
Binding IC₅₀(nM)

Lebrikizumab
1.11

Construct 128
0.95

Construct 129
0.71

Construct 130
1.05

Construct 131
0.79

Construct 132
0.99

Construct 133
0.89

Construct 134
1.08

Construct 135
1.03

Construct 136
1.02

Construct 137
0.89

Construct 138
1.01

Construct 139
1.09

Construct 141
0.81

Construct 142
0.77

Construct 143
0.74

Construct 144
0.94

*See construct sequences in Tables 2-8.

B. Inhibition of IL-13-Induced Phosphorylation of STAT6 in HT-29 Cells

Inhibition of STAT6 phosphorylation in HT-29 cells was used to evaluate the functional activity of antibodies to block IL-13-induced biological activity. An IC₅₀of 0.28 nM of Construct 133 was observed for inhibiting phosphorylation of STAT6 in HT-29 cells, as compared to 0.16 nM for dupilumab, 0.23 nM for lebrikizumab, and 0.41 nM for tralokinumab, respectively.

TABLE 15

Inhibition of IL-13-Induced Phosphorylation

of STAT6 in HT-29 Cells

Construct ID*
pSTAT6 Inhibition IC₅₀(nM)

Lebrikizumab
0.23

Tralokinumab
0.41

Dupilumab
0.16

Construct 128
0.28

Construct 129
0.33

Construct 130
0.28

Construct 131
0.22

Construct 132
0.37

Construct 133
0.28

Construct 134
0.20

Construct 135
0.23

Construct 136
0.30

Construct 137
0.33

Construct 138
0.19

Construct 139
0.28

Construct 140
0.33

Construct 141
0.25

Construct 142
0.29

Construct 143
0.36

Construct 144
0.30

*See construct sequences in Tables 2-8.

C. Inhibition of IL-13 TARC Secretion by Engineered Anti-IL13 Antibody Variants

Human A549 cells express IL4Rα/IL13Rα1 receptor, which responds to binding to human IL-13 by inducing pSTAT6 phosphorylation, thereby triggering expression of downstream genes involved in TH2 type allergic response. Thymus and Activation Regulated Chemokine (TARC), also known as CCL17, is one such gene product that is secreted by multiple cell types and plays a role in attracting effector immune cells such as eosinophils that are involved in inflammation. A549 cells were contacted with engineered anti-IL-13 antibodies and TARC assays were performed (FIG. 4). Anti-IL-13 antibodies inhibited secretion of TARC as measured by ELISA. The TARC secretion IC₅₀profiles (Table 16) were similar to lebrikizumab, thus confirming there was a preservation of potency of the anti-IL13 antibodies for IL-13 sequestrant activity in cell-based assays.

TABLE 16

TARC secretion

TARC

Release

IC50

Construct ID*
(nM)

Lebrikizumab
0.9

Construct 2
0.9

Construct 15
0.9

Construct 19
1.1

Construct 19
1.0

Construct 96
1.0

Construct 98
0.9

Construct 107
1.3

Construct 108
1.0

Construct 110
1.0

Construct 114
1.1

Dupilumab control
0.8

Control (Irrelevant
No

IgG1 LAGA YTE)
Inhibition

*See construct sequences in Tables 2-8.

Variants of lebrikizumab with one or more amino acid substitutions in the heavy chain constant region (Constructs 128-131), variants of Constructs 15 or 98 with one or more amino acid substitutions in the heavy chain constant region (Constructs 133-136 or 137-140, respectively), and variants with one or more amino acid substitutions in the heavy chain constant region (Constructs 132 and 141-144) were tested in the same assay (Table 17 and FIG. 5). An IC₅₀of 0.86 nM by Construct 133 for inhibiting release of TARC in A549 cells was observed, as compared to 1.11 nM for dupilumab, 0.74 nM for lebrikizumab, and 4.14 nM for tralokinumab, respectively.

TABLE 17

Inhibition of IL-13-Induced Release of TARC in A549 Cells

Construct ID*
TARC Inhibition IC₅₀(nM)

Lebrikizumab
0.74

Tralokinumab
4.14

Dupilumab
1.11

Construct 128
1.01

Construct 129
0.92

Construct 130
1.00

Construct 131
0.99

Construct 132
0.87

Construct 133
0.86

Construct 134
0.99

Construct 135
0.91

Construct 136
0.89

Construct 137
0.87

Construct 138
0.97

Construct 139
1.02

Construct 140
0.94

Construct 141
0.73

Construct 142
0.92

Construct 143
0.92

Construct 144
0.91

*See construct sequences in Tables 2-8.

D. Inhibition of IL-13-Induced Proliferation of TF-1 Cells

An IC₅₀of 0.16 nM by Construct 133 for inhibiting proliferation of IL-13-induced TF-1 cells was observed, as compared to 0.19 nM for dupilumab, 0.20 nM lebrikizumab, and 0.59 nM for tralokinumab, respectively.

Variants of lebrikizumab with one or more acid substitutions in the heavy chain constant region (Constructs 128-131), variants of Constructs 15 or 98 with one or more amino acid substitutions in the heavy chain constant region (Constructs 133-136 or 137-140, respectively), and variants with one or more amino acid substitutions in the heavy chain constant region (Constructs 132 and 141-144) were also tested in the same assay (Table 18 and FIG. 6).

TABLE 18

Inhibition of IL-13-Induced Proliferation of TF-1 Cells

TF-1 Proliferation

Construct ID*
Inhibition IC₅₀(nM)

Lebrikizumab
0.20

Tralokinumab
0.59

Dupilumab
0.19

Construct 128
0.20

Construct 129
0.21

Construct 130
0.15

Construct 131
0.13

Construct 132
0.13

Construct 133
0.15

Construct 134
0.18

Construct 135
0.21

Construct 136
0.15

Construct 137
0.16

Construct 138
0.23

Construct 139
0.20

Construct 140
0.14

Construct 141
0.19

Construct 142
0.20

Construct 143
0.17

Construct 144
0.17

*See construct sequences in Tables 2-8.

E. Inhibition of IL-13-Induced Phosphorylation of STAT6 and CD23 Expression in Primary Human Lymphocytes

In primary human lymphocytes, Construct 133 potently blocked IL-13 activity in a dose-dependent manner as exhibited by an IC₅₀of 0.44 nM inhibiting phosphorylation of STAT6 compared to 0.38 nM for lebrikizumab and an IC₅₀0.85 nM in inhibiting CD23 expression compared to 0.81 nM for lebrikizumab. The results demonstrated the strong antagonistic activity that Construct 133 possessed against IL-13-mediated signalling in primary human cells.

A variant of Construct 98 with one or more amino acid substitutions in the heavy chain constant region (Construct 137), and a variant with one or more amino acid substitutions in the heavy chain constant region (Construct 141) were also tested in the same assay (Table 19, FIG. 7, and FIG. 8).

TABLE 19

Inhibition of IL-13-Induced Phosphorylation

of STAT6 and CD23 in Human PBMCs

pSTAT6 Inhibition
CD23 Expression

Construct ID*
IC₅₀(nM)
Inhibition IC₅₀(nM)

Lebrikizumab
0.38
0.81

Construct 133
0.44
0.85

Construct 137
0.44
1.01

Construct 141
0.41
0.86

Example 2: Expression of Engineered Anti-IL-13 Antibodies is Improved Over Lebrikizumab

Transient expression of antibodies was performed by co-transfection of paired HC and LC constructs into CHO cells using the PEI method as described above. The relative expression of the engineered antibody constructs from the CHO cell lysates compared to lebrikizumab were then determined (Table 20) in a small-scale expression screening experiment.

TABLE 20

Expression of engineered anti-IL-13 antibodies

Fold Improvement in

Transient CHO Expression

Construct*
Over lebrikizumab

Lebrikizumab
1.0

Construct 2
1.4

Construct 3
8.0

Construct 4
6.4

Construct 5
4.3

Construct 6
5.4

Construct 7
7.2

Construct 8
3.7

Construct 9
4.3

Construct 10
2.1

Construct 11
2.6

Construct 12
3.5

Construct 13
5.2

Construct 14
3.1

Construct 15
5.9

Construct 16
9.1

Construct 17
8.4

Construct 18
6.4

Construct 19
6.8

Construct 20
4.7

Construct 21
3.9

Construct 22
4.5

Construct 23
2.9

Construct 24
0.2

Construct 25
13.2

Construct 26
9.4

Construct 90
9.9

Construct 91
9.7

Construct 92
11.5

Construct 93
8.9

Construct 94
5.6

Construct 95
3.3

Construct 96
6.8

Construct 97
5.2

Construct 98
6.8

Construct 99
3.5

Construct 100
8.1

Construct 101
12.2

Construct 102
4.1

Construct 103
6.2

Construct 104
6.4

Construct 105
3.5

Construct 106
3.9

Construct 107
8.5

Construct 108
6.2

Construct 109
6.0

Construct 110
9.7

Construct 111
12.4

Construct 112
12.9

Construct 113
0.2

Construct 114
4.4

Construct 115
9.1

Construct 116
7.8

Construct 117
5.8

Construct 118
11.8

Construct 119
9.1

Construct 120
7.2

Construct 121
5.8

Construct 122
7.8

Construct 123
8.9

Construct 124
9.5

Construct 125
5.8

Construct 126
6.2

Construct 127
0.9

*See construct sequences in Tables 2-8.

Example 3: Thermostability of Engineered Anti-IL-13 Antibodies

Differential Scanning Fluorometry (DSF) was utilized to measure melting temperatures (Tm2) of lebrikizumab and the IL-13 antibodies described in Table 21. While the majority of variants exhibited a non-inferior Tm2 profile to lebrikizumab, there were a handful of variants that exhibited a significantly higher melting temperature, such as Construct 5 and Construct 15 (Table 21). Additionally, nearly all variants exhibited higher aggregation temperature, Tagg, compared to lebrikizumab. Tagg is a measure of the propensity of the mAb for forming higher molecules weight aggregates, and higher values are more desirable. Thus, the majority of the engineered variants had a more desirable aggregation temperature.

TABLE 21

Thermostability of engineered anti-IL-13 antibodies

Tagg

Tm2
473

Construct ID*
(° C.)
(° C.)

Lebrikizumab
71.8
68.5

Construct 2
72.2
71.2

Construct 3
73.3
72.1

Construct 4
73.4
72.1

Construct 5
75.9
76.1

Construct 6
72.4
72.8

Construct 7
72.3
72.8

Construct 8
72.1
72.6

Construct 9
69.1
72.3

Construct 15
77.4
77.1

Construct 16
72.4
73.0

Construct 17
72.5
72.9

Construct 18
73.1
73.1

Construct 19
71.8
72.8

Construct 20
71.1
72.0

Construct 95
72.8
76.2

Construct 96
70.8
71.2

Construct 98
70.8
72.0

Construct 104
68.6
74.1

Construct 106
71.1
75.2

Construct 107
71.2
74.1

Construct 108
72.5
73.8

Construct 110
71.4
74.0

Construct 114
70.9
73.8

*See construct sequences in Tables 2-8.

Example 4: Engineered Anti-IL-13 Antibodies Exhibit Reduced Hydrophobicity

Hydrophobic interaction chromatography (HIC) was performed to measure the propensity of the engineered anti-IL-13 antibodies for interaction with hydrophobic surfaces (Table 22). Shorter retention times indicate less degree of hydrophobicity. All of the novel IL-13 antibodies tested showed shorter retention times (RT) compared to lebrikizumab. Thus, all of the engineered anti-13 antibodies tested exhibited reduced hydrophobicity compared to lebrikizumab.

TABLE 22

Hydrophobicity of engineered anti-IL-13 antibodies

HIC

RT

Construct ID*
(min)

Lebrikizumab
15.2

Construct 2
15.3

Construct 15
13.9

Construct 19
14.1

Construct 95
13.3

Construct 96
14

Construct 98
13.7

Construct 104
14.1

Construct 106
13.3

Construct 107
13.3

Construct 108
14.1

Construct 110
14.4

Construct 114
13.4

*See construct sequences in Tables 2-8.

Example 6: An Engineered Anti-IL13 Antibody Variant and Lebrikizumab have the Same Epitope on IL-13

Epitope binning describes a technique that characterizes whether two antibodies specific to the same target (in this case, IL-13) can each bind the target at the same time. mAb pairs are binned together if they block each other's ability to bind to the target antigen. mAb pairs that bin together typically bind to the same or overlapping epitopes on the antigen.

To characterize the binding of Construct 133, which comprises SEQ ID NOs: 3, 39, 439, and 469, vs. lebrikizumab, lebrikizumab was immobilized onto a sensor chip surface capable of measuring mAb-antigen interactions. IL-13 was first injected into the flow channel, where binding of IL-13 to lebrikizumab generated a response. Construct 133 was subsequently injected into the flow channel and the interaction response was recorded. In these studies, no response was observed after Construct 133 injection (see results in Table 23). This indicated that Construct 133 and lebrikizumab binned together and provided evidence to support that the two mAbs likely bind to a similar or the same epitope on IL-13.

TABLE 23

Antibody Binding

Competitor Antibody or
Immobilized

Construct ID*
Lebrikizumab

Lebrikizumab
+

Tralokinumab
−

Cendakimab
−

Construct 133
+

+ indicates antibodies that bin with lebrikizumab.

− indicates antibodies that do not bin with lebrikizumab.

*See construct sequence 133 in Tables 2-8.

In a similar study, tralokunumab-ldrm (Adbry™) was found to have a binning response, suggesting that it has a different epitope on IL-13 than lebrikizumab.

To further characterize the epitopes of Construct 133 and lebrikizumab, hydrogen-deuterium exchange mass-spectrometry (HDX-MS) and cross-linking mass-spectrometry (XL-MS) were performed, as known in the art. Briefly, HDX-MS was performed using either IL-13 alone at a concentration of 20 uM or a mixed solution of IL-13 and purified antibody, with a final concentration of 20 uM and 40 uM, respectively. Incubation times of 15 s, 60 s, 180 s, 600 s, 1800 s, and 7200 s were performed before the exchange reaction was quenched and the protein mixture subject to proteolysis followed by LC-MS using a Waters Q-ToF Xevo G2-XS. Deuterium incorporation was determined for both IL-13 and the mixture, and peptide regions where deuterium incorporation was inhibited were considered likely to be involved in the binding to the purified antibody. Briefly, XL-MS was performed using a mixed solution of IL-13 and purified antibody, with a final concentration of 14.7 uM and 0.7 uM, respectively. 20 uL of this mixture was mixed with 2 uL of DSS (2 mg/mL stock in DMF) and the final solution was allowed to incubate for 180 minutes at room temperature. After this incubation, samples were subject to proteolysis using trypsin, chymotrypsin, ASP-N, elastase and thermolysin and analyzed using LC-MS using a Q-Exactive MS. Peptides were referenced against peptides identified from a previous peptide mapping experiment of IL-13 alone. IL-13 peptide regions that showed cross-linking to corresponding peptides from the antibody variable region were considered likely to be involved in the binding to the purified antibody. Both methods provided complementary data indicating specific amino acid regions where Construct 133 and lebrikizumab are likely to bind. This provided further evidence to support that the two mAbs likely bind to a highly overlapping epitope on IL-13 (FIG. 1).

These studies provide evidence that Construct 133 binds the same region on IL-13 as lebrikizumab and therefore they are more likely to have the same biological effect than if Construct 133 recognized a different region.

Example 7: An Engineered Anti-IL-13 Antibody Variant Demonstrated Significantly Extended Half-Life in NHPs and Pharmacokinetic Analysis of Anti-IL-13 Antibodies

Extended Half-Life of an Anti-IL-13 Antibody Variant in NHPs

To demonstrate the potential of engineered anti-IL13 antibody variants to improve dosing over current and anticipated standard of care mAbs in Alzheimer's disease (AD), among other diseases, Construct 133, which comprises SEQ ID NOs: 3, 39, 439, and 469, was studied in female non-human primates (NHPs) following a single bolus dose of 3 mg/kg, given either IV or SQ. Blood samples were collected serially starting with a sample pre-dose and subsequently at 0.167, 1, 4, 8, 24, 48, 96, 168, 336, 504, 674, 840, 1334, 1680, and 2160 hours post-dose. PK parameters of maximum observed serum concentration (C_max), time to maximum observed serum concentration (T_max), area under the serum concentration versus time curve from time 0 extrapolated to infinity (AUC_0-inf), clearance (CL), volume of distribution at steady-state (V_ss), half-life (T_1/2) and absolute subcutaneous bioavailability (F) were calculated. Data was analyzed to show mean serum concentration with standard deviation over time and a regression fit was performed.

In head-to-head studies of Construct 133 versus lebrikizumab in NHPs, both IV and SQ formulations of Construct 133 showed a significantly longer half-life than lebrikizumab. In these studies, the average half-life of Construct 133 was 27.6 days, as compared to 18 days for lebrikizumab, as shown in FIG. 9. Further, Construct 133 exhibited an average clearance rate of 1.45 (mL day⁻¹kg⁻¹) in NHPs. The steady-state volume of distribution was observed to be 55.65 (mL kg⁻¹). Construct 133 was well-absorbed, with subcutaneous bioavailability determined to be 81.22%. Lebrikizumab exhibited an average clearance rate of 2.93 (mL day⁻¹kg⁻¹) in NHPs. The steady-state volume of distribution was observed to be 52.10 (mL kg⁻¹). Lebrikizumab was well-absorbed, with subcutaneous bioavailability determined to be 75.70%. Without being bound by theory, because Construct 133 was engineered to have a YTE amino-acid substitution in the Fc region, the half-life of the IgG may have been prolonged by increasing binding to neonatal Fc receptor (FcRn) under acidic pH conditions. FcRn-bound IgG is recycled via lysosomal salvage, resulting in the IgG returning to the circulation. Construct 133's prolonged half-life may enable less frequent dosing compared to currently available treatments, which could reduce injection burden and increase compliance for patients living with atopic dermatitis and other IL-13-driven diseases.

In a non-head-to-head comparison against third-party NHP data, Construct 133 demonstrated the highest normalized AUC_0-∞ (C_norm*day), or area under the curve (AUC) from dosing to infinity, among antibodies with the YTE substitution, as shown in FIG. 10. Thus, the PK profile of Construct 133 appears to provide the greatest sustained concentrations, or levels of drug in the blood stream, relative to other antibodies with the YTE substitution.

The half-life extension for mAbs with YTE amino acid substitutions is dependent on the type of target (e.g., receptor vs. soluble). Therefore, the translation of NHP half-life data to human half-life data for mAbs with soluble targets was studied, and it was found that human half-life is approximately three to four times longer than NHP half-life (mean: 3.5×, median 3.1×; data not shown).

It is expected, based on this NHP half-life data, that the antibodies disclosed herein (e.g., Construct 133) will have a human half-life of approximately 80 to 110 days based on comparable mAbs with YTE amino acid substitution.

Further, based on PK modeling, with a 33-day human half-life (which, to Applicant's knowledge, would be lower than the lowest half-life for a mAb with the YTE amino acid substitutions and a soluble target reported to date), it is believed that the antibodies disclosed herein can be dosed effectively with an every two month maintenance dosing schedule. With a 50-day half-life, it is believed that the antibodies disclosed herein can be dosed effectively with an every three month maintenance dosing schedule.

To understand the maintenance dosing schedule that the antibodies disclosed herein may be able to achieve, known PK parameters for lebrikizumab were used. These PK parameters provided an understanding of how lebrikizumab was distributed throughout the body and cleared. Based on these known parameters, a two-compartment PK model with first-order absorption was built, which is standard for mAbs, to predict concentration or drug levels, over time of both lebrikizumab and the antibodies disclosed herein. Key parameters included 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), 0.239 day-1 for absorption rate (ka) and 85.6% for bioavailability.

It is believed that efficacy in inflammatory conditions, such as AD, is driven by C_trough, or the minimal concentration of the mAb. Therefore, based on the model described above, the target C_troughof the antibodies disclosed herein was set to be equal to lebrikizumab's C_troughin maintenance with every one month dosing, which was 31.3 mg/L. Given the overlapping epitopes of lebrikizumab and certain antibodies disclosed herein, and similarity in potency across multiple in vitro assays, the necessary exposures for potential clinical activity of the antibodies disclosed herein can be predicted. By modeling K_elimination, the elimination rate constant or the fraction of drug eliminated in a given time, and half-life to maintain concentrations of the disclosed antibodies above 31.3 mg/L, at least a 33-day half-life is would be required to dose the disclosed antibodies every two months in maintenance and at least a 50-day half-life would be required to dose the disclosed antibodies every three months in maintenance assuming a dose of 300 mg.

Thus, with a 33-day human half-life, it is believed that the antibodies disclosed herein can be dosed effectively with an every two month maintenance dosing schedule. With a 50-day half-life, it is believed that the antibodies disclosed herein can be dosed effectively with an every three month maintenance dosing schedule.

Pharmacokinetic Analysis of Anti-IL-13 Antibodies

In further experiments, multiple in vivo pharmacokinetic (PK) studies were performed where lebrikizumab, additional variants of Construct 15 or Construct 98 with one or more amino acid substitutions in the heavy chain constant region (Constructs 133-137 or 137 and 140, respectively), and/or additional variants with one or more amino acid substitutions in the heavy chain constant region (Constructs 141 and 144) were also tested.

Studies were performed using cynomolgus monkey (Macaca fascicularis), where any matching or subcutaneous (SQ)/intravenous (IV) cohorts were either all female, ranging from 1.5 kg to 2.0 kg in weight, or all males, ranging from 2.9 kg to 3.3 kg in weight. Animals were administered test agents by IV bolus and/or SQ injection on Day 0 at a dose of 3 mg/kg for each antibody and serum samples were taken regularly throughout the study.

PK parameters were determined from cynomolgus serum samples up to day 56 (1334 hours), with a subset of cohorts up to day 90 (2160 hours), with average PK curves are shown in FIG. 11 for IV administration and FIG. 12 for SQ administration. The PK analysis demonstrated that Constructs 133, 134, 135, 136, 137, 140, 141, and 144 each had improved half-life and reduction in serum clearance rates compared to those of lebrikizumab as reported in Table 24. In cases where bioavailability (F) could be determined, Constructs 133, 134, and 141 were shown to possess equivalent bioavailability to that of lebrikizumab (Table 25).

TABLE 24

Half-life and Serum Clearance Rates

AUC_inf

CL*

Construct ID^# and

(ng ·
Half-
(mL ·
V_ss*

Administration

hours ·
Life
day⁻¹
(mL ·

Group
Animal
mL⁻¹)
(Days)
· kg⁻¹)
kg⁻¹)

Lebrikizumab - IV
1501
17447678.05
11.02
4.13
51.38

1502
28812691.42
18.86
2.50
55.87

1501
33491428.36
24.35
2.15
70.54

Lebrikizumab - SQ
2501
28290795.91
18.82
1.93
52.83

2502
14531783.14
11.33
3.75
42.26

2503
17545785.64
10.42
3.11
39.72

Construct 133 - IV
6501
54367740.94
30.25
1.32
53.97

6502
49429927.46
28.27
1.46
56.14

6503
47738132.48
26.22
1.51
52.07

Construct 133 - SQ
7501
50202816.21
30.85
1.16
53.73

7502
31546038.62
22.44
1.85
60.32

7503
41329262.82
27.65
1.41
57.68

Construct 134 - IV
3501
52254317.47
21.38
1.38
47.07

3502
33366131.55
17.24
2.16
54.75

3503
77329739.21
41.87
0.93
46.90

Construct 134 - SQ
4501
54533364.13
50.94
0.96
65.60

4502
36701086.34
20.48
1.43
42.05

4503
27442862.48
14.49
1.91
38.48

Construct 135 - SQ
5501
50614453.99
29.68
1.42
57.79

5502
75200216.97
40.07
0.96
55.48

5503
61123113.94
27.93
1.18
48.56

Construct 136 - SQ
8501
47846929.29
27.86
1.50
56.97

8502
32127535.46
21.51
2.24
66.76

8503
44101872.29
30.83
1.63
68.10

Construct 137 - SQ
9501
46216823.54
16.57
1.56
52.59

9502
32421239.31
25.86
2.22
68.74

9503
44629524.73
34.27
1.61
70.01

Construct 140 - SQ
10501
51739935.51
27.32
1.39
49.24

10502
41305658.5
21.82
1.74
53.20

10503
47527303.18
32.84
1.51
72.48

Construct 141 - IV
4089
45698126.79
27.2
1.58
60.29

2095
62600360.39
31.99
1.15
55.01

3027
53748965.77
33.88
1.34
63.50

Construct 141 - SQ
1131
56004213.41
45.72
0.97
66.44

1083
38648918.97
31.47
1.41
64.56

1127
27810354.27
21.22
1.96
63.03

Construct 144 - SQ
11501
28455075.58
21.78
2.53
85.42

11502
22141956.08
18.99
3.25
81.00

11503
45675112.33
43.35
1.58
103.64

*These values are adjusted for bioavailability in cohorts Lebrikizumab, Construct 133, Construct 134, and Construct 141.

^#See construct sequences in Tables 2-8.

TABLE 25

Construct Bioavailability

Construct ID*
Bioavailability (%)

Lebrikizumab
75.70%

Construct 133
81.22%

Construct 134
72.83%

Construct 141
75.57%

*See construct sequences in Tables 2-8.

Example 8. Inhibition of IL-13 Induced Secretion of CCL2 and CCL26 and Expression of NTRK1 in HaCaT Cells

Inhibition of CCL26 (eotaxin-3) and CCL2 (MCP-1) secretion (FIG. 13 and FIG. 14, respectively) and NTRK1 expression (FIG. 15) by HaCaT cells was used to evaluate the functional activity of antibodies to block IL-13-induced biological activity. HaCaT cells were seeded at 20,000 cells in 100 uL of DMEM+10% FBS and cultured overnight at 37° C. The next day, a 150 uL mixture of hIL-13 and purified antibody were added to the wells, resulting in a final concentration of 50 ng/ml of IL-13 with 0-206.5 nM purified antibody. Cells were then further incubated at 37° C. for 48 hours. Following incubation, culture supernatant was collected and levels of secreted CCL26 and CCL2 were measured using a commercial Luminex-based immunoassay kit (R&D Systems) and analyzed according to manufacturer's instructions. Determined concentrations of CCL26 and CCL2 in each well were analyzed using GraphPad Prism. IC₅₀values were determined as the concentration of antibody required to inhibit 50% of the maximum concentration detected with incubation of 50 ng/ml of IL-13 alone.

TABLE 26

CCL26 and CCL2 secretion and NTRK1 expression

CCL2
CCL26
NTRK1

Secretion
Secretion
Expression

Construct ID*
IC₅₀(nM)
IC₅₀(nM)
IC₅₀(nM)

Lebrikizumab
0.076
0.055
0.056

Construct 133
0.077
0.060
0.062

Construct 136
0.074
0.052
0.053

Construct 141
0.075
0.055
0.054

*See construct sequences in Tables 2-8.

Example 9. Monomer Purity after Affinity Capture from Stable Pools

The monomer purity from one-step affinity capture is a determinant for the final yield and unit cost of an antibody under cGMP production. To characterize this, briefly, CHO stable pools were generated separately for each antibody in a workstream that led to master cell bank selection for cGMP production. The affinity capture step was performed using a Mabselect SuRe column. Novel IgG1 variants (e.g., Constructs 132, 133, 136, 137, 140, 141, and 144) remained a clear solution with <15% aggregate after the one-step purification. Novel IgG4 variants (Constructs 134, 135, 138, 139, 142, and 143) had an opalescent appearance with some precipitation and an aggregation sensitivity (>68% aggregate) when using an elution buffer of 50 mM sodium citrate, 150 mM sodium chloride at pH 3.0. The novel IgG4 variants had lower aggregate levels when eluted with either 50 mM acetic acid, pH 2.8 or with 100 mM sodium acetate, 800 mM arginine at pH 3.5. At the higher pH of 3.5, the arginine was needed to retain a suitable recovery.

Results are summarized in Table 27. Novel IgG1 and IgG4 variants demonstrate greater monomer purity directly out of affinity capture with optimized elution conditions when compared to lebrikizumab variants (Constructs 128-131).

TABLE 27

Anti-IL-13 Antibody Monomer Purity

One-Step Monomer

Construct ID*
Purity (%)

Construct 128
87.7

Construct 129
90.5

Construct 130
81.6

Construct 131
82.9

Construct 132
94.7

Construct 133
90.9

Construct 134
91.7

Construct 135
91.4

Construct 136
90.3

Construct 137
92.7

Construct 138
94.0

Construct 139
92.0

Construct 140
89.7

Construct 141
94.1

Construct 142
90.1

Construct 143
91.5

Construct 144
92.4

*See construct sequences in Tables 2-8.

Example 10. Accelerated Stability

As demonstrated by this example, novel variants in an IgG1 construct had a lower propensity to aggregate and were more resistant to changes in the basic species under various stress conditions, as shown in Table 28. The proportion of basic species was determined through capillary isoelectric focusing (ciEF), performed as known in the art. The variants related to lebrikizumab (Constructs 128-131) and IgG4 variants (Constructs 134, 135, 142, and 143); as described in Examples 1-7) were more susceptible to aggregation and changes in the basic species compared to the novel IgG1 variants (e.g., Constructs 132, 133, 136, 137, 140, 141, and 144).

TABLE 28

Anti-IL-13 Antibody Stability Change

40° C.

Stability-
40° C.
pH 3.5
pH 3.5

Change
Stability-
Stability -
Stability -

in
Change
Change
Change

Monomer
Basic
Monomer
Basic

Construct ID*
Purity
Species
Purity
Species

Construct 128
−10.0%
+26.5%
−10.0%
+6.3%

Construct 129
−3.2%
+8.2%
−12.7%
+5.7%

Construct 130
−2.2%
−13.8%
−1.1%
+1.5%

Construct 131
−2.1%
−11.2%
−1.6%
+0.6%

Construct 132
−0.8%
+2.4%
−0.7%
+1.2%

Construct 133
−2.1%
+0.9%
−1.3%
+0.9%

Construct 134
−1.4%
+10.3%
−19.5%
+13.3%

Construct 135
−1.8%
+2.1%
−15.7%
+8.0%

Construct 136
−0.9%
+1.5%
−1.4%
+0.4%

Construct 137
−1.5%
+2.4%
−1.3%
+1.6%

Construct 140
−3.6%
+1.5%
−1.4%
+0.8%

Construct 141
−2.5%
+0.0%
−0.5%
+0.5%

Construct 142
−4.0%
+7.1%
−8.9%
+6.5%

Construct 143
−4.3%
+5.1%
−11.1%
+5.1%

Construct 144
−3.0%
+2.0%
−0.1%
+1.2%

*See construct sequences in Tables 2-8.

Assessment of clones for changes in monomer purity and basic species were evaluated at day 0 and day 14 for 40° C. stability and at day 0 and day 2 for pH 3.5 stability.

N.T.—Not Tested.

While the invention has been particularly shown and described with reference to a preferred embodiment and various alternate embodiments, it will be understood by persons skilled in the relevant art that various changes in form and details can be made therein without departing from the spirit and scope of the invention.

All references, issued patents and patent applications cited within the body of the instant specification are hereby incorporated by reference in their entirety, for all purposes.

Informal sequence listing

SEQ ID

Description
Sequence
NO

Heavy
QVQLQESGPGLVAPSQSLSITCTVSGFSLNAYSVNWVRQP
SEQ ID

Chain
PGKGLEWLGMIWGDGKIVYNSALKSRLNISKDSSKSQVFL
NO: 1

Variable
KMSSLQSDDTARYYCAGDGYYPYAMDNWGHGTSVTVSS

domain

HC0

Heavy
QVQLQESGPGLVAPSQSLSITCTVSGFSLNAYSVNWVRQP
SEQ ID

Chain
PGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKSQVFL
NO: 2

Variable
KMSSLQSDDTARYYCAGDGYYPYAMDNWGHGTSVTVSS

domain

HC0_M

Heavy
EVQLQESGPGLVKPSETLSLTCTVSGFSLNAYSVNWIRQPP
SEQ ID

Chain
GKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNQVSLK
NO: 3

Variable
LSSVTAADTAVYYCAGDGYYPYAMDNWGQGTTVTVSS

domain

HC1

Heavy
EVQLVQSGAEVKKPGASVKVSCKASGFSLNAYSVNWVR
SEQ ID

Chain
QAPGQGLEWLGMIWGDGKIVYNSALKSRLTITKDSSTSTV
NO: 4

Variable
YMELSSLRSEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC2

Heavy
EVQLVQSGAEVKKPGSSVKVSCKASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGQGLEWLGMIWGDGKIVYNSALKSRLTITKDSSTSTVY
NO: 5

Variable
MELSSLRSEDTAVYYCAGDGYYPYAMDNWGQGTTVTVS

domain
S

HC3

Heavy
EVQLVESGGGLVKPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 6

Variable
LQMNSLKTEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC4

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 7

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5

Heavy
EVQLQESGPGLVKPSETLSLTCTVSGGSLNAYSVNWVRQP
SEQ ID

Chain
PGKGLEWLGMIWGDGKIVYNSALKSRLTISLDTSKSQVFL
NO: 8

Variable
KMSSLTAADTAVYYCARDGYYPYAMDNWGQGTTVTVSS

domain

HC6

Heavy
QVQLQESGPGLVKPSETLSLTCTVSGGSLNAYSWNWVRQ
SEQ ID

Chain
PPGKGLEWLGYIYGDGKTNYNPALKSRLTISLDTSKSQVF
NO: 9

Variable
LKMSSLTAADTAVYYCARDGYYYYAMDVWGQGTTVTV

domain
SS

HC7

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGYSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 10

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m1

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLRAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 11

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m2

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLHAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 12

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m3

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLDAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 13

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m4

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLYAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 14

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m5

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLSAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 15

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m6

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNRYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 16

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m7

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNKYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 17

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m8

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNHYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 18

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m9

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNQYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 19

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m10

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNEYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 20

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m11

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNSYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 21

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m12

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNYYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 22

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m13

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAESVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 23

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m14

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWSDGKIVYNSALKSRLTISKDSSKNTVY
NO: 24

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m15

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWADGKIVYNSALKSRLTISKDSSKNTVY
NO: 25

Variable
LQMNSLRAEDTAVYYCAGDGYYPYAMDNWGQGTTVTV

domain
SS

HC5m16

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 26

Variable
LQMNSLRAEDTAVYYCAGHGYYPYAMDNWGQGTTVTV

domain
SS

HC5m17

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 27

Variable
LQMNSLRAEDTAVYYCAGDLYYPYAMDNWGQGTTVTVS

domain
S

HC5m18

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 28

Variable
LQMNSLRAEDTAVYYCAGDKYYPYAMDNWGQGTTVTV

domain
SS

HC5m19

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 29

Variable
LQMNSLRAEDTAVYYCAGDGYYGYAMDNWGQGTTVTV

domain
SS

HC5m20

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 30

Variable
LQMNSLRAEDTAVYYCAGDGYYAYAMDNWGQGTTVTV

domain
SS

HC5m21

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 31

Variable
LQMNSLRAEDTAVYYCAGDGYYSYAMDNWGQGTTVTV

domain
SS

HC5m22

Heavy
EVQLLESGGGLVQPGGSLRLSCAASGFSLNAYSVNWVRQ
SEQ ID

Chain
APGKGLEWLGMIWGDGKIVYNSALKSRLTISKDSSKNTVY
NO: 32

Variable
LQMNSLRAEDTAVYYCAGDGYYTYAMDNWGQGTTVTV

domain
SS

HC5m23

Light Chain
NIVLTQSPASLAVSLGQRATISCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPV
NO: 33

domain
EADDAASYYCQQNNEDPRTFGGGTKLEIK

LC0

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSRTDFTLTISSL
NO: 34

LC1
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSRTDFTLTISSL
NO: 35

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC2

Light Chain
EIVLTQSPATLSVSPGERATLSCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGQAPRLLIYLASNLESGIPARFSGSGSRTEFTLTISSL
NO: 36

domain
QSEDFAVYYCQQNNEDPRTFGGGTKVEIK

LC3

Light Chain
DIVLTQSPLSLPVTPGEPASISCRASKSVDSYGNSFMHWYL
SEQ ID

Variable
QKPGQSPQLLIYLASNLESGVPDRFSGSGSRTDFTLKISRVE
NO: 37

domain
AEDVGVYYCQQNNEDPRTFGGGTKVEIK

LC4

Light Chain
DIVLTQSPDSLAVSLGERATINCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSL
NO: 38

domain
QAEDVAVYYCQQNNEDPRTFGGGTKVEIK

LC5

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 39

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6

Light Chain
EIVLTQSPATLSVSPGERATLSCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGQAPRLLIYLASNLESGIPARFSGSGSGTEFTLTISSL
NO: 40

domain
QSEDFAVYYCQQNNEDPRTFGGGTKVEIK

LC7

Light Chain
DIVLTQSPLSLPVTPGEPASISCRASKSVDSYGNSFMHWYL
SEQ ID

Variable
QKPGQSPQLLIYLASNLESGVPDRFSGSGSGTDFTLKISRVE
NO: 41

domain
AEDVGVYYCQQNNEDPRTFGGGTKVEIK

LC8

Light Chain
DIVLTQSPASLAVSPGERATISCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISRV
NO: 42

domain
EADDVAVYYCQQNNEDPRTFGGGTKLEIK

LC9

Light Chain
DIVLTQSPASLAVSPGERATISCRASQSVDSNGNNFLHWY
SEQ ID

Variable
QQKPGQPPKLLIYLASNRESGVPDRFSGSGSGTDFTLTISR
NO: 43

domain
VEADDVAVYYCQQNNHTPRTFGGGTKLEIK

LC10

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSRMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 44

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m1

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSSMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 45

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m2

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIRLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 46

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m3

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIFLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 47

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m4

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASHLESGVPSRFSGSGSGTDFTLTISSL
NO: 48

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m5

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASDLESGVPSRFSGSGSGTDFTLTISSL
NO: 49

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m6

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASQLESGVPSRFSGSGSGTDFTLTISSL
NO: 50

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m7

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASELESGVPSRFSGSGSGTDFTLTISSL
NO: 51

domain
QPEDFATYYCQQNNEDPRTFGGGTKVEIK

LC6_m8

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 52

domain
QPEDFATYYCQQNHEDPRTFGGGTKVEIK

LC6_m9

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 53

domain
QPEDFATYYCQQNYEDPRTFGGGTKVEIK

LC6_m10

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 54

domain
QPEDFATYYCQQNSEDPRTFGGGTKVEIK

LC6_11

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 55

domain
QPEDFATYYCQQNNRDPRTFGGGTKVEIK

LC6_m12

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 56

domain
QPEDFATYYCQQNNDDPRTFGGGTKVEIK

LC6_m13

Light Chain
DIQLTQSPSSLSASVGDRVTITCRASKSVDSYGNSFMHWY
SEQ ID

Variable
QQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSL
NO: 57

domain
QPEDFATYYCQQNNQDPRTFGGGTKVEIK

LC6_m14

Parental
AYSVN
SEQ ID

Kabat

NO: 58

HCDR1

HC5_m7
RYSVN
SEQ ID

Kabat

NO: 59

HCDR1

HC5_m8
KYSVN
SEQ ID

Kabat

NO: 60

HCDR1

HC5_m9
HYSVN
SEQ ID

Kabat

NO: 61

HCDR1

HC5_m10
QYSVN
SEQ ID

Kabat

NO: 62

HCDR1

HC5_m11
EYSVN
SEQ ID

Kabat

NO: 63

HCDR1

HC5_m12
SYSVN
SEQ ID

Kabat

NO: 64

HCDR1

HC5 m13
YYSVN
SEQ ID

Kabat

NO: 65

HCDR1

HC5_m14
AESVN
SEQ ID

Kabat

NO: 66

HCDR1

Lebrikizumab
GFSLSAY
SEQ ID

Chothia

NO: 67

HCDR1

Parental
GFSLNAY
SEQ ID

Chothia

NO: 68

HCDR1

HC6
GGSLNAY
SEQ ID

Chothia

NO: 69

HCDR1

HC7
GGSLNAY
SEQ ID

Chothia

NO: 70

HCDR1

HC5_m1
GYSLNAY
SEQ ID

Chothia

NO: 71

HCDR1

HC5_m2
GFSLRAY
SEQ ID

Chothia

NO: 72

HCDR1

HC5_m3
GFSLHAY
SEQ ID

Chothia

NO: 73

HCDR1

HC5_m4
GFSLDAY
SEQ ID

Chothia

NO: 74

HCDR1

HC5_m5
GFSLYAY
SEQ ID

Chothia

NO: 75

HCDR1

HC5_m7
GFSLNRY
SEQ ID

Chothia

NO: 76

HCDR1

HC5_m8
GFSLNKY
SEQ ID

Chothia

NO: 77

HCDR1

HC5_m9
GFSLNHY
SEQ ID

Chothia

NO: 78

HCDR1

HC5_m10
GFSLNQY
SEQ ID

Chothia

NO: 79

HCDR1

HC5_m11
GFSLNEY
SEQ ID

Chothia

NO: 80

HCDR1

HC5_m12
GFSLNSY
SEQ ID

Chothia

NO: 81

HCDR1

HC5_m13
GFSLNYY
SEQ ID

Chothia

NO: 82

HCDR1

HC5_m14
GFSLNAE
SEQ ID

Chothia

NO: 83

HCDR1

Lebrikizumab
GFSLSAYS
SEQ ID

IMGT

NO: 84

HCDR1

Parental
GFSLNAYS
SEQ ID

IMGT

NO: 85

HCDR1

HC6
GGSLNAYS
SEQ ID

IMGT

NO: 86

HCDR1

HC5_m1
GYSLNAYS
SEQ ID

IMGT

NO: 87

HCDR1

HC5_m2
GFSLRAYS
SEQ ID

IMGT

NO: 88

HCDR1

HC5_m3
GFSLHAYS
SEQ ID

IMGT

NO: 89

HCDR1

HC5_m4
GFSLDAYS
SEQ ID

IMGT

NO: 90

HCDR1

HC5_m5
GFSLYAYS
SEQ ID

IMGT

NO: 91

HCDR1

HC5_m6
GFSLSAYS
SEQ ID

IMGT

NO: 92

HCDR1

HC5_m7
GFSLNRYS
SEQ ID

IMGT

NO: 93

HCDR1

HC5_m8
GFSLNKYS
SEQ ID

IMGT

NO: 94

HCDR1

HC5_m9
GFSLNHYS
SEQ ID

IMGT

NO: 95

HCDR1

HC5_m10
GFSLNQYS
SEQ ID

IMGT

NO: 96

HCDR1

HC5_m11
GFSLNEYS
SEQ ID

IMGT

NO: 97

HCDR1

HC5_m13
GFSLNYYS
SEQ ID

IMGT

NO: 98

HCDR1

HC5_m14
GFSLNAES
SEQ ID

IMGT

NO: 99

HCDR1

Parental
MIWGDGKIVYNSALKS
SEQ ID

Kabat

NO: 100

HCDR2

HC7
YIYGDGKTNYNPALKS
SEQ ID

Kabat

NO: 101

HCDR2

HC5_m15
MIWSDGKIVYNSALKS
SEQ ID

Kabat

NO: 102

HCDR2

HC5_m16
MIWADGKIVYNSALKS
SEQ ID

Kabat

NO: 103

HCDR2

Parental
WGDGK
SEQ ID

Chothia

NO: 104

HCDR2

HC7
YGDGK
SEQ ID

Chothia

NO: 105

HCDR2

HC5_m15
WSDGK
SEQ ID

Chothia

NO: 106

HCDR2

HC5_m16
WADGK
SEQ ID

Chothia

NO: 107

HCDR2

Parental
IWGDGKI
SEQ ID

IMGT

NO: 108

HCDR2

HC7
IYGDGKT
SEQ ID

IMGT

NO: 109

HCDR2

HC5_m15
IWSDGKI
SEQ ID

IMGT

NO: 110

HCDR2

HC5_m16
IWADGKI
SEQ ID

IMGT

NO: 111

HCDR2

Parental
DGYYPYAMDN
SEQ ID

Kabat and

NO: 112

Chothia

HCDR3

HC7
DGYYYYAMDV
SEQ ID

Kabat and

NO: 113

Chothia

HCDR3

HC5_m17
HGYYPYAMDN
SEQ ID

Kabat and

NO: 114

Chothia

HCDR3

HC5_m18
DLYYPYAMDN
SEQ ID

Kabat and

NO: 115

Chothia

HCDR3

HC5_m19
DKYYPYAMDN
SEQ ID

Kabat and

NO: 116

Chothia

HCDR3

HC5_m20
DGYYGYAMDN
SEQ ID

Kabat and

NO: 117

Chothia

HCDR3

HC5_m21
DGYYAYAMDN
SEQ ID

Kabat and

NO: 118

Chothia

HCDR3

HC5_m22
DGYYSYAMDN
SEQ ID

Kabat and

NO: 119

Chothia

HCDR3

HC5_m23
DGYYTYAMDN
SEQ ID

Kabat and

NO: 120

Chothia

HCDR3

HC5_m12
GNSLNSYS
SEQ ID

IMGT

NO: 121

HCDR1

SEQ ID

NO: 122

SEQ ID

NO: 123

SEQ ID

NO: 124

SEQ ID

NO: 125

SEQ ID

NO: 126

SEQ ID

NO: 127

SEQ ID

NO: 128

SEQ ID

NO: 129

Parental
AGDGYYPYAMDN
SEQ ID

IMGT

NO: 130

HCDR3

HC6
ARDGYYPYAMDN
SEQ ID

IMGT

NO: 131

HCDR3

HC7
ARDGYYYYAMDV
SEQ ID

IMGT

NO: 132

HCDR3

HC5_m17
AGHGYYPYAMDN
SEQ ID

IMGT

NO: 133

HCDR3

HC5_m18
AGDLYYPYAMDN
SEQ ID

IMGT

NO: 134

HCDR3

HC5_m19
AGDKYYPYAMDN
SEQ ID

IMGT

NO: 135

HCDR3

HC5_m20
AGDGYYGYAMDN
SEQ ID

IMGT

NO: 136

HCDR3

HC5_m21
AGDGYYAYAMDN
SEQ ID

IMGT

NO: 137

HCDR3

HC5_m22
AGDGYYSYAMDN
SEQ ID

IMGT

NO: 138

HCDR3

HC5_m23
AGDGYYTYAMDN
SEQ ID

IMGT

NO: 139

HCDR3

HC1_m6
AGDGYYPYAMDN
SEQ ID

IMGT

NO: 140

HCDR3

Parental
RASKSVDSYGNSFMH
SEQ ID

Kabat and

NO: 141

Chothia

LCDR1

LC10
RASQSVDSNGNNFLH
SEQ ID

Kabat and

NO: 142

Chothia

LCDR1

LC6_m1
RASKSVDSYGNSRMH
SEQ ID

Kabat and

NO: 143

Chothia

LCDR1

LC6_m2
RASKSVDSYGNSSMH
SEQ ID

Kabat and

NO: 144

Chothia

LCDR1

SEQ ID

NO: 145

SEQ ID

NO: 146

SEQ ID

NO: 147

SEQ ID

NO: 148

Parental
KSVDSYGNSF
SEQ ID

IMGT

NO: 149

LCDR1

LC10
QSVDSNGNNF
SEQ ID

IMGT

NO: 150

LCDR1

LC6_m1
KSVDSYGNSR
SEQ ID

IMGT

NO: 151

LCDR1

LC6_m2
KSVDSYGNSS
SEQ ID

IMGT

NO: 152

LCDR1

Parental
LASNLES
SEQ ID

Kabat and

NO: 153

Chothia

LCDR2

LC6_m5
LASHLES
SEQ ID

Kabat and

NO: 154

Chothia

LCDR2

LC6_m6
LASDLES
SEQ ID

Kabat and

NO: 155

Chothia

LCDR2

LC6_m7
LASQLES
SEQ ID

Kabat and

NO: 156

Chothia

LCDR2

LC6_m8
LASELES
SEQ ID

Kabat and

NO: 157

Chothia

LCDR2

LC10
LASNRES
SEQ ID

Kabat and

NO: 158

Chothia

LCDR2

SEQ ID

NO: 159

SEQ ID

NO: 160

SEQ ID

NO: 161

SEQ ID

NO: 162

SEQ ID

NO: 163

SEQ ID

NO: 164

Parental
QQNNEDPRT
SEQ ID

Kabat,

NO: 165

Chothia and

IMGT

LCDR3

LC10
QQNNHTPRT
SEQ ID

Kabat,

NO: 166

Chothia and

IMGT

LCDR3

LC6_m9
QQNHEDPRT
SEQ ID

Kabat,

NO: 167

Chothia and

IMGT

LCDR3

LC6_m10
QQNYEDPRT
SEQ ID

Kabat,

NO: 168

Chothia and

IMGT

LCDR3

LC6_m11
QQNSEDPRT
SEQ ID

Kabat,

NO: 169

Chothia and

IMGT

LCDR3

LC6_m12
QQNNRDPRT
SEQ ID

Kabat,

NO: 170

Chothia and

IMGT

LCDR3

LC6_m13
QQNNDDPRT
SEQ ID

Kabat,

NO: 171

Chothia and

IMGT

LCDR3

LC6_m14
QQNNQDPRT
SEQ ID

Kabat,

NO: 172

Chothia and

IMGT

LCDR3

SEQ ID

NO: 173

SEQ ID

NO: 174

SEQ ID

NO: 175

SEQ ID

NO: 176

SEQ ID

NO: 177

SEQ ID

NO: 178

SEQ ID

NO: 179

SEQ ID

NO: 180

SEQ ID

NO: 181

SEQ ID

NO: 182

SEQ ID

NO: 183

SEQ ID

NO: 184

SEQ ID

NO: 185

SEQ ID

NO: 186

SEQ ID

NO: 187

SEQ ID

NO: 188

HC
QVQLQESGPGLVAPSQSLSITCTVSGFSLN
SEQ ID

Framework

NO: 198

Region 1

HC0 Kabat

HC
QVQLQESGPGLVAPSQSLSITCTVSGFSLN
SEQ ID

Framework

NO: 198

Region 1

HC0_M

Kabat

HC
EVQLQESGPGLVKPSETLSLTCTVSGFSLN
SEQ ID

Framework

NO: 200

Region 1

HC1 Kabat

HC
EVQLVQSGAEVKKPGASVKVSCKASGFSLN
SEQ ID

Framework

NO: 201

Region 1

HC2 Kabat

HC
EVQLVQSGAEVKKPGSSVKVSCKASGFSLN
SEQ ID

Framework

NO: 202

Region 1

HC3 Kabat

HC
EVQLVESGGGLVKPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 203

Region 1

HC4 Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5 Kabat

HC
EVQLQESGPGLVKPSETLSLTCTVSGGSLN
SEQ ID

Framework

NO: 205

Region 1

HC6 Kabat

HC
QVQLQESGPGLVKPSETLSLTCTVSGGSLN
SEQ ID

Framework

NO: 206

Region 1

HC7 Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGYSLN
SEQ ID

Framework

NO: 207

Region 1

HC5_m1

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLR
SEQ ID

Framework

NO: 208

Region 1

HC5_m2

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLH
SEQ ID

Framework

NO: 209

Region 1

HC5_m3

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLD
SEQ ID

Framework

NO: 210

Region 1

HC5_m4

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLY
SEQ ID

Framework

NO: 211

Region 1

HC5_m5

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLS
SEQ ID

Framework

NO: 212

Region 1

HC5_m6

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m7

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m8

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m9

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m10

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m11

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m12

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m13

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m14

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m15

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m16

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m17

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m18

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m19

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m20

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m21

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m22

Kabat

HC
EVQLLESGGGLVQPGGSLRLSCAASGFSLN
SEQ ID

Framework

NO: 204

Region 1

HC5_m24

Kabat

LC
NIVLTQSPASLAVSLGQRATISC
SEQ ID

Framework

NO: 230

Region

1LC0 Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC1 Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC2 Kabat

LC
EIVLTQSPATLSVSPGERATLSC
SEQ ID

Framework

NO: 233

Region 1

LC3 Kabat

LC
DIVLTQSPLSLPVTPGEPASISC
SEQ ID

Framework

NO: 234

Region 1

LC4 Kabat

LC
DIVLTQSPDSLAVSLGERATINC
SEQ ID

Framework

NO: 235

Region 1

LC5 Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6 Kabat

LC
EIVLTQSPATLSVSPGERATLSC
SEQ ID

Framework

NO: 233

Region 1

LC7 Kabat

LC
DIVLTQSPLSLPVTPGEPASISC
SEQ ID

Framework

NO: 234

Region 1

LC8 Kabat

LC
DIVLTQSPASLAVSPGERATISC
SEQ ID

Framework

NO: 239

Region 1

LC9 Kabat

LC
DIVLTQSPASLAVSPGERATISC
SEQ ID

Framework

NO: 239

Region 1

LC10 Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m1

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m2

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m3

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m4

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m5

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m6

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m7

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m8

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m9

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m10

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m11

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m12

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m13

Kabat

LC
DIQLTQSPSSLSASVGDRVTITC
SEQ ID

Framework

NO: 231

Region 1

LC6_m14

Kabat

Lebrikizumab-
WIRQPPGKALEWLA
SEQ ID

HC

NO: 255

HC
WVRQPPGKGLEWLG
SEQ ID

Framework

NO: 256

Region 2

HC0

HC
WVRQPPGKGLEWLG
SEQ ID

Framework

NO: 256

Region 2

HC0_M

Kabat

HC
WIRQPPGKGLEWLG
SEQ ID

Framework

NO: 258

Region 2

HC1 Kabat

HC
WVRQAPGQGLEWLG
SEQ ID

Framework

NO: 259

Region 2

HC2 Kabat

HC
WVRQAPGQGLEWLG
SEQ ID

Framework

NO: 259

Region 2

HC3 Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC4 Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5 Kabat

HC
WVRQPPGKGLEWLG
SEQ ID

Framework

NO: 263

Region 2

HC6 Kabat

HC
WVRQPPGKGLEWLG
SEQ ID

Framework

NO: 263

Region 2

HC7 Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m1

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m2

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m3

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m4

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m5

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m6

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m7

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m8

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m9

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m10

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m11

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m12

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m13

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m14

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m15

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m16

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m17

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m18

Kabat H

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m19

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m20

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m21

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m22

Kabat

HC
WVRQAPGKGLEWLG
SEQ ID

Framework

NO: 262

Region 2

HC5_m24

Kabat

Lebrikizumab-
WYQQKPGQPPKLLIY
SEQ ID

LC

NO: 286

LC
WYQQKPGQPPKLLIY
SEQ ID

Framework

NO: 286

Region 2

LC0 Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC1 Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC2 Kabat

LC
WYQQKPGQAPRLLIY
SEQ ID

Framework

NO: 290

Region 2

LC3 Kabat

LC
WYLQKPGQSPQLLIY
SEQ ID

Framework

NO: 291

Region 2

LC4 Kabat

LC
WYQQKPGQPPKLLIY
SEQ ID

Framework

NO: 286

Region 2

LC5 Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6 Kabat

LC
WYQQKPGQAPRLLIY
SEQ ID

Framework

NO: 290

Region 2

LC7 Kabat

LC
WYLQKPGQSPQLLIY
SEQ ID

Framework

NO: 291

Region 2

LC8 Kabat

LC
WYQQKPGQPPKLLIY
SEQ ID

Framework

NO: 292

Region 2

LC9 Kabat

LC
WYQQKPGQPPKLLIY
SEQ ID

Framework

NO: 286

Region 2

LC10 Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m1

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m2

Kabat

LC
WYQQKPGKAPKLLIR
SEQ ID

Framework

NO: 300

Region 2

LC6_m3

Kabat

LC
WYQQKPGKAPKLLIF
SEQ ID

Framework

NO: 301

Region 2

LC6_m4

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m5

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m6

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m7

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m8

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m9

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m10

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m11

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m12

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m13

Kabat

LC
WYQQKPGKAPKLLIY
SEQ ID

Framework

NO: 288

Region 2

LC6_m14

Kabat

Lebrikizumab-
RLTISKDTSKNQVVLTMTNMDPVDTATYYCAG
SEQ ID

HC

NO: 311

HC
RLNISKDSSKSQVFLKMSSLQSDDTARYYCAG
SEQ ID

Framework

NO: 312

Region 3

HC0 Kabat

HC
RLTISKDSSKSQVFLKMSSLQSDDTARYYCAG
SEQ ID

Framework

NO: 313

Region 3

HC0_M

Kabat

HC
RLTISKDSSKNQVSLKLSSVTAADTAVYYCAG
SEQ ID

Framework

NO: 314

Region 3

HC1 Kabat

HC
RLTITKDSSTSTVYMELSSLRSEDTAVYYCAG
SEQ ID

Framework

NO: 315

Region 3

HC2 Kabat

HC
RLTITKDSSTSTVYMELSSLRSEDTAVYYCAG
SEQ ID

Framework

NO: 315

Region 3

HC3 Kabat

HC
RLTISKDSSKNTVYLQMNSLKTEDTAVYYCAG
SEQ ID

Framework

NO: 317

Region 3

HC4 Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5 Kabat

HC
RLTISLDTSKSQVFLKMSSLTAADTAVYYCAR
SEQ ID

Framework

NO: 319

Region 3

HC6 Kabat

HC
RLTISLDTSKSQVFLKMSSLTAADTAVYYCAR
SEQ ID

Framework

NO: 317

Region 3

HC7 Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m1

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m2

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m3

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m4

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m5

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m6

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m7

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m8

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m9

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m10

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m11

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m12

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m13

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m14

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m15

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m16

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m17

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m18

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m19

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m20

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m21

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m22

Kabat

HC
RLTISKDSSKNTVYLQMNSLRAEDTAVYYCAG
SEQ ID

Framework

NO: 318

Region 3

HC5_m24

Kabat

Lebrikizumab-
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC
SEQ ID

LC

NO: 343

LC
GVPARFSGSGSRTDFTLTIDPVEADDAASYYC
SEQ ID

Framework

NO: 344

Region 3

LC0 Kabat

LC
GVPSRFSGSGSRTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 345

Region 3

LC1 Kabat

LC
GVPSRFSGSGSRTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 345

Region 3

LC2 Kabat

LC
GIPARFSGSGSRTEFTLTISSLQSEDFAVYYC
SEQ ID

Framework

NO: 347

Region 3

LC3 Kabat

LC
GVPDRFSGSGSRTDFTLKISRVEAEDVGVYYC
SEQ ID

Framework

NO: 348

Region 3

LC4 Kabat

LC
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC
SEQ ID

Framework

NO: 349

Region 3

LC6 Kabat

LC
GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC
SEQ ID

Framework

NO: 351

Region 3

LC7 Kabat

LC
GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC
SEQ ID

Framework

NO: 352

Region 3

LC8 Kabat

LC
GVPDRFSGSGSGTDFTLTISRVEADDVAVYYC
SEQ ID

Framework

NO: 353

Region 3

LC9 Kabat

LC
GVPDRFSGSGSGTDFTLTISRVEADDVAVYYC
SEQ ID

Framework

NO: 353

Region 3

LC10 Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m1

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m2

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m3

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m4

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m5

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m6

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m7

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m8

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m9

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m10

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m11

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m12

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m13

Kabat

LC
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
SEQ ID

Framework

NO: 349

Region 3

LC6_m14

Kabat

Lebrikizumab-
WGQGSLVTVSS
SEQ ID

HC

NO: 368

HC
WGHGTSVTVSS
SEQ ID

Framework

NO: 369

Region 4

HC0

HC
WGHGTSVTVSS
SEQ ID

Framework

NO: 369

Region 4

HC0_M

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC1 Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC2 Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC3 Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC4 Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5 Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC6 Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC7 Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m1

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m2

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m3

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m4

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m5

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m6

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m7

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m8

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m9

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m10

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m11

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m12

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m13

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m14

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m15

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m16

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m17

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m18

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m19

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m20

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m21

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m22

Kabat

HC
WGQGTTVTVSS
SEQ ID

Framework

NO: 371

Region 4

HC5_m24

Kabat

Lebrikizumab-
FGGGTKVEIK
SEQ ID

LC

NO: 400

LC
FGGGTKLEIK
SEQ ID

Framework

NO: 401

Region 4

LC0 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC1 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC2 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC3 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC4 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC5 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC7 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC8 Kabat

LC
FGGGTKLEIK
SEQ ID

Framework

NO: 401

Region 4

LC9 Kabat

LC
FGGGTKLEIK
SEQ ID

Framework

NO: 401

Region 4

LC10 Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m1

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m2

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m3

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m4

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m5

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m6

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m7

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m8

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m9

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m10

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m11

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m12

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6_m13

Kabat

LC
FGGGTKVEIK
SEQ ID

Framework

NO: 400

Region 4

LC6 m14

Kabat

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 425

hIgG1
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 426

hIgG4
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 427

IgG4-SP
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 428

IgG4-SPLE
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEELG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF
NO: 429

IgG2
GTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVA

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWL

NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR

EEMTKNQVSLTCLVKGFYPSDIA

VEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRW

QQGNVFSCSVMHEALHNHYTQKSLSLSP

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 430

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

N297A
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 431

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

D265A
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 432

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALA
AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 433

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LAGA
LAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 434

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAGA
AAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 435

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAPG
AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 436

hIgG1-YTE
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 437

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

N297A/YTE
LLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 438

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

D265A/YTE
LLGGPSVFLFPPKPKDTLYITREPEVTCVVVAVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 439

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALA/YTE
AAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 440

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LAGA/YTE
LAGAPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 441

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAGA/YTE
AAGAPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 442

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAPG/YTE
AAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHNHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 443

hIgG1-LS
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVLHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 444

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

N297A/LS
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVLHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 445

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

D265A/LS
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVLHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 446

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALA/LS
AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVLHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 447

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LAGA/LS
LAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVLHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 448

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAGA/LS
AAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVLHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 449

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAPG/LS
AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVLHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 450

hIgG1-DHS
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVDHHD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 451

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

N297A/DHS
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVDHHD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 452

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

D265A/DHS
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVDHHD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 453

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALA/DHS
AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVDHH

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHSHYTQKSLSLSP

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 454

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LAGA/DHS
LAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVDHHD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 455

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAGA/DHS
AAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVDHH

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 456

hIgG1-
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LALAPG/DHS
AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVDHH

DWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC

SVMHEALHSHYTQKSLSLSPG

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 457

IgG4-YTE
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLG

GPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 458

IgG4-
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLG

SP/YTE
GPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 459

IgG4-
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEELG

SPLE/YTE
GPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 460

IgG4-LS
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHSY

TQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 461

IgG4-SP/LS
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHSH

YTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 462

IgG4-
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEELG

SPLE/LS
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHSH

YTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 463

IgG4-DHS
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLG

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVDHHDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHS

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 464

IgG4-
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLG

SP/DHS
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVDHHDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHS

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 465

IgG4-
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEELG

SPLE/DHS
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVDHHDWL

NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHS

HYTQKSLSLSLGK

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF
NO: 466

IgG2-YTE
GTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVA

GPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWL

NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR

EEMTKNQVSLTCLVKGFYPSDIA

VEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRW

QQGNVFSCSVLHEALHSHYTQKSLSLSP

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF
NO: 467

IgG2-LS
GTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVA

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWL

NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR

EEMTKNQVSLTCLVKGFYPSDIA

VEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRW

QQGNVFSCSVMHEALHNHYTQKSLSLSP

Heavy
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
SEQ ID

Chain
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF
NO: 468

IgG2-DHS
GTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVA

GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVDHHDWL

NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSR

EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHS

HYTQKSLSLSP

Light Chain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE
SEQ ID

Human
AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS
NO: 469

kappa LC
KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Lebrikizumab
QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNW
SEQ ID

Heavy
IRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKN
NO: 470

Chain
QVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSL

Variable
VTVSS

Region

Lebrikizumab
DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSF
SEQ ID

Light Chain
MHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFT
NO: 471

Variable
LTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK

Region

Human IL-
MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGP
SEQ ID

13
VPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGM
NO: 472

Full
YCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLH

sequence
VRDTKIEVAQFVKDLLLHLKKLFREGRFN

Cynomolgus
MALLLTMVIALTCLGGFASPSPVPPSTALKELIEELV
SEQ ID

Monkey IL-
NITQNQKAPLCNGSMVWSINLTAGVYCAALESLINVSGCS
NO: 473

13
AIEKTQRMLNGFCPHKVSAGQFSSLRVRDTKIEVAQFVKD

Full
LLVHLKKLFREGQFN

sequence

Mouse IL-
MALWVTAVLALACLGGLAAPGPVPRSVSLPLTLKE
SEQ ID

13
LIEELSNITQDQTPLCNGSMVWSVDLAAGGFCVALDSLTNI
NO: 474

Full
SNCNAIYRTQRILHGLCNRKAPTTVSSLPDTKIEVAHFITKL

sequence
LSYTKQLFRHGPF

Rat IL-13
MALWVTAVLALACLGGLATPGPVRRSTSPPVALRE
SEQ ID

Full
LIEELSNITQDQKTSLCNSSMVWSVDLTAGGFCAALESLTN
NO: 475

sequence
ISSCNAIHRTQRILNGLCNQKASDVASSPPDTKIEVAQFISK

LLNYSKQLFRYGH

Human IL-
MHPLLNPLLLALGLMALLLTTVIA
SEQ ID

13

NO: 476

Leader

sequence

Cynomolgus
MALLLTMVIALTCLGGFA
SEQ ID

Monkey IL-

NO: 477

13

Leader

sequence

Mouse IL-
MALWVTAVLALACLGGLA
SEQ ID

13

NO: 478

Leader

sequence

Rat IL-13
MALWVTAVLALACLGGLA
SEQ ID

Leader

NO: 479

sequence

Human IL-
LTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPL
SEQ ID

13
CNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLS
NO: 480

Main chain
GFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFR

sequence
EGRFN

Cynomolgus
SPSPVPPSTALKELIEELVNITQNQKAPLCNGSMVW
SEQ ID

Monkey IL-
SINLTAGVYCAALESLINVSGCSAIEKTQRMLNGFCPHKVS
NO: 481

13
AGQFSSLRVRDTKIEVAQFVKDLLVHLKKLFREGQFN

Main chain

sequence

Mouse IL-
APGPVPRSVSLPLTLKELIEELSNITQDQTPLCNGSM
SEQ ID

13
VWSVDLAAGGFCVALDSLTNISNCNAIYRTQRILHGLCNR
NO: 482

Main chain
KAPTTVSSLPDTKIEVAHFITKLLSYTKQLFRHGPF

sequence

Rat IL-13
TPGPVRRSTSPPVALRELIEELSNITQDQKTSLCNSS
SEQ ID

Main chain
MVWSVDLTAGGFCAALESLTNISSCNAIHRTQRILNGLCN
NO: 483

sequence
QKASDVASSPPDTKIEVAQFISKLLNYSKQLFRYGH

hIgG1-LA
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 484

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

N297A/LA
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 485

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

D265A/LA
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 486

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALA/LA
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 487

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEA

LHAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LAGA/LA
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 488

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALAGA/LA
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 489

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEA

LHAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALAPG/LA
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 490

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEA

LHAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

N434A
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 491

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

N297A/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 492

N434A
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

D265A/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 493

N434A
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALA/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 494

N434A
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE

ALHAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LAGA/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 495

N434A
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALAGA/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 496

N434A
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE

ALHAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALAPG/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 497

N434A
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE

ALHAHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

N434W
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 498

GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HWHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

N297A/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 499

N434W
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HWHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

D265A/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 500

N434W
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HWHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALA/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 501

N434W
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE

ALHWHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LAGA/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 502

N434W
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK

FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP

PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK

TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL

HWHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALAGA/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 503

N434W
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE

ALHWHYTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
SEQ ID

LALAPG/
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
NO: 504

N434W
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV

KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTL

PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE

ALHWHYTQKSLSLSPG

hIgG1/DQ
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 505

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

N297A/DQ
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 506

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYASTYRVVSVLQVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

D265A/DQ
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 507

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVAVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALA/DQ
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 508

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LAGA/DQ
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 509

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAGA/DQ
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 510

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGA

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAPG/DQ
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 511

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHQDWLN

GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSR

DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN

HYTQKSLSLSPG

hIgG1/DW
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 512

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLWVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

N297A/DW
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 513

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYASTYRVVSVLWVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

D265A/DW
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 514

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVAVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLWVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALA/DW
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 515

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLWVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LAGA/DW
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 516

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLWVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAGA/DW
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 517

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGA

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLWVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAPG/DW
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 518

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLWVLHQDWLN

GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSR

DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN

HYTQKSLSLSPG

hIgG1/YD
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 519

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLYISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

N297A/YD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 520

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLYISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

D265A/YD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 521

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLYISRDPEVTCVVVAVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALA/YD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 522

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLYISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LAGA/YD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 523

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA

PSVFLFPPKPKDTLYISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAGA/YD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 524

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGA

PSVFLFPPKPKDTLYISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAPG/YD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 525

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLYISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN

GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSR

DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN

HYTQKSLSLSPG

hIgG1/QVV
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 526

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

N297A/QVV
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 527

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYASTYRVVSVLQVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

D265A/QVV
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 528

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALA/QVV
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 529

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LAGA/QVV
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 530

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAGA/QVV
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 531

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGA

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAPG/QVV
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 532

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLQVLHVDWLN

GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSR

DELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTP

PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN

HYTQKSLSLSPG

hIgG1/DDR
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

VV
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 533

YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVDNAKTKPREEQYNSTYRVVSVLRVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

N297A/DD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 534

RVV
YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVDNAKTKPREEQYASTYRVVSVLRVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

D265A/DD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 535

RVV
YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRDPEVTCVVVAVSHEDPEVKFNW

YVDGVEVDNAKTKPREEQYNSTYRVVSVLRVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALA/DDR
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 536

VV
YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVDNAKTKPREEQYNSTYRVVSVLRVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LAGA/DD
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 537

RVV
YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVDNAKTKPREEQYNSTYRVVSVLRVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

LALAGA/D
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
SEQ ID

DRVV
YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGA
NO: 538

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVDNAKTKPREEQYNSTYRVVSVLRVLHVDWLN

GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD

ELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPP

VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH

YTQKSLSLSPG

hIgG1-
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
SEQ ID

LALAPG/D
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
NO: 539

DRVV
YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG

PSVFLFPPKPKDTLMISRDPEVTCVVVDVSHEDPEVKFNW

YVDGVEVDNAKTKPREEQYNSTYRVVSVLRVLHVDWLN

GKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSR

DELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTP

PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN

HYTQKSLSLSPG

Number	Name	Date	Kind
7615213	Kasaian et al.	Nov 2009	B2
7674459	Fung et al.	Mar 2010	B2
7863426	Wan et al.	Jan 2011	B2
8067199	Fung et al.	Nov 2011	B2
8088618	Fung et al.	Jan 2012	B2
8221752	Kasaian et al.	Jul 2012	B2
8318160	Fung et al.	Nov 2012	B2
8734797	Fung et al.	May 2014	B2
8734801	Fung et al.	May 2014	B2
9067994	Fung et al.	Jun 2015	B2
9605065	Fung et al.	Mar 2017	B2
9920120	Yu et al.	Mar 2018	B2
10000562	Deshmukh et al.	Jun 2018	B2
10093730	Hass et al.	Oct 2018	B2
10112994	Giulianotti et al.	Oct 2018	B2
10597446	Yu et al.	Mar 2020	B2
10597447	Yu et al.	Mar 2020	B2
10683348	Fuh et al.	Jun 2020	B2
10723795	Hass et al.	Jul 2020	B2
10738131	Chen et al.	Aug 2020	B2
10752703	Chen et al.	Aug 2020	B2
10882922	Yang et al.	Jan 2021	B2
10947307	Deshmukh et al.	Mar 2021	B2
11192960	Yang et al.	Dec 2021	B2
11226341	Arron et al.	Jan 2022	B2
11299539	Giulianotti et al.	Apr 2022	B2
11434286	Lin et al.	Sep 2022	B2
11434287	Fung et al.	Sep 2022	B2
11453727	Rao et al.	Sep 2022	B2
11725050	Hass et al.	Aug 2023	B2
11754573	Morgan et al.	Sep 2023	B2
11827671	Soubrane et al.	Nov 2023	B2
11840566	Rommelaere et al.	Dec 2023	B2
11891437	Famili et al.	Feb 2024	B2
20030031666	Debinski et al.	Feb 2003	A1
20060063228	Kasaian et al.	Mar 2006	A1
20070292442	Wan et al.	Dec 2007	A1
20090098142	Kasaian et al.	Apr 2009	A1
20100129360	Kasaian et al.	May 2010	A1
20140044645	Arron	Feb 2014	A1
20150225479	Huille et al.	Aug 2015	A1
20160207995	Yansura et al.	Jul 2016	A1
20160230226	Abbas et al.	Aug 2016	A1
20160272706	Carmen	Sep 2016	A1
20160363591	Streicher et al.	Dec 2016	A1
20170067108	Abbas et al.	Mar 2017	A1
20170298119	Wollacott	Oct 2017	A1
20170334985	Wu et al.	Nov 2017	A1
20180251538	Fung et al.	Sep 2018	A1
20180356429	Morimoto et al.	Dec 2018	A1
20190002552	Deshmukh	Jan 2019	A1
20190024178	Abbas et al.	Jan 2019	A1
20190062836	Abbas et al.	Feb 2019	A1
20200165679	Abbas et al.	May 2020	A1
20210115124	Koenig et al.	Apr 2021	A1
20210155684	Deshmukh et al.	May 2021	A1
20210188965	Rommelaere et al.	Jun 2021	A1
20210261649	Parry et al.	Aug 2021	A1
20220033520	Lazar et al.	Feb 2022	A1
20220089728	Degenhardt et al.	Mar 2022	A1
20220153854	Rommelaere et al.	May 2022	A1
20220177564	Rommelaere et al.	Jun 2022	A1
20220177566	Rommelaere et al.	Jun 2022	A1
20220228107	Smith et al.	Jul 2022	A1
20220275102	Cameron et al.	Sep 2022	A1
20220372131	Lin et al.	Nov 2022	A1
20220389449	Paul et al.	Dec 2022	A1
20230235088	Rao et al.	Jul 2023	A1
20230250165	Yu et al.	Aug 2023	A1
20230357381	Bardroff et al.	Nov 2023	A1
20240101675	Demishtein et al.	Mar 2024	A1
20240117030	Agostinelli et al.	Apr 2024	A1

Number	Date	Country
1703893	Apr 2012	EP
1711528	Jul 2012	EP
2332575	Nov 2014	EP
3060685	May 2019	EP
2805728	Feb 2020	EP
3218403	May 2020	EP
3091029	Dec 2022	EP
3528838	Jul 2023	EP
3443006	Aug 2023	EP
3718564	Oct 2023	EP
3083682	Apr 2024	EP
2005062967	Jul 2005	WO
2008140455	Nov 2008	WO
2015038888	Mar 2015	WO
2017011773	Jan 2017	WO
2018220216	Dec 2018	WO
2021021676	Feb 2021	WO
2022097060	May 2022	WO
2023287590	Jan 2023	WO
2023019260	Feb 2023	WO
2023044313	Mar 2023	WO
2023215769	Nov 2023	WO
2023245187	Dec 2023	WO
2024227141	Oct 2024	WO

Number	Date	Country
63469167	May 2023	US
63462822	Apr 2023	US
63353367	Jun 2022	US

	Number	Date	Country
Parent	PCT/US2023/068621	Jun 2023	WO
Child	18979795		US

Antibodies that bind interleukin 13 and methods of use

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Term Extension

Abstract

Description

Claims

CROSS REFERENCE TO RELATED APPLICATIONS

US Referenced Citations (72)

Foreign Referenced Citations (24)

Non-Patent Literature Citations (22)

Related Publications (1)

Provisional Applications (3)

Continuations (1)

Entry
Dall'Acqua WF, et al., “Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn),” J Biol Chem., vol. 281(33):23514-23524 (2006).
Deuschl, F. et al., “Molecular characterization of the hypothetical 66.3-kDa protein in mouse: Lyso-somal targeting, glycosylation, processing and tissue distribution,” FEBS Letters, vol. 580: 5747-5752 (2006).
Dumet, C. et al., “Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development,” Mabs, vol. 11(8):1341-1350 (2019) doi: 10.1080/19420862.2019.1664365.
Gutierrez, A. et al., “Of 'hamsters and men: A new perspective on host cell proteins,” Human Vac-cines, vol. 8 (9): 1172-1174 (2012).
Hammitt LL, et al. “Nirsevimab for prevention of RSV in healthy late-preterm and term infants,” N Engl J Med., vol. 386(9):837-846 (2022).
Hezareh M, et al., “Effector function activities of a panel of mutants of a broadly neutralizing anti-body against human immunodeficiency virus type 1,” J Virol., vol. 75(24):12161-12168 (2001) doi:10.1128/JVI.75.24.12161-12168.2001.
International Preliminary Report on Patentability, PCT/US2023/068621, dated Dec. 10, 2024, 9 pages.
International Search Report and Written Opinion, PCT/US2023/068621, dated Jun. 11, 2024, 13 pages.
Kato Y, et al., “Hydrophobic interaction chromatography at low salt concentration for the capture of monoclonal antibodies,” J Chromatogr., vol. 1036:45-50 (2004).
Liu et al., “Recovery and purification process development for monoclonal antibody production,” mAbs, vol. 2 (5): 480-499 (2010).
Lytvyn, Y. et al., “Targeting Interleukin 13 for the Treatment of Atopic Dermatitis,” Pharmaceutics, vol. 15(2):568 doi: 10.3390/pharmaceutics15020568 (2023).
NCT04718103, “A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype (SWIFT-2)” 2 pages.
Ortega H, et al., “Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites,” Clin Pharmacol Drug Dev., vol. 3(1):57-62 (2014). doi:10.1002/cpdd.60.
Ridker PM, et al., “IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RES-CUE): a double-blind, randomised, placebo-controlled, phase 2 trial,” Lancet, vol. 397(10289):2060-2069 (2021) doi:10.1016/S0140-6736(21)00520-1.
Robbie GJ, et al., “A novel investigational Fc-modified humanized monoclonal antibody, motavi-zumab-YTE, has an extended half-life in healthy adults,” Antimicrob Agents Chemother., vol. 57(12):6147-6153 (2013) doi: 10.1128/AAC.01285-13.
Robbie GJ, et al., “Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncyt-ial virus monoclonal antibody, in adults and children,” Antimicrob Agents Chemother., vol. 56(9):4927-4936 (2012). doi:10.1128/AAC.06446-11.
Rocca A, et al. “Passive immunoprophylaxis against respiratory syncytial virus in children: where are we now?” Int J Mol Sci., vol. 22(7):3703 (2021) doi:10.3390/ijms22073703.
Saunders KO, “Conceptual approaches to modulating antibody effector functions and circulation half-life,” Front Immunol., vol. 10:1296 (2019) doi:10.3389/fimmu.2019.01296.
Shukla, A. et al., “Downstream processing of monoclonal antibodies-application of platform approaches,” J. Chromatogr., 28-39 (2007).
Singh D, et al., “A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in pa-tients with asthma,” Br J Clin Pharmacol., vol. 88(2):702-712 (2022).
Vanderlaan, Martin et al., “Hamster phospholipase B-like 2 (PLBL2): A host-cell protein impurity in therapeutic monoclonal antibodies derived from Chinese hamster ovary cells,” BioProcess Interna-tional, vol. 13. (2015).
Wines BD, et al., “The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte recep-tors Fc gamma RI and Fc gamma Rlla bind to a region in the Fc distinct from that recognized by neo-natal FcR and protein A,” J Immunol., vol. 164(10):5313-5318 (2000) doi:10.4049/jimmunol.164.10.5313.